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Abstract 
It has long been a goal of the bioprocessing field to be able to produce proteins in a cost-
effective and efficient manner. The most basic stage of protein production is to optimize the 
growth of the cells in question to give higher specific protein productivity. The current 
method of choosing high-producing mammalian cells is labour-intensive and time-
consuming, representing an opportunity to employ new analytical methodologies in an 
effort to expedite progress. The established cell line construction and selection methods 
rely heavily on achieving high cell growth rates, assessed in terms of confluence, in the early 
stages of cell line development.  
It would be advantageous to measure the intracellular concentration of key metabolites 
including glucose and glutamine as the cells are growing. This would allow the user to have 
more information regarding the wellbeing and growth potential of these cells. This would 
possibly allow a more informed decision to be made at an earlier stage during cell line 
selection so the underperforming cells are discarded and not carried to the next stages of 
cell line selection.  
In this thesis the construction, optimisation and use of FRET biosensors for the in vivo 
measurement of glucose and glutamine in Chinese Hamster Ovary cells will be discussed. 
Experiments have been conducted in batch and fed-batch cultures as well as small-scale 
investigations using the BioLector™. The work presented in this thesis suggests the use of 
genetically encoded FRET biosensors allows for quantification of intracellular metabolite 
concentrations via FRET ratios during cell growth. These FRET biosensors also show that it 
may be possible to predict intracellular glucose or glutamine concentrations based solely on 
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the FRET ratio of these cells.  It has also been suggested that in a smaller volume micro 
fermentation system called the BioLector™ these biosensor transfected cell lines can be 
used to detect changes in intracellular glucose/glutamine levels. In an experiment where 
commercially tested feeds were used to assess the usefulness of the biosesnors, the results 
reveal a possible correlation between high initial FRET ratios and high cell concentrations. 
These biosensor cell lines were then used for cell line selection and results indicate that the 
FRET ratio may also be used as a tool to discard various cell lines based on time of 
progression.  Using data in the the final study, it may be concluded that the early progressed 
cell lines may not necessarily be the highest  protein producers and with, respect to scFv 
production, no product specific differences exist. The results indicate the usefulness of 
these FRET biosensors as tools in aiding the process of information gathering at an early 
stage during cell line selection.  
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Chapter 1. Introduction 
Biopharmaceuticals are drugs produced using biotechnology methods; the main focus of the 
biopharmaceutical industry is to produce drugs that cannot be synthesised chemically. 
During the past 20 years, biopharmaceuticals such as recombinant proteins and monoclonal 
antibodies have advanced the prevention and treatment of many serious illnesses (Walsh et 
al., 2006). One of the first recombinant proteins produced was insulin marketed by 
Genentech in 1982. During the last ten years there has been a large increase in the number 
of biopharmaceuticals in development and approved for patient use (Figure 1). 
Approximately 200 products have gained regulatory approval through 2012. The major 
companies involved include several large multinationals such as Pfizer, Novartis, and 
GlaxoSmithKline each with revenues between US$40 and US$70 billion annually. As the left 
Panel of Figure 1 demonstrates, Roche and Amgen products have the highest growth rate in 
terms of sales. In 2010, sales of monoclonal antibodies (mAbs), hormones and fusion 
proteins in the United States were approximately US$33.5 billion, which constitutes 60% of 
the total US biotechnology market and represents a 23% growth over their previous year 
sales (Aggarwal et al., 2010). MAbs ($18 billion) and hormones ($11 billion) are the highest 
selling biopharmaceutical products as depicted in the right Panel of Figure 1.  
 
Figure 1: The biotechnology market.  
A: The top 10 Biotechnology companies and their sales growth rates 
in 2010, B: The top 9 categories of biologics sold in the United States 
in 2010, adapted from Aggarwal et al. (2011) 
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Figure 2: Immunoglobulin design schematic 
The light and heavy chains as well as the scFv with the various fragments 
 
Antibodies (immunoglobulins) are naturally occurring immune system proteins which 
recognise foreign objects (antigens), bind to them, and elicit further involvement from the 
immune system, which leads to the clearance or destruction of the antigen (Figure 2).  Each 
antibody consists of four polypeptide chains, two heavy chains and two light chains joined 
together to form a Y-shaped molecule. The amino acid sequences at the tips of the Y shape 
are responsible for antigen recognition and therefore vary among different antibodies. This 
variable region is composed of 110 – 130 amino acids and includes the N-termini of the light 
and heavy chains. Treating the antibody with a protease can cleave this variable region 
producing an antigen binding fragment, which is the smallest unit still capable of antigen 
recognition.  One type of antibody fragment is the single chain variable fragment (scFv), a 
fusion protein of the variable regions of the heavy and light chains of antibodies connected 
with a short linker peptide usually between 10 and 25 amino acids Ahmad et al., 2012). 
Although most currently approved antibody-based biopharmaceuticals typically consist of 
full antibodies of the immunoglobulin G (IgG) format, antibody fragments such as the scFv 
are increasingly being used in the pharmaceutical development programmes (Zuberbühler 
et al., 2009).   Other antibody-derived products include the fragment antigen binding (Fab) 
and variable fragment (Fv). These can be equipped with radioisotopes or other markers that 
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may be used to locate the target antigen or employed in therapy ScFvs have a high potential 
in the pharmaceutical and biotechnology market, since their small size enables the 
production of targeted fusion proteins against tumours receptors viruses and proteins for 
applications in drug delivery and imaging (Lu et al., 2011). They are used for several medical 
applications including cancer treatment and radio-immunoimaging (Kim et al., 2002), in 
gene therapy for Crohn's disease and for the treatment of rheumatoid arthritis (Kaushik and 
Moots 2005).  scFvs are typically more stable than full length IgGs and can be stored for 
years. They can also be produced more rapidly and inexpensively. Because of their small 
size, scFvs penetrate more quickly into cells and tissues and are rapidly cleared from the 
blood.  This results in low exposure of healthy tissues to conjugated drugs in cancer 
treatment.  There is also a much lower possibility of developing an autoimmune response 
(Fife et al., 2006). Overall, it is clear that these fragments are very useful and industrially 
relevant.  
Once a compound is identified as a potential drug there are several phases of development, 
which must be undertaken in order to determine the formulation and dosing as well as to 
ensure safety and efficacy when used in patients. This requires a combination of in vitro and 
in vivo (pre-clinical) studies followed by clinical trials (Pucca et al., 2011). To be able to 
undertake these trials, one needs to be able to make sufficient amounts of the desired 
product in the same form that it will be given to the patients if approved. This involves the 
generation of one or more recombinant cell lines that produce the product of interest in 
high amounts with the appropriate post-translational modifications. The generation of 
recombinant cell lines for the production of a biopharmaceutical follows a well-defined 
multi-step scheme. The current industrial methods for development and selection of 
mammalian cell lines are lengthy and expensive processes, which involve the maintenance 
and evaluation of a large number of cultures over a wide range of volumes (Figure 3). This 
process begins with the molecular cloning of the gene of interest (GOI) into a mammalian 
expression vector, which contains a selection marker (most commonly dihydrofolate 
reductase, DHFR, or glutamine synthetase, GS) that allows for the isolation of cells that have 
successfully taken up the vector (Southern and Berg 1982). Following DNA transfection, cells 
are then subjected to selective conditions to recover those that have stably integrated the 
exogenous genes into a chromosome.  This creates a population of cells, each of which may 
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contain different numbers of gene copies, integrated at different genetic loci (Wurm et al., 
2004). 
The next step is the isolation and evaluation of several hundreds of individual cells to 
recover a few candidate production cell lines. This is usually accomplished by visual 
assessment of cell confluence and one or more rounds of limiting dilution cloning in order to 
obtain a monoclonal cell line.  As the culture volume increases from 96-well plates to 24-
well plates to tissue culture 25cm2 flasks and then Erlenmeyer flasks, the cell lines are 
progressed based on confluence (or cell concentration when cells are in suspension 
cultures) and a productivity assessment. This process continues until 5-10 transfected cell 
lines are chosen. At that stage testing is conducted to assess cell growth characteristics, 
productivity and product quality. These 5-10 transfectants are expanded and then each is 
evaluated in laboratory scale bioreactors, under conditions that mimic those of large scale 
production facilities. A fed-batch culture strategy is used to monitor growth, productivity 
and product structure. This strategy is used to reach a high cell density, which allows higher 
volumetric protein production (Zhou et al., 1996). This methodology can be problematic, 
because there are no reliable methods for predicting growth characteristics and production 
capabilities of cells in large bioreactors early in the cell line development process. 
 
 
 
 
 
 
 
Figure 3: An overview of the current cell line selection process 
Additionally, the current approach favours the selection of fast-growing cells, but it has 
been shown that these cells are not necessarily the most productive at large scale (Porter et 
al., 2010; Barnes and Dickson, 2006). Barnes and Dickson described the current cell line 
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selection methods as “discarding the best cell lines and leaving good cell lines”. The fastest 
growing cells may not be the best producers possibly due to rapid utilization of metabolites 
for fast growth. This may be because they utilise the vast majority of their nutrients for cell 
growth at the expense of having enough energy for protein production.  Therefore, it would 
be interesting to measure intracellular metabolite levels during cell growth and determine 
whether this information can be used to make a more informed choice about which cell 
lines to pass on to the next stage of cell line selection.  
A significant improvement to current practice would be the development of a system that 
offers the ability to consider the suitability and manufacturability of cells at an earlier stage 
in the decision-making process. Therefore any method that allows real-time, non-invasive 
analysis of growth- and production-related characteristics would be of great benefit. This is 
because it will provide data that could suggest which cell lines are more amenable to growth 
and production in large-scale bioreactors and thus reduce the development time and cost. 
For the improvement of the above method, the use of biosensors for process control is 
suggested by this thesis. To be able to control fermentation online monitoring methods are 
used that allow real time control. Online metabolite measurements allow users to better 
their feeding strategies to increase production yields and hence increase the efficiency of 
therapeutic protein production. Measuring the health of the cells will give the user a higher 
confidence level and will result in cell lines that give the most consistent results. Detecting 
abnormal growth rates online will let users discard these cells and keep the healthy cell 
lines.  
One of the ways that growth and well-being of cells can be monitored is by the 
measurement of important metabolite during growth. Glucose and glutamine are utilized by 
the cell for energy and as a source of carbon. Therefore Intracellular concentrations of 
glucose and glutamine are vital in feeding strategies. Online monitoring would allow fixed, 
low concentration of glucose/glutamine to be fed which will provide a constant and regular 
source of energy for the cells to grow and produce the specific protein of interest.  
The following chapters will discuss efforts to the select and validate in vivo genetically 
encoded biosensors to measure the concentrations of glucose and glutamine during the 
culture of Chinese hamster ovary (CHO) cells in a variety of industrially-relevant applications 
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in order to gain real-time information on metabolite concentrations. The implementation of 
these biosensors at both the shake-flask scale and the small-scale BioLector® parallel culture 
system was performed in order to ascertain whether the biosensors provided useful 
information at multiple scales. The results in this thesis highlight the usefulness of 
measuring the Förster resonance energy transfer (FRET) ratio as a tool for possible 
prediction of the intracellular levels of glucose and glutamine, and suggest an ability to 
correlate the metabolite concentrations to more complex properties of interest such as 
recombinant protein productivity. Finally, this thesis will conclude by summarising the main 
findings of the work as well as provide recommendations for future research.  
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Chapter 2. Literature Review 
This chapter gives an overview of the relevant background for this study.  First, the various 
potential expression systems for the production of therapeutic proteins and the advantages 
and disadvantages of each are described. Particular attention is paid to CHO cells, the host 
cell line used in this work.  Next, the chapter discusses existing high-throughput methods 
and culture devices. The chapter continues with details on the use of biosensors and the 
various design strategies used in the literature. FRET biosensors are then introduced and 
explained in detail: how they work, the various design schematics and the existing work with 
FRET metabolite biosensors.   
2.1 Host expression systems   
There are many host systems for the production of therapeutic proteins including bacterial, 
yeast, plant, insect and mammalian cells. Different systems are used depending on the 
protein to be produced and selecting the right expression system for a given protein is one 
of the most important decisions. Table 1.1 shows the different host systems, outlining the 
various aspects of each system and the advantages and disadvantages associated with each.  
When choosing a cell line it is important to consider the product characteristics and 
maximum yields associated with different systems. Product characteristics include: solubility, 
biological activity, and toxicity in humans.  The product produced must be soluble in the 
native environment of the host cells. Biological activity describes the  
beneficial or adverse effects of a drug on living matter. Glycosylation varies with the host 
cell line, and non-glycosylated proteins can be more immunogenic than glycosylated 
proteins. As summarised in Table 1, host systems vary in their ability to express recombinant 
proteins and to perform post-translational modifications (PTM). PTM is the modification of a 
protein after its translation; this can be via the addition of functional groups (acetate, 
phosphate and carbohydrates) to regulate the biological activity of a protein (Mann and 
Jensen 2003). Only a subset of these PTMs is associated with therapeutic proteins. 
Acetylation and phosphorylation regulate various intracellular processes, including gene 
expression and signal transduction (Bannister et al., 2000). Such PTMs are not often 
characteristic of biopharmaceuticals. In contrast, glycosylation, i.e. the addition of sugar 
residues to the peptide backbone, affects the characteristics of many biopharmaceuticals 
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and can influence product stability and biological activity (Walsh and Jefferis, 2006). Time is 
also an important factor as different expression systems have varying development and 
culture times. Below is an overview of the different host systems. 
Table 1: Comparison of expression systems  
 Bacterial      
(E. coli) 
Yeast Plant cells Insect cells Mammalian 
cells 
Cell growth 
(doubling time) 
Rapid 
(30 Min) 
Rapid 
(90 Min) 
Moderate          
(12-18H) 
Slow 
(18-24H) 
Slow 
(24 H) 
Cost of growth 
medium 
Low Low Low High High 
Expression level High Low – high Moderate Low – high Moderate 
N-linked 
glycosylation 
None High Mannose Yes Simple, 
No Sialic Acid 
Complex 
O-linked 
glycosylation 
No Yes Yes Yes Yes 
Project Cost Low Low Low Middle High 
Recommended use Antigen 
protein, 
protein 
standards, 
functional 
proteins 
Proteins with 
glycosylation, 
vaccines, insect 
cell system 
Protein 
production 
(lactoferrin, 
lysozyme) 
 
Proteins with 
glycosylation, 
assay 
standards, 
secreted 
form, 
alternative to 
yeast system 
Functional 
study, PTM 
study, assay 
standards 
 
Advantages 
 
Simple, 
robust, 
lowest cost, 
highest yield 
 
Simple, low cost, 
good for certain 
proteins 
 
Synthesise 
proteins 
with PTM closely 
resembling 
mammalian 
 
Relatively 
higher yield, 
better  PTM 
 
Natural protein 
configuration, 
best PTM 
 
Disadvantages 
 
Lack of post 
translation 
modification 
 
Longer time, 
different PTM 
 
limited in their 
product 
spectrum 
for glycosylated 
proteins 
 
Longer time, 
higher cost 
 
Highest 
cost, lower 
yield 
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2.1.1 Bacterial host systems 
The Escherichia coli expression system has been used for over 30 years. It was the first 
expression system introduced in the biotechnology industry to produce recombinant insulin 
(Goeddel et al., 1979). This system offers high expression levels, inexpensive culture media 
and rapid fermentation scale-up. Cell growth is fast and this leads to short fermentation 
times. The biggest and most important drawback in the case of E.coli is the inability to post-
translationally modify proteins. This is due to the lack of enzymatic machinery and the 
absence of an endoplasmic reticulum (ER) or Golgi apparatus (where glycotransferase 
enzymes reside in eukaryotes). If proteins are folded incorrectly, they can accumulate as 
aggregates in the bacterial cell. In order to avoid toxic effects on the host system, the 
bacteria store these aggregates in structures referred to as inclusion bodies (Flick et al., 
2004). Formation and accumulation of proteins in inclusion bodies is a common problem in 
protein expression using bacterial hosts that introduces further modification steps ex vivo. 
These deficiencies restrict their use for industrial glycoprotein production (Rabouille et al., 
1995 and De Graffenried et al., 2004). 
There have, however, been attempts to overcome the lack of post-translational 
modifications. Kowarik et al. (2006) presented a study in which they used the 
Campylobacter jejuni pgl locus to transfer the N-linked protein glycosylation machinery to E. 
coli, resulting in recombinant glycoproteins with the engineered N-glycosylation sites. This is 
an important result as the establishment of recombinant proteins glycosylation in E. coli is a 
key step towards the production of pharmacologically important N-glycosylated proteins in 
E.coli (Kowarik et al., 2006). However, the N-linked glycan produced by these cells is too 
dissimilar to the structures produced by mammalian cells. This is an issue as the resultant 
product may cause immunogenic effects in the body and decreased efficacy of any 
therapeutic protein that would be produced with the current system (Kawasaki et al., 2009; 
Chung et al., 2008 and Hamilton et al., 2006).  
2.1.2 Yeast host systems 
The yeast species Saccharomyces cerevisiae and Pichia pastoris have been used as 
production organisms for commercial biopharmaceutical products including insulin, 
hepatitis surface antigen, and human serum albumin. These expression systems offer high 
  26 
efficiency, high cell densities, high yields and low fermentation costs (Table 1). Yeast cells 
are easy to grow at large scale and have simple nutritional demands, which therefore lower 
the cost of culture media (Cregg, 1993).   
However, therapeutic glycoproteins cannot be produced in standard yeast expression 
systems, which lack several of the transferase enzymes found in the mammalian Golgi 
apparatus (Gerngross, 2004). Yeast are therefore not able to produce post-translationally 
modified proteins that are identical to mammalian cell lines, instead producing a high 
mannose oligosaccharide (Gerngross et al., 2004; Li et al., 2006 and Hamilton et al., 2006). 
As a result, the glycoproteins produced in yeast have significant immunogenicity and short 
serum half-lives in humans (Czlapinski and Bertozzi, 2006).  
Li et al. (2006) published work on the construction of humanised IgGs in glycoengineered 
P.pastoris, using a plasmid to introduce the DNA encoding for homologs of many of the 
missing enzymes. Their method allows human antibodies with specific human N-glycan 
structures to be produced in this modified yeast strain (Li et al., 2006) These enzymes 
include a yeast (Kluveromyces lactis) GlcNAc transporter, a mouse β-1,2 GlcNAc transferase 
I, a rat GlcNAc transferase II, Drosophila Mannosidase II, UDP-Gal transporter and a Homo 
sapiens β-1,4 galactosyl transferase. This group glycoengineered several lines of P.pastoris 
to produce many forms of rituximab (anti CD-20 antibody) in order to demonstrate the 
applicability of this system. 
The same group carried out further research that allowed P.pastoris to secrete human 
glycoproteins with fully complex terminally sialylated N-glycans. Fourteen heterologous 
genes were introduced that replicated the steps of mammalian glycosylation in yeast 
(Hamilton et al., 2006). These included the genes listed above as well as a Homo sapiens 
CMP–sialic acid synthase (CSS) and a mouse CMP–sialic acid transporter (CST) (Hamilton et 
al., 2006). The cell lines produced secreted complex glycoproteins with greater than 90% 
terminal sialylation. The initial results suggest this is a promising strategy; however more 
investigations must be undertaken to show that this is a viable and competitive option at 
production scale. 
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2.1.3 Insect cells 
Insect cell systems reach high expression levels and scale up can be easily achieved using 
high-density suspension cultures (Ahn et al., 2008). The baculovirus insect cell expression 
system is well suited for recombinant glycoprotein production and has been used in viral 
vaccine development (such as influenza virus and HPV vaccine development, Zang et al., 
1995), signal protein production, and cytokine production (Mirzaei et al., 2009). The cells 
are, however, sensitive to shear forces, the culture media are expensive compared to 
microbial fermentation media and there is the possible risk of infection with mammalian 
viruses. 
There are also differences in the post-translational modification of proteins. While 
mammalian cells produce compositionally more complex N-glycans containing terminal 
sialic acid residues, insect cells mostly produce simpler N-glycans with terminal mannose 
residues (Jarvis et al., 1996) and therefore lack the oligosaccharide side chains that contain 
the final galactose and terminal sialic acid residues (Jarvis and Finn ., 1996). Furthermore, 
insect cells show low activity of some glycosyl transferase enzymes, including N-
acetylglucosaminyltransferase (GnTII), which adds an N-acetylglucosamine (GLcNAc) residue 
to the alpha 1,6 arm of the N-linked oligosaccharide (Kornfield and Kornfield, 1985). This 
further obstructs the synthesis of mammalian-like glycoforms (Leonard et al., 2006). The N-
glycosylation pathway of baculovirus infected insect cells is thus different from the 
mammalian one. However these major limitations may be overcome by glycoengineering 
approaches to allow improved N-glycan processing and generate human-type complex 
glycosylation (Jacobs and Callewaert, 2009). For example, Schneider-2 insect cells that 
produce fully complex type N-glycans, lacking only terminal sialic acids have been reported 
very recently (Lim et al., 2011). 
2.1.4 Plant cells 
The moss Physcomitrella patens is a commonly used system for the production of 
recombinant pharmaceutical proteins (Decker and Reski, 2004) such as interleukin-2 and 
interleukin-4 (Magnuson et al., 1998). Plant cells express most of the required enzymes for 
glycosylation, however, they also have additional transferases that can add non-mammalian 
sugars such as xylose to complex oligosaccharides (Tekoah et al., 2004). Plant cells can add 
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α-1,3-fucose and 1,3-xylose sugars that are reported to be immunogenic or allergenic in 
humans. Significant progress has been achieved over the past years towards 
glycoengineered transgenic plants equipped with different components of the mammalian 
glycosylation machinery even allowing multi-antennary and 2,6-sialylated N-glycosylation 
to some extent (Castilho et al., 2010; Nagels et al., 2011)                    
2.1.5 Mammalian cells 
The production of proteins in mammalian cells is an important tool in many scientific and 
commercial fields. Mammalian cells have been used in life sciences research, biomedicine, 
vaccination and diagnostic applications and were introduced for the production of 
biopharmaceuticals, specifically interferon, in 1979. The recombinant proteins produced in 
mammalian expression systems have structural and functional features that are usually very 
close to the native human forms (Hossler et al., 2009). The relatively low expression levels 
combined with the high price of cell culture reagents make it more expensive to produce 
recombinant proteins in mammalian cells than in microbial or plant systems. Mammalian 
cells are also susceptible to viral infections and for safety at least one virus deactivation step 
is used in the final part of the production process (Liu et al., 2000).  
A plethora of mammalian cell lines exist for the production of biopharmaceuticals, including 
mouse myeloma cells (e.g. NS0), hybridoma, human embryonic kidney cells (HEK) 293 and 
CHO cells. Table 2 below shows that CHO cells have the highest maximum protein yield. It 
must also be noted that over 60% of all therapeutic glycoproteins are made with the CHO 
cell expression system (Kyriakopoulos and Kontoravdi, 2013). 
Table 2:  Characteristics of the different mammalian expression systems. 
Origin Cell line Medium Transfection Maximum 
protein 
yield 
Products Reference 
Hamster CHO CD-CHO Stable 5.0 g/L Rituxan™, 
Avastin©, 
Xolair™, 
Herceptin™ 
Lonza, 
Urlaub et 
al., 1980; 
Puck et al., 
1967; 
Mouse 
Myeloma 
GS-NS0 CDM4 NSO  Stable 2.0 g/L Synagis™, 
Zenapax©, 
 
Bebbington 
et al., 1992 
Human HEK 293 Freestyle  Transient 2.0 g/L Xigris™ Pham et 
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al., 2006 
Mouse Hybridoma CD 
Hybridoma 
Transient > 2.0 g/L Arzerra™ Osterborg 
et al., 2010 
 
2.1.5.1 NS0 cells 
NS0 cells were derived from a plasmacytoma induced in a mouse by peritoneal injection of 
mineral oil (Barnes et al., 2000). NS0 cells do not produce any endogenous antibody so they 
are often used as hosts for recombinant protein production. They are an alternative to the 
more commonly used CHO cells.  However, NS0 cell lines require additional medium 
components to support cell growth (cholesterol and lipids) that can affect downstream 
processing (Seth et al., 2005).   
2.1.5.2 Hybridoma cells 
Hybridoma cells are the result of the fusion of an antibody-producing B lymphocyte and a 
lymphocyte tumour (myeloma) cell (Köhler and Milstein heralded in 1975) (Milstein et al., 
1981). They provide a source for monoclonal antibodies (mAbs). It is their ability to generate 
mAbs to virtually any protein antigen that makes them an extremely useful scientific tool 
(Majidi et al., 2009).  Hybridoma cells typically have protein production levels ranging from 
<100mg/L up to > 2.0 g/L (Kontoravdi et al., 2010).  
2.1.5.3 HEK-293 cells  
Human embryonic kidney (HEK)-293 cells are a population of cells generated by adenoviral 
transformation of primary cultures of kidney epithelial cells (Graham et al., 1977). They are 
a useful cell type to produce adenovirus, other viral vectors and effectively glycosylated 
human recombinant proteins. Their transcription, translation and post-translation 
modification machineries for expressing mammalian ion channels are conserved and so 
HEK-293 cells are frequently used to investigate expression of ion channels (Raymond et al., 
1996; Zhu et al., 1998). As explained by Thomas et al. (2005), the main attributes that have 
made the HEK-293 cell line a popular choice to study isolated receptor channels include its 
quick and easy reproduction and maintenance, amenability to transfection using a wide 
variety of methods, and high efficiency of transfection and protein production.  
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2.1.5.4 Chinese Hamster Ovary cells  
CHO cells have been used in the laboratory since 1919, where they were used for typing 
pneumococci (Yeriganian et al., 1985). In 1957, Dr Theodore T. Puck isolated an ovary from a 
female Chinese hamster and established cells in culture plates. These cells were very 
resilient and had a fast doubling time (Tijo et al., 1958). Puck and Kao subsequently showed 
that CHO cells could be mutated and various useful auxotrophs isolated, which led to the 
movement of CHO cells from laboratory benches to industrial reactors (Kao & Puck, 1967). 
They found that these mutants showed different nutritional requirements for maintaining 
maximum growth and viability.  They could also be adapted to growth in suspension culture. 
This work led to the isolation of mutants with varying degrees of deficiencies in metabolic 
enzymes like adenine phosphoribosyl transferase (APRT) and DHFR (Taylor et al., 1977; 
Urlaub et al., 1980). To prove the safety of CHO cells for use in the production of therapeutic 
proteins Weibe et al. demonstrated that of 44 human viruses tested 84% did not replicate in 
CHO cells. These included HIV, influenza, polio and measles. Since then, they have been 
used to produce many proteins industrially as summarised in Table 3.   
Table 3: Selected list of approved biologics produced in Chinese Hamster Ovary cell 
lines, modified from Jayapal et al., 2007 and Aggarwal et al., 2008. 
 
 
 
Table 3 illustrates that the proteins produced in CHO cells have aided the treatment of many 
diseases including cancer, haemophilia and asthma. This is because of the enormous 
adaptive nature of CHO cells. CHO cells are robust, easier to handle, and are usually higher 
Product Type Therapeutic use Manufacturer Year of approval 
Yervoy™ mAb Melanoma Bristol- Myers 2011 
Prolia© mAb Osteoporosis Amgen 2010 
Rituximab™ Humaniased IgG1  Lymphomas/ 
Leukemia  
Biogen 2009 
Vectibix™ Anti-EGFRmAb Metastatic 
colorectal cancer 
Amgen 2006 
Advate™ Factor VIII Hemophilia A Baxter 2003  
Xolair™ Anti-IgE mAb Moderate/ severe 
asthma  
Genetech 2003 
Aransep™ EPO Anemia Amgen 2001 
Activase ® Tissue plasminogen 
activator 
Acute myocardial 
infarction  
Genetech 1987 
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producers than NS0 and hybridoma cell lines (Davis et al., 2000). They are preferred because 
the products created from CHO cells show glycosylation patterns similar to those of human 
proteins and therefore generate reduced immunogenicity (Chadd et al., 2001). They have 
been adapted to grow in chemically-defined animal component-free media, and have been 
adapted to grow in suspension (Ye et al., 2009). Nearly 70% of all recombinant glycoproteins 
produced are made in CHO cells (Jayapal et al., 2007). All of the above drugs are produced in 
a similar fashion, via the introduction of the gene of interest into the desired host using 
recombinant DNA technology.  
2.2 Mammalian cell transfection methods 
Transfection is the process of introducing nucleic acids into eukaryotic cells by non-viral 
methods; these can be chemical, lipid or physical methods. There are two types of 
transfection strategies: stable and transient (Groskreutz & Schenborn, 1997). When rapid 
expression is required, e.g. for vector testing or short-term provision of product, then the 
transient method is used.  However, if it is desirable for the transfected gene to remain in 
the genome of the cell, as is the case for industrial bioprocesses of approved products, 
stable transfection methods are performed. A marker gene is co-transfected, which gives 
the cell a selectable advantage over cells which did not incorporate the gene of interest, for 
example resistance towards a certain toxin.  Some of the transfected cells will have 
integrated the foreign genetic material into their genome. Once the toxin is added to the 
cell culture, only those cells with the marker gene integrated into their genomes will be able 
to proliferate, while other cells will die. After applying this selection pressure, only the cells 
with a stable incorporation of the genetic material of interest remain viable and can be 
cultivated further. They then undergo cell line selection in terms of their cell growth 
characteristics and recombinant protein productivity.  
 
2.3 Miniaturised bioreactor systems 
Scaled-down cell culture methods are important for many reasons. There are economic 
advantages in being able to replicate laboratory-scale stirred tank bioreactors at a smaller 
scale. One can also conduct a large number of cultivations under controlled conditions as 
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well as gathering a vast amount of data in a small amount of time. Many authors have used 
mircotitre plates and added an optical sensor or measuring device to monitor the conditions 
within this small space. Girrard et al. (2001) added a simple pH dye in the growth medium 
and used a plate reader to measure oxygen concentrations over time. A more complex 
system was implemented by John et al. (2003), where oxygen sensors were coated on the 
bottom of the wells and again a plate reader was used to measure oxygen concentrations. 
Kensy et al. (2005) developed a new online monitoring technique using 24-well micro-titre 
plates. This was based on immobilised fluorophores at the bottom of the plate. The plate 
was fixed to a sensor dish reader, which was fixed to an orbital shaker. This allowed them to 
measure dissolved oxygen and pH in E.coli fermentation. This particular study did not 
compare the specific cell growth rates in their device to larger scales so it was not possible 
to test the usefulness of using this small scale as a comparative tool to large-scale 
bioreactors. However, a later paper showed that in this system bacterial and yeast biomass 
concentrations of up to 50 g/L dry cell weight could be linearly correlated to scattered light 
intensities (Kensy et al., 2005). The same authors also report in another study that scale-up 
from microtiter plates to stirred tank fermenters is possible for standard microbial 
expression systems with low viscosity (Kensy et al., 2009). The two previously mentioned 
studies used this BioLector™ with microbial and bacterial systems. The work described 
below is also useful to test the usefulness on this micro fermentation system with 
mammalian cells. The BioLector™ (m2p-labs) operates with 96- or 48-well plates with up to 
2 mL working volume and monitors the temperature, pH and dissolved oxygen tension, 
without offering a control system for any variables apart from CO2 and temperature for the 
entire plate. The BioLector™ can track fluorescent signals from each well, for example, from 
fluorescent proteins acting as sensors or reporters. 
A much more complex system called the SimCellTM platform was used by Amanullah et al. 
(2009). The SimCellTM system is an example of a novel parallel microbioreactor unit that is 
robotically operated. It was developed by BioProcesses Corp and is made up of micro-
bioreactor arrays with 6 gas-permeable microbioreactors each at a total volume of 500µL. It 
contains 5 incubators that can hold 43 micoarrays in total.  In their study, they presented 
the use of this device for fed-batch culture of CHO cells producing an IgG4 mAb. They 
measured dissolved oxygen (DO), pH, cell density, glucose control and temperature. DO was 
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measured with sensors, pH was measured with pH sensitive fluorophore, cell density was 
measure with optical density. They also showed that similar results were obtained when 
compared to a lab-bench top reactor and reported that the results were reproducible 
(Amanullah et al., 2009). 
The AmbrTM is a system that mimics mammalian cell cultures in bioreactors at microscale 
(10-15mL). It utilises disposable micro-bioreactors with an integrated impeller, gas sparging 
tube, sensors for pH and DO. The AmbrTM system has been used for CHO and NS0 cells. 
Unlike plate-based systems, the AmbrTM allows individual control of the environmental 
conditions as well as feeding and sampling.  This set up was used by Lewis et al. (2010), 
where they observed growth profiles for CHO cell lines that were cultured simultaneously in 
all 24 vessels under identical process conditions.  They compared data to literature and 
found that the cell lines in the 24 micro-bioreactors displayed comparable viability and 
antibody production. In a more recent paper by Hsu et al. (2012), a more comprehensive 
comparison was made. They simultaneously cultured 4 CHO cells lines in the AmbrTM 
system, 2L bioreactors and shake flasks. They compared the online controls (temperature, 
DO, pH) between the AmbrTM and 2L bioreactors, as well as culture performance in terms of 
cell growth and product quality across all scales. They concluded that the cultures in the 
shake flask do not perform as well as the AmbrTM or the 2L bioreactor (Hsu et al., 2012).  
Applikon have also developed a microwell plate system called MicroFlask©. The system 
consists of specialised plate covers and clamps that transform any micro-titre well plate (6, 
24 and 96 wells) into a miniature bioreactor. This system was used by Warr et al. (2011) to 
evaluate cell lines before scale up to shake flasks. 28 mAb-producing clones in hydrolysate-
containing media were compared with standard shake flask evaluation data. Their results 
show that the top 8 cell lines identified in a ‘Late’ screen were the same as the top 8 lines 
identified in shake flasks. But only 5 of the top 8 lines in the ‘Early’ screen were in the top 8 
lines in shake flasks. So whilst the results are comparable, there is therefore, a possibility of 
discarding a high producing line in early stage screening (Warr et al., 2011). 
Pall Life Sciences have also commercialised the Micro-24 microreactor system. The Pall 
Micro-24© has a working volume of 3-7 mL with 24 parallel microreactors and, again offers 
independent control of each reactor in terms of temperature, dissolved oxygen and pH. The 
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same company has recently released a new single use bioreactor system that has a unique 
agitation system. It allows control strategies for mammalian cells which are suspension 
adapted in the scale of 2-20 L. This uses the “Allegro 3-D biocontainer” which allows rocking 
in two planes (bi-axial). This new rocking method allows cultures to reach higher densities 
(http://www.biosciencetechnology.com/product-releases/2013/06/single-use-bioreactor-
system-enhances-cell-culture-performance#.UptdCCeGqXQ). It must also be stated that 
there are many more miniaturised bioreactor systems such as many microfluidic systems. 
However, it was of interest in this thesis to focus on the above sub-set as they are 
commercially available systems. 
2.4 Biosensors  
A biosensor is an integrated device consisting of a biological recognition component and a 
transducer capable of detecting the biological reaction and converting it into a signal that 
can be processed (Figure 4). These biological components can be enzymes, antibodies, 
receptors, whole cells or lipids (DeYoung et al., 1983). The transducers (a device or chemical 
substance that converts the input energy of one form to output energy in another form), on 
the other hand, can be chemical signals, mass, light or heat.  
There are a few characteristics that a biosensor must possess: first it should be highly 
specific for the purpose it has been chosen for, be stable under the conditions in which it 
will operate, show good stability in different scales of use and yield reproducible results. The 
biosensor should also have no interference with other biological processes happening within 
the target cell. An important factor is that most biosensors have a non-invasive nature.  
A suitable transducer has to exhibit certain properties. It must be conveniently excitable, 
without simultaneous excitation of the biological matrix, and detectable with common 
instrumentation. It must also be soluble in relevant buffers or cell culture media. A key 
factor is its stability under relevant conditions (Resch-Genger et al., 2008). Fluorescence 
techniques are very well suited to achieve these goals. Examples of transducers that are 
used as fluorophores include organic dyes, quantum dots (QDs) and proteins (Table 4 
compares their relative properties).  
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Figure 4: A schematic representation of the general principle of biosensors  
The biological components can be enzymes, antibodies or microbes. The 
transducers give rise to the observable event which can be in the form of light 
emissions, sounds or heat outputs (Nakamura et al., 2003). 
 
 
 
 
Organic dyes show a large degree of variability depending on which dye is used. The 
absorption and emission spectra, fluorescence quantum yield, and fluorescence lifetime of 
dyes often vary with environmental conditions. Another disadvantage is their poor 
photostability (Lenz et al., 2002). Quantum dots (QDs) have the potential to be used as 
useful tools for in vitro and in vivo imaging, but their large size (6-60nm) coupled with 
difficulties in producing biologically useful conjugates have hindered their widespread use in 
live cell imaging. This is because it is difficult for quantum dot conjugates to penetrate the 
cell membrane (Jamieson et al., 2007).  
Fluorescent proteins are genetically encoded markers that can be fused to virtually any 
target protein of interest. The original jellyfish green fluorescent protein (GFP) has been 
modified to produce many “enhanced” versions (Shaner et al., 2007). Variations of the 
original GFP have yielded high-performance blue, cyan, and yellow derivatives that are 
among the most popular markers in use. Additionally, new colour variants in the orange, 
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red, and far red spectral regions have been obtained from reef corals and related organisms. 
In this respect proteins hold a major advantage over the above methods, most importantly, 
their non-invasive nature is critical for use in living cells.  
 
Table 4: Comparison of the properties of organic dyes, quantum dots and 
proteins as transducers as adapted from Nann et al. (2008) 
Shows that proteins have no toxicity and have a high thermal stability, can also 
be genetically encoded.  
 
Property Organic dye Quantum dots Proteins 
Size ~0.5 nm 6–60 nm 1-25nm 
Toxicity Very low to high     (dye 
dependent) 
Heavy metal leakage must be 
prevented, 
potential toxicity 
None 
Thermal stability Dye dependent High  High 
Binding to 
biomolecules 
Via functional groups 
Often several dyes bind to a 
single bio-molecule ex vivo 
Via ligand chemistry 
Several bio-molecules bind to  
single quantum dots ex vivo 
Via traditional 
molecular biology 
techniques 
Genetically encoded No No Yes 
 
 
Many groups that have engineered fast maturing FPs include Evdokimov et al. (2006), 
Weidenmann et al. (2002), Shcherbo et al. (2007) and Fisher and Delisa (2008).  
Weidenmann et al. (2002) reports that the far red FP they tested not only had a five times 
faster maturation time than wild type FP, but it also displayed reduced oligomerisation.  
Shcherbo et al. (2007) implemented their far-red fast maturing FP, which is ten times faster 
than wild-type and shows high pH stability, to observe deep animal tissue imaging. 
Biosensors which use FPs have disadvantages, namely photobleaching and a short distance 
of measurement. The issue of photobleaching, which can restrict the use of FPs in long-term 
monitoring of cellular events, has been addressed with the use of a two photon microscope 
which decreases the donor photobleaching rate (Li et al., 2006). Also, some groups have 
actually exploited the photobleaching nature of FRET biosensors to establish a process 
called fluorescence lifetime imaging (FLIM), a quantitative imaging technique for measuring 
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dynamic processes in biological specimens (Spring et al., 2009). With the addition of a video 
camera, this method allows fluorescence intensity imaging in real time. 
Another challenge for FP-based biosensors is the resulting burden of producing a another 
recombinant protein, whilst maintaing a high growth rate as well as a high production rate 
of the protein product of interest. This burden has a direct effect on growth as the amount 
of energy available for growth is decreased as the foreign protein has its own energy 
demands and the host has its own need for growth energy as well as protein production 
energy.  This is called the metabolic burden and was first seen by Bentley et al, (1990), who 
observed “a linear decrease in growth rate with increasing foreign protein content”. The 
metabolic burden is defined as the amount of resources (raw material and energy), which 
are withdrawn from the host metabolism for maintenance and expression of the foreign 
DNA (Sørensen & Mortensen 2005). A few techniques can be used to reduce the metabolic 
burden, including lowering of the working temperature of the culture and different media 
formulations. During these techniques the transcription rates could be measured to see 
what effects these had on protein production (Sørensen & Mortensen 2005). 
2.4.1 Types of biosensor 
Biosensors are classified by the type of biological recognition component or transducers 
used. A biosensor might be described as a catalytic biosensor (Orellana et al., 2007) if its 
recognition element is an enzyme or whole cells derived from microorganisms. Another 
type of biosensor might be described as a ‘bioaffinity’ biosensor if the basis of its operation 
is a specific biological complex formation (Ikariyama et al., 1985). A third type of biosensor 
uses the reaction of an antibody with an antigen; this is called an immunosensor.  
The aim of this work is to monitor intracellular concentrations of metabolites within cells 
using biosensors. This requires a method that is fast, sensitive and reliable. Fluorescence 
techniques have been shown to be very efficient in this respect. Fluorescence methods 
include several unique experimental parameters (excitation and emission wavelength, 
intensity and fluorescence lifetime) and offer nanometer-scale resolution and possible 
sensitivity down to the single-molecule level (Resch-Genger et al., 2008). An example of a 
bio-affinity biosensor that uses florescence is called the Förster Resonance Energy Transfer 
(FRET) sensor, which is widely used to study molecular events from single cells to whole 
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organisms.  The metabolite FRET biosensors consist of two components: a pair of signalling 
fluorophores and a receptor that possesses a recognition capability (in this specific case this 
is the glucose or glutamine periplasmic binding protein – PBP, discussed later).   
2.4.2 FRET biosensors 
First discovered in 1948 by Theodor Förster (Förster et al., 1948), FRET is “a non-radiative 
transfer of energy from a photo-excited donor to an acceptor fluorescent molecule located 
in close proximity” (<100Å) (Li et al., 2006). This means the passing of energy (electron 
excitation) from a donor to an acceptor that is nearby.  In FRET biosensors, a biological 
event such as ligand cleavage or binding causes a conformational change in the sensor. This 
then induces a change in the proximity of the fluorophores, leading to a change in FRET 
efficiency measured by the change in the emission spectrum (Li et al., 2006). The rate of 
transfer (KT) is given by equation (1)    
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where τD is the fluorescence lifetime of the donor, R0 is the Förster radius, and r is the 
distance between the donor and acceptor fluorophores. The energy transfer efficiency E is 
defined by the ratio of transferred energy to the total of energy absorbed by the donor 
(equation 2).  
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       (2) 
where KD=1/τD is the rate at which photons are emitted by the donor, and the ki are the 
rates of all other pathways involved in the loss of energy by the donor.  Since the efficiency 
of energy transfer E from the donor to the acceptor is dependent on the inverse of the sixth 
power of the distance separating them, as shown in Equation 1 and 2, FRET is usually limited 
to distances less than about 10 nm (10-100Å) and thus provides a sensitive tool for 
investigating a variety of phenomena that produce changes in molecular proximity. FRET 
efficiency is affected by several factors; firstly, if using fluorescent proteins as FRET pairs 
they must share a close physical proximity (10-100Å). Secondly, there must be an overlap 
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between the donor emission and the acceptor excitation spectra (spectral overlap). Thirdly, 
the dipoles of these FRET pairs must be arranged in a linear fashion to allow more efficient 
energy transfer between the two fluorophores (Deuschle et al., 2005).  
 
 
Figure 5: The large spectral overlap between cyan and yellow fluorescent 
proteins. Berkeley.edu.com. 
2.4.3 How to measure FRET signal changes 
The most common way to measure FRET signal changes is the ratiometric method. This 
measures the change in emission intensities of the donor and acceptor fluorophores upon 
excitation of the donor. During FRET, the amount of emitted photons (emission intensity) 
from the donor fluorophore decreases and the emission intensity from the acceptor 
fluorophore increases as energy is transferred between the two. Kd is defined as the 
dissociation constant; this is a useful measurement to describe the strength of binding (or 
affinity) between receptors [R] their ligands [L].  
The formation of a ligand-protein complex [LC] can be described by a two-state process: 
                                                                                             (3) 
the corresponding dissociation constant  is defined the following equation:  
                                                                               
       
    
                                                        (4)
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Where [R], [L] and [LC] represent the concentrations of the receptor (protein), ligand and 
ligand complex. 
The dissociation constant has units of concentration and its value corresponds to the 
concentration of ligand [L] at which the binding site on a particular protein is half occupied. 
This means the concentration of ligand, at which the concentration of receptor (protein) 
with ligand bound [C], equals the concentration of protein with no ligand bound [R]. The 
smaller the dissociation constant, the more tightly bound the ligand is, or the higher the 
affinity between ligand and receptor (protein). The two glucose FRET biosensors under 
investigation in this study have Kd values of 3200µM (FLIPglu-3200µ-Delta13) and 600μM 
(FLIPglu-600µ-Delta11aphrodite) for glucose, while the glutamine biosensor (D157N) has a 
Kd value of 7.2mM for glutamine. Another important factor to consider when measuring 
FRET signal ratios is the linear range of measurement. This is the range of metabolite 
concentration (i.e. glucose or glutamine) where the FRET signal intensity is directly 
proportional to the amount of metabolite, i.e. the fluorescence readings have one-to-one 
correspondence to metabolite concentrations. This allows the user to calibrate the sensor 
and then use the calibration curve to translate a fluorescence reading into the 
corresponding metabolite concentration.  
2.4.4 Fluorescent proteins as fluorophores in FRET experiments  
When selecting which FP variants to use as FRET pairs there are a few considerations to 
reflect on. The FPs should express efficiently and without toxicity in the chosen system and 
should be bright enough to provide sufficient signal above auto-fluorescence to be reliably 
detected. In addition, the FPs should be insensitive to environmental effects that could bias 
experimental results such as pH, temperature, fluorescence lifetime and quantum yield (see 
below in enhanced variants). Moreover, the FP should have high photostability to be 
visualised for the duration of the experiment. To obtain a FRET signal at least two 
fluorophores must be used. Table 5 highlights the properties of some of the fluorescent 
proteins used for FRET. The first FP pair designed for FRET analysis was an enhanced blue 
variant (EBFP) combined with EGFP. This however had the problem of potential phototoxity 
at the excitation peak of the EBFP (Heim and Tsien, 1996), because the excitation 
wavelength falls in the ultraviolet range.  
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Table 5: The various properties of fluorescent proteins used in FRET 
investigations.  
The brightness is the product of the molar coefficient and the quantum yield, 
the photostability rate is the time taken to bleach from an emission rate of 
1000 photons per second to 500 photons per second in a fluorescence 
microscope. 
 
Protein Colour of 
spectral 
class 
Excitation 
peak  
(nm) 
Emission 
peak (nm) 
Brightness Photo- 
stability 
Reference 
ECFP Cyan 433/445 475/503 13 64 Zacharias et al., 2002 
mCerulean Cyan 433/445 475/503 27/24 36 Rizzo et al., 2004 
EYFP Yellow 514 527 51 60 Veening et al. 2004 
mVenus Yellow 515 528 53 15 Nagai et al., 2002 
mCitrine Yellow 516 529 59 49 Wang et al., 2008 
tdTomato Orange 554 581 95 98 Niino et al., 2009 
mCherry Red 587 610 17 96 Albertazzi et al., 2008 
mKate Far-red 588 635 15 166 Markwardt et al., 2011 
 
There are many positive points in using FPs for FRET biosensor pairs. Firstly, they can be 
made simply via genetic manipulation. The DNA encoding the biosensor can be inserted into 
cells via stable or transient transfections and the cell induced to synthesise the biosensor 
protein. It is also easy to track multiple target proteins in vivo and in real time with this non-
invasive method (Wang et al., 2008).  
Table 6 highlights certain potential disadvantages: when cellular proteins are labelled with 
FPs it is important that their large size does not hinder the normal cellular functions (Day 
and Schaufele, 2008). FPs also use a rate-limiting maturation step to gain fluorescence; if 
this is a long process it will decrease the intensity and hence usefulness of the FP. This issue 
has been addressed by many investigators. For example, Bevis and Glick (2002) used 
random and directed mutagenesis to create FP variants that mature ten-fifteen times faster 
than the wild-type protein and therefore the time taken to gain florescence is much less.  
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Table 6: Advantages and disadvantages of using protein fluorophores for 
FRET biosensors, adapted from Piston and Kremers (2007), Truong et al. 
(2001), and Azpiazu and Guatam, (2004). 
This table shows that FP can be easily made, delivered into cells and can be 
targeted to tissues or organelles.  
 
Advantages Disadvantages 
Can be made via simple genetic manipulations FPs gain fluorescence through a rate limiting step 
(fluorophore maturation) could be up to 12 hours 
Can be delivered into cells by transient transfection or 
stable transfection with subsequent expression 
FPs are susceptible to photobleaching 
Can be targeted to organelles and tissues (allows imaging 
from single cells to organisms) by using proteins as 
fluorophores 
FRET is affected by distance, the FRET pairs must 
be close enough to achieve an efficient signal 
(~100Å) 
 
The most effective FP FRET pair that meets the above criteria remains a high-performance 
ECFP as the donor coupled to a high-performance EYFP or its derivatives such as citrine, 
Venus or Aphrodite as the acceptor (Van der krogt et al., 2008; Day and Schaufele 2008). 
This pair is so efficient because ECFP has a high extinction coefficient, quantum yield and 
photostability (Miyawaki et al., 1997). Other pairs have been used that include GFP or 
yellow fluorescent protein (YFP) as the donor coupled with orange or red derivatives such as 
kusabira orange (Karasawa et al., 2003) or mCherry (Shaner et al., 2004) as the acceptor. 
However, even though these FPs have better qualities on their own, the most popular FRET 
pair remains ECFP/mCerulean as the donor and EYFP as the acceptor (Van der krogt et al., 
2008).   
Another important FP that has been engineered is mAmetrine, which has favourable 
spectral shift properties when paired with tdTomato (Ai et al., 2008). This gives this pair an 
important property, in that they can be used simultaneously with a Teal Fluorescent Protein 
(mTFP1) coupled to a high-performance enhanced yellow FP (EYFP). Improvements have 
been made to ECFP. For example, Rizzo et al. (2004) used a site-directed mutagenesis 
approach design a new variant (mCerulean). They report that this FP has a greatly improved 
quantum yield and a higher fluorescence lifetime. mCerulean is two and half times brighter 
than ECFP and exhibits a greatly improved signal-to-noise ratio (Rizzo et al., 2004). Kremers 
et al. (2006) implemented a similar method to produce another variant called SCFP3A.   
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Several YFP variants have also been produced: Griesbeck et al. (2001) used an expression 
screen in E. coli and identified an improved mutant of YFP (mCitrine), which has twice the 
photostability of previous YFPs at 37°C (Griesbeck et al., 2001). Another example of an 
improved YFP variant is mVenus (Nagai et al., 2002). YFPs are relatively acid-sensitive and so 
Nagai et al. (2002) engineered mVenus, which is relatively tolerant of high acidic (pH 3-7) 
conditions . Deuschle et al. (2005) also engineered a variant of mVenus and ECFP containing 
different codons called Aphrodite.  
2.4.5 FRET applications 
The following section will examine the different types of FRET biosensor designs that have 
been reported and the applications associated with each. There are four common design 
strategies used, these include: intermolecular FRET biosensors, intramolecular FRET 
biosensor, cleavage biosensors and FRET biosensor using multiple FPs. Table 7 summarises a 
few applications for these four design methods. 
Table 7:  Applications of the four different FRET designs. 
Showing the various applications used for the four main design strategies.  
 
The intermolecular FRET design is used to study interactions between proteins. Biosensors 
are created by fusing the donor and acceptor FP separately to the interacting proteins of 
interest as illustrated by Figure 6. When the intermolecular interaction of these separate 
fusion proteins occurs (ligand binding to its sensory domain), the donor and acceptor are 
brought closer and this causes a FRET signal to be observed.  
FRET design strategy  Application Examples 
Intermolecular FRET biosensor Protein-protein interactions Hodgson et al., 2010 
Azpiazu & Guatam 2004 
Intramolecular FRET biosensor Protein conformational changes Komatsu et al., 2011                 
Allen et al., 2008  
Cleavage biosensor Protein catalytic functions 
(proteolysis, phosphorylation) 
Chiang & Truong 2005           
Onuki et al., 2002 
FRET biosensor using multiple FPs Signaling molecules, cellular events 
and nucleic acids 
Pilic & Schultz 2008  
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Llopis et al. (2000) demonstrated the intermolecular ligand-dependent FRET which existed 
in HeLa cells,  using ECFP tagged to the retinoic acid receptor (RAR) and EYFP tagged to the 
nuclear receptor interaction domains of the co-activators steroid receptor coactivator-1 
(SRC-1).  Their results indicate that based on FRET signals the RAR nuclear receptor activates 
transcription by binding to SRC-1. Other examples include the investigation by Azpiazu et al. 
(2004) that demonstrate G-protein coupled receptors (GPCRs) bind to G-proteins (table 7). 
They tagged Gα with CFP and Gβγ with YFP. When Gα-CFP and Gβγ-YFP were bound 
together a FRET signal was generated and when they separated the FRET signal 
disappeared.   
 
 
Figure 6: A schematic representation of an intermolecular FRET biosensor design 
One FP is attached to the sensory domain and the other on the substrate. When 
there is no binding of the substrate and the sensory domain there is no FRET. When 
binding occurs he FPs are bought close enough tighter for a FRET signal to be seen. 
 
The cleavage FRET biosensor design is implemented to study protease activity as 
demonstrated in Figure 7.  A linker region with a potential protease recognition site is, 
attached to a FRET pair, yielding a FRET signal when the fusion protein is produced. 
However, when a protease cleaves the biosensor irreversibly, the FRET signal is disrupted (Li 
et al., 2006). This type of biosensor is a popular indicator of protein cleavage and is used in 
apoptosis experiments (e.g. Xu et al., 1998; Onuki et al., 2002).  Xu et al. (1998) used this 
method to observe caspase-3 (CPP32) cleavage via activation by tumor necrosis factor 
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(TNF). CPP32 is an important cellular protease which is cleaved during programmed cell 
death. Using FRET to monitor this process is suggested to have greatly improved the study 
of apoptosis in live cells (Xu et al., 1998). 
      
Figure 7: a) A schematic representation of a cleavage FRET biosensor design. 
b) The reverse mechanism for the cleavage FRET biosensor design 
When the recognition site is unbound there is a FRET signal, when the ligand or 
substrate cleaves the binding site the FPs are pushed apart and no FRET is 
seen. The reverse is also true.  
 
An intramolecular FRET design is used to study the conformational changes that occur 
during protein-ligand interactions. When proteins undergo conformational changes it is 
usually a result of biochemical stimulation (Li et al., 2006). This can be a change in 
temperature, pH or a ligand binding to its substrate.  As Figure 8 shows, when the ligand is 
not bound to its substrate no FRET signal is observed. When the ligand binds, however, the 
two fluorophores are brought close enough together and a FRET signal is visualised. This can 
also work in reverse, with the disruption of two close fluorophores leading to disappearance 
of FRET (7b).  
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Many groups have used intramolecular FRET design in biosensors. Miyawaki et al. (1997) 
used intramolecular FRET biosensors to create novel Ca2+ indicators named cameleons (via 
tandem fusion of CFP to CaM, M13 peptide to YFP). They demonstrated that when there is 
an increase in Ca2+ concentration, the CaM component of the cameleons bind Ca2+ and wrap 
around the fused M13 peptide. This conformational change results in a decrease in the 
distance between the two GFP mutants and this corresponded with an increase in the FRET 
signal. This type of biosensor has also been used in a metabolite biosensing, which will be 
discussed in further detail in Section 2.3.6. 
 
 
Figure 8: A schematic representation of an intramolecular FRET biosensor 
design 
The two FPs are on opposite sides of the same structure. When unbound the 
two lobes are far apart no FRET will occur. When bound the two lobes will 
undergo a conformational change so the FPs are bought into a close vicinity 
and then a FRET signal is seen.  
 
Multiple FRET pairs can be used to image two molecular events using multiple FPs. This is 
usually done in the form of a triplet design of ECFP-EYFP-ERFP (Figure 9). Three different 
FRET signals are distinguished: ECFP to EYFP, ECFP to ERFP and EYFP to ERFP. Galperin et al. 
(2004) used this method to analyse multi-protein interactions in living cells. They developed 
a fluorescence microscopy method called three-chromophore fluorescence resonance 
energy transfer (3-FRET). Their 3-FRET method is capable of measuring FRET signals within a 
system of three donor-acceptor pairs, such as CFP-YFP, CFP-mRFP and YFP-mRFP in vitro and 
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in vivo.  A similar method was used by He et al. (2005) who employed a triplet FRET pairing 
system: CFP→ YFP→ mRFP. This was achieved because their group generated a monomeric 
mutant of dsRed called: monomeric RFP, it was important because the excitation and 
emission maxima of mRFP occur at 584 nm (from 520 to 630 nm) and 607 nm (from 580 to 
700 nm), respectively. So as a result mRFP is a good FRET acceptor for YFP-derived energy, 
but only minimally for energy from CFP (He et al., 2005). Therefore using mRFP as a final 
FRET acceptor it is possible that CFP→YFP →mRFP linked FRET could be employed to detect 
physical interactions between proteins that form trimers in living cells (He et al., 2005).  
 
 
Figure 9: A schematic representation of a biosensor design for FRET using 
multiple FPs. 
Here three FRET ratios are seen. ECFP to EYFP, ECFP to ERFP and EYFP to 
ERFP 
 
2.4.6 Metabolite biosensors  
Bacterial periplasmic binding proteins (PBPs) are located between the inner and outer 
membranes of gram-negative bacteria (Quiocho and Ledvina, 1996). They have been used 
as the detection element in genetically-encoded metabolite sensors, in which they are fused 
linearly to protein fluorophores (Fehr et al., 2005; Hou et al.,2011). PBPs bind a variety of 
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molecules, including carbohydrates, amino acids, peptides and vitamins, and mediate their 
transport into the cells. In addition, they initiate chemotaxis by activating flagellar motion. 
Also, PBPs may serve as chaperones for the refolding of denatured proteins (Richarme and 
Caldas., 1997).  
An exceptional feature of the PBP structure is two large polypeptide lobes connected via 
flexible tethers. When ligand binding occurs, a large conformational change is induced so 
that the two lobes fold together (Oh et al., 1993). This property lends itself perfectly for the 
application of intramolecular FRET biosensors where conformation change and distance 
orientation leads to an observable change in emission. The first FRET biosensor was based 
on CFP and YFP attached to the E.coli periplasmic maltose binding protein (MBP). Using site-
directed mutagenesis amino acids involved in maltose binding were changed producing 
FLIPmal-25µM, a fluorescent indicator protein for maltose with a Kd of 25µM (Fehr et al., 
2002). FRET biosensors based on PBPs are a very valuable tool and have been used to detect 
sugars (Deuschle et al., 2005; Fehr et al., 2002,2003; Lager et al., 2003), and amino acids 
(Okumoto et al., 2005 and Yang et al., 2010). In 2011, Hou et al. described a protocol for 
monitoring glucose levels in the cytosol of mammalian cell cultured through the use of FRET 
glucose sensors (Hou et al., 2011). Specifically, they targeted FRET sensors to specific 
organelles and compartments in the cytosol, in particular the nuclei and the ER lumen. ER 
targeting was done by flanking the biosensor with a KDEL ER retention signal (Takanaga et 
al., 2008). Nuclear targeting was done with the SV40 large T antigen. A recent review 
suggested that FRET technology in transgenic animals will become a key tool to study 
glucose flux (Hou et al., 2011). These biosensors have also been used to identify the glucose 
transporters present in carbon- starved yeast cells and new transporters in plants (Bermejo 
and Haerizadeh 2010). 
2.4.6.1 Glucose biosensor 
The majority of the FRET-based glucose biosensors use the periplasmic glucose/galactose-
binding protein (GGBP) from E. coli for glucose sensing. GGBP is a type I PBP and is involved 
in chemotaxis towards glucose and galactose in many bacteria, so GGBP is able to detect 
both glucose and galactose, but its affinity for glucose is approximately two times higher 
compared to that for galactose (Frommer et al., 2005).  In 2003, a study by Fehr et al. used 
FRET biosensors for glucose to determine cytosolic glucose levels in COS-7 cells. This group 
  49 
used a glucose/galactose periplasmic binding protein (GGBP), which was flanked with GFP 
variants by attaching a CFP and a  YFP via six amino acid linkers at the N and C termini (as 
shown in Figure 10). This gave them a fluorescent indicator protein for glucose with a Kd of 
170nM (FLIPglu-170n) (Fehr et al., 2003). FLIPglu-170n measures intracellular glucose 
concentrations between 0.02 to 1.5µM, this biosensor also has a higher affinity for galactose 
than glucose (Fehr et al., 2003).From this biosensor an affinity mutant with a Kd of 600μM 
was generated, which showed lower substrate specificity. This allowed specific monitoring 
of reversible glucose dynamics in COS-7 cells in the physiological range. This mutant was 
engineered by a mutation of phenylalanine-16 of GGBP into alanine and has a range for 
glucose quantification between 0.07mM and 5.3mM. A further advantage was that a higher 
maximum ratio change of 0.29 in FLIPglu-600µ-Delta11aphrodite was obtained which 
allowed more sensitive measurements than FLIPglu-170nM (Fehr et al., 2003). This 
biosensor had a lower affinity for glucose. 
 
Figure 10:  Domain structure of the FLIP cassette used for construction of the 
biosensors  
Different PBPs were flanked by short linker sequences (green) and fused 
between ECFP and EYFP (Deuschle et al., 2005). 
 
In 2003 Ye and Schultz used a FRET-based system in which a fusion protein was constructed 
by fusing two fluorescent proteins to E. coli glucose-binding protein, one to each end—
green fluorescent protein at the C terminus of the donor and yellow fluorescent protein at 
the N terminus which is the acceptor. Due to the nature of the conformational change of 
substrate binding a decrease in FRET was observed (Ye & Schultz, 2003). Their sensor has a 
range on the order of 10 μM of glucose. Fehr et al., 2005 used a glucose biosensor called 
FLIPglu-600μER to analyse ER glucose transport as well as metabolism in the ER of intact 
human hepatoma cells (Fehr et al., 2005). Their study used another biosensor called FLIPglu-
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600μ to measure changes of steady state glucose levels in the cytosol. The two results 
were compared and it was reported that glucose accumulation in the ER was the same as 
that of the cytosol and hence the ER membrane contains a high amount of glucose transport 
systems. This biosensor had an affinity for glucose of 590 μM (Fehr et al., 2005).  
 
Deuschle et al. (2005) generated many mutant biosensors including: FLIPglu-600µ-
Delta11aphrodite, FLIPglu-3200µ-Delta13 and FLIPglu-170nM) to measure glucose changes 
over a wide range of concentrations in epidermal cells and intact roots of the plant 
Arabidopsis. These mutants enabled a wide range of glucose measurements (nM to mM). 
They also generated these mutants to serve as internal controls based on a linear range of 
measurements. In assays, very high or very low affinity mutants (mutants that bind at very 
high concentrations or very low concentrations) are not expected to respond to glucose as 
they will either always be saturated or never reach the necessary concentrations to be 
detected (Deuschle et al., 2005).  The linker regions were truncated to decrease the 
rotational averaging and increase the allosteric coupling. They began to delete regions from 
the N and C terminus, Deletions of up to 20 amino acids did not influence sensor properties. 
Of the 13 biosensors they tested, six showed an increased response, with the best (FLIPglu-
600µ-Delta11aphrodite, 31-amino-acid truncation; Δratio=−0.7 *28% decrease+) showing a 
threefold improvement relative to the original terminally fused sensor (FLIPglu-600μ, Δ 
ratio=−0.25 *8% decrease+ (Deuschle et al., 2005). This same protein was used in 2008, the 
molecular nature of glucose accumulation and elimination in Arabidopsis roots tips was 
addressed (Chaudhuri et al., 2008). This glucose biosensor measured a range of 2µM to 
3.2mM for plant tips.  
Continuous glucose monitoring has been achieved using FRET biosensors by Veetil et al., 
2010. Their glucose biosensor was called AcGFP1-GBPcys-mCherry.  It uses a green-red FRET 
pair and responds to glucose in a micromole range (25 to 800 μM) (Veetil et al., 2010). Hsieh 
et al., 2012 reported work on a glucose biosensor that shows affinity within the human 
physiological glucose range (1-30mM). In their method two cysteines were introduced in the 
GGBP, then when glucose binds one of these becomes inaccessible. They measured the 
binding with FRET. This ligand protection strategy provides a simple method for labelling 
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GGBP (the same GGBP motif is used for all these glucose biosensors) with two different 
fluorophores to construct FRET-based glucose sensors with glucose affinity within the 
human physiological glucose range (1-30 mM) (Hsieh et al., 2012). 
 
2.4.6.2 Glutamine biosensor 
A similar method was used to construct a fluorescent indicator protein for glutamine where 
the glutamine binding protein (QBP) from E.coli was fused to two variants of GFP. The QBP 
sequence was split in two halves, and citrine (enhanced yellow fluorescent protein - EYFP) 
was inserted between amino acid 98 and 99 of QBP. The QBP-ECFP linker was shortened by 
the terminal 3 codons of QBP (ECFP on the N-terminus and YFP on the C-terminus (Yang et 
al., 2010).  In 2007 this construct was used to test the flux of arginine into plant cells 
(Bogner and Ludewig, 2007). The biosensor was modified by mutations in the ligand-binding 
pocket in order to enable its use for monitoring glutamine flux.  These mutations were 
based on previous work on glutamate receptors, which resemble the binding domain of 
QBP.  Specifically, an aspartate amino acid was exchanged with an asparagine (D157N) 
residue, which allowed a biosensor to be constructed that responded to millimolar 
glutamine concentration. D157N has a Kd of ~6mM. Yang et al. (2010) used this biosensor to 
monitor glutamine flux in plant root tips. In the same paper another glutamine biosensor 
was developed called T70A with a Kd of 18.8mM. However this glutamine biosensor had a 
threefold lower affinity than D157N.  
 
Gruenwald et al. (2012) reported on an array of improved FRET-based glutamine sensors 
based on the E.coli glutamine binding protein, glnH. Their sensors utilised a recently 
reported FRET pair, monomeric Teal Fluorescent Protein (mTFP)1 and Venus. Their design 
mechanism meant that the mTFP1 and Venus are located in the same lobe, the 
conformational change in the glnH domain is unlikely to induce a significant change in the 
distance between the two FPs (they are very close). When glutamine binds a conformational 
change is seen in the second lobe, opening up a larger space in the vicinity of C-terminus 
where the Venus molecule is fused, so the binding pocket is opened here and this is where 
the glutamine can bind. This larger binding pocket increased the FRET efficieny where one 
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molecule of glutamine can bind to cause FRET. They conclude that with this new glutamine 
biosensor they were able to demonstrate that the glutamine uptake and efflux can be 
monitored within a range of 1-22mM (Gruenwald et al., 2012).   
 
2.4 Conclusion 
A discussion of the various expression systems has been set out in the beginning of this 
chapter. For therapeutic proteins to be produced in a manner that causes no immunogenic 
responses in the body an expression system is suggested for proteins requiring mammalian 
post-translational modifications. For this purpose CHO cells are used as the expression 
system in this work, as they provide human like glycosylation patterns on therapeutic 
proteins produced using this expression system. It is also noted that CHO cells are used for 
the production of 70% of glycoproteins (Li et al., 2010) produced in industry and therefore 
this cell line is highly industrially relevant.  
Current methods for cell line selection are time consuming and labour intensive. Small scale 
high throughput systems offer fast screening of large numbers of cells but many do not 
allow online measurements for important metabolites. To be able to obtain information on 
the health and suitability of cells to pass on to the next stage it is suggested that FRET 
biosensors are used. These are genetically encoded, non- invasive and will allow online in 
situ measurements for glucose and glutamine to be taken. This thesis will also look at a 
small-scale culture system called the BioLector™ to assess its usefulness as a tool for 
automated cell line selection.  
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Chapter 3. Materials and Methods 
This chapter describes the experimental materials and methods used in this work. It 
includes information on the design, production and in vitro testing of the glucose and 
glutamine biosensors. It continues with details on the mammalian cell culture system, the 
transfection of the DNA vectors encoding for the FRET biosensors into the host cell line, and 
the in vivo calibration of the sensors. This section concludes with the description of the 
methodology for two studies. The first is the comparison of commercially available 
specialised feeds for CHO cell culture. The second is the transfection of two single chain 
antibody products into the cell lines already expressing for the biosensors, and the 
evaluation of the metabolic and protein-producing characteristics of the resulting cell lines.  
It must also be stated that, in vivo means in living cells whilst in vitro refers to experiments 
on cellular components outside of living cells (e.g. purified proteins).  
3.1 FRET biosensors 
3.1.1 Biosensor construction 
Two glucose FRET biosensors were selected for initial testing based on literature data 
(Deuschle et al., 2005), pRSET- FLIPglu-600µ-Delta11aphrodite (Addgene number 13569), 
and FLIPglu-3200µ-Delta13 (Addgene number 13560). The sensors in the E coli expression 
plasmid pRSETb were kindly supplied by Professor Wolf Frommer and transformed into 
competent E. coli BL21Gold cells (Agilent). FLIPglu-600µ-Delta11aphrodite is a fusion of 
ECFP and EYFP (Aphrodite) to the E.coli glucose/galactose periplasmic binding protein 
(GGBP).   
 
The glucose FRET sensor plasmids were chemically transformed directly into competent E 
coli BL21 (DE3) Gold cells (Agilent) for protein production following the manufacturer’s 
instructions. The cells were plated on selective medium (LB agar plus 50 g/mL ampicillin) 
and incubated overnight at 37oC.  A single colony was used to inoculate a 10 mL culture 
from which plasmid DNA was extracted using the Qiagen Spinprep Miniprep kit (Qiagen). 
The gene encoding for the FLIPglu-600µ-Delta11aphrodite biosensor was PCR amplified 
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from the original vector and cloned into the pCDNA4/TO vector (Invitrogen) using the 
primers in Appendix A and the EcoRI and PstI restriction sites (Figure 11). 
 
 
                
 
 
plasmid pRSET-
FLIPglu600mΔ11Aphrodite (kindly 
supplied by Professor Wolf Frommer at 
the Carnegie Institution for Science, 
Stanford University) 
Vector chemically transformed 
into BL21(DE3) Gold E.coli cells 
PCR amplified from original 
This was digested and ligated into the 
mammalian vector using enzymes 
EcoRI, Pstl 
 
                            
ECFP GGBP YCFP 
 
Figure 11: A diagrammatic representation of the molecular biology steps 
taken for the construction of the glucose biosensor. 
 
The glutamine FRET construct in the pUTKan plant expression vector was kindly supplied by 
Dr Uwe Ludewig at the Hohenheim University. This construct was based on previous work in 
which a cassette of the glutamine binding protein (QBP) sequence, citrine, a mutant version 
of the enhanced yellow fluorescent protein (EYFP, Clontech) and the enhanced cyan 
fluorescent protein (ECFP) (Clontech) were fused. In this construct, the QBP sequence was 
split in two halves, and citrine was inserted between amino acid 98 and 99 of QBP (Yang et 
al., 2010). The QBP-ECFP linker was shortened by the terminal 3 codons of QBP (amino acids 
TEP), and the neighbouring glycine was exchanged to arginine, to reduce the flexibility of 
the linker. The amino acid substitution D157N has been made to the QBP to increase affinity 
for glutamine and several mutations have been incorporated to improve FRET efficiency. 
The plasmid was digested with BamHI and SalI to release the insert, which was subsequently 
ligated into the corresponding restriction sites in the vector pET41a in frame with the N-
terminal purification tags.  This vector was then transformed into chemically competent 
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BL21(DE3) Gold E.coli cells (Agilent) for protein expression. In order to create the 
mammalian expression plasmid, the insert was ligated into a pcDNA4 / TO vector cassette 
that had been prepared by digestion with BamHI and Xhol (SalI and XhoI create compatible 
overhanging ends) (Figure 12).  
 
 
 
                
 
 
pUTKan plant expression vector was 
digested with Bam HI and Sall to 
release insert 
Cloned into pET41 using same 
enzymes 
This was digested and ligated into the 
mammalian vector using enzymes 
BamHI and XhoI 
 
                           
Vector chemically transformed 
into BL21(DE3) Gold E.coli cells 
 
Figure 12: A diagrammatic representation of the molecular biology steps 
taken for the construction of the glutamine biosensor. 
 
 
3.1.2 Production of biosensors in E.coli 
As mentioned above the FRET sensor proteins were expressed in BL21 Gold E.coli cells 
(Agilent). A single colony of freshly transformed cells was inoculated into 500 mL of LB broth 
plus 50 µg/mL of ampicillin (for the glucose biosensor) or 30 µg/mL of Kanamycin (for the 
glutamine biosensor) in a 2 L plastic baffled flask (Nalgene) under sterile conditions. The 
cultures were incubated at room temperature in a Thermo Scientific MaxQ horizontal 
shaking cabinet at a speed of 225 rpm.  For producing the glucose biosensor cells were 
incubated for 2-3 days in the absence of inducer (protein production relied on the basal 
expression of the leaky T7 promoter).  For the glutamine biosensor cells were incubated for 
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1 day to allow biomass accumulation and then induced by the addition of Isopropyl β-D-1-
thiogalactopyranoside (IPTG) to a final concentration of 1 mM.  Cells were incubated an 
additional 2 days to allow protein production. 
 
The following steps are the same for both glucose and glutamine biosensors. The cells were 
harvested by centrifugation for 15 minutes at 4800g at 4oC in an Eppendorf 5810R 
centrifuge. The pellet was re-suspended in 5 mL ice cold lysis buffer (20mM Tris-Cl, pH 8.0) 
and transferred to a 50 mL Falcon tube. The cells were lysed by sonication using a Sonics 
VibraCellTM sonicator (5-6 times at a pulse of 15 seconds on, 15 seconds off for 3 minutes 
and an amplitude of 40%). Samples were centrifuged for 1 hour at 4800g to remove cell 
debris. The lysate was decanted into a fresh 50 mL Falcon tube and 1mL Ni-NTA (Qiagen) 
was added.  The protein and resin were incubated for 1.5 hours at 4°C with agitation at 60 
rpm in order to facilitate the binding of the histidine tag to the resin.  The mixture was 
decanted into a disposable plastic polyprep column (Qiagen) and the flow through was 
collected.  The column was washed with 10 mL ice-cold wash buffer (20 mM Tris-CL, pH 8.0, 
10 mM imidazole) twice at 4°C. The protein was then eluted with 5 x 1 mL additions of ice-
cold elution buffer (20 mM Tris-CL, pH 8.0, 500 mM Imidazole). To obtain the highest 
concentration of protein, eluate was collected in 5 separate fractions.  Each was assayed for 
protein concentration using absorbance at 280 nm (Nano-drop™, ThermoScientific).  
 
For the glucose biosensor, the three most concentrated fractions from the elution were 
combined and injected into a Slide-a-Lyzer® dialysis cassette (Membrane Molecular weight 
cut-off 20,000 Da) and dialyzed against 50 mM sodium phosphate buffer pH 7.0 (to remove 
the imidazole) overnight in the cold room in the dark in order to facilitate buffer exchange.  
When subjected to a similar dialysis, the glutamine biosensor precipitated, so this step was 
omitted and purified protein was directly stored at 4°C for further use. 
3.1.3 Fluorescence measurements and FRET ratio calculations  
The fluorescence measurements in this study were made either in a Tecan™ Infinite 200Pro 
fluorescence plate reader, a SpectraMax Gemini XS fluorescence plate reader (Molecular 
Devices) or the BioLector™. For the Tecan™ the excitation wavelength of 430nm ±35 was 
used while emission wavelengths of 465nm ±35 for the blue and 520nm ±10 for the yellow 
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wavelength were used. The Spectramax Gemini had an emission at 460nm ±10 (CFP) and at 
538nm ±25 (YFP) upon excitation at 444nm ±35. The FRET measurements taken in the 
BioLector™ were with the blue filter which has an excitation of 420nm ±10 and an emission 
of 470nm ±35. This excitation of 420nm ±30 was used to get a positive or negative FRET 
signal via the absence or presence of a yellow (532nm ±10) emission. The ratios were 
calculated as the fluorescent intensity of the yellow filter divided by the fluorescent 
intensity of the blue filter (both in arbitrary units).  
3.1.4 Titration curves 
Titration was carried out in the Spectramax Gemini. The protein was used as stock 
concentration (0.5mg/mL) and titrated with various glucose (from 1 mM to 1 M) or 
glutamine (1-50 mM) standards prepared in 50mM sodium phosphate buffer, pH 7.0. A 
single wavelength was first used to set the gain (444 nm excitation and 460 nm emission). 
Measurements were then repeated at both emission wavelengths. Using the change in ratio 
upon ligand binding, the Kd of the FLIPglu biosensors and the glutamine biosensor was 
determined by fitting ligand titration curves to a single-site binding isotherm using equation 
(5). Triplicate measurements from 5 separate protein preparations were taken for each 
biosensor. 
 
                                 
      
         
 
    
    
 
    
      
                                                (5) 
Where, [S]: Substrate concentration [S]b: concentration of bound substrate, N: the number of 
binding sites, [P]t: total concentration of binding protein, r: ratio, rmin: minimum ratio in the 
absence of ligand and rmax: maximum ratio at saturation. This was adapted from Fehr et al. (2003). 
3.1.5 Protein temperature and standards stability tests 
FLIPglu-600µ-Delta11aphrodite and the glutamine biosensor (DI57N) were purified using the 
protein purification steps previously described with one exception. After an overnight 
incubation in the cold room, the proteins were subjected to three different temperatures: 
4oC, room temperature (~25°C) and 37oC. Daily samples were removed and FRET 
measurements taken as described in the preceding section.  
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3.1.6 Glucose-6-Phosphate binding and amino acid interference tests 
To test the specificity of the glucose biosensor, the binding efficiency for glucose in the 
presence of glucose-6-phosphate (G6P) was tested. For these experiments, the glucose 
biosensor was purified as described above and titrated against standards of different 
concentrations of glucose, glucose-6-phosphate, and the two compounds together.  
Fluorescence measurements and FRET ratio calculations were performed as described 
above. The specificity of the glutamine biosensor was assessed in the presence of other 
amino acids using purified protein and 1 mM glutamine supplemented with the maximum 
intracellular concentrations of each of the other amino acids, as reported in other studies 
(Hansen and Emborg 1994) reached at any point during batch cell culture. For cysteine,  
unpublished data from Kontoravdi et al was used as a reference. Fluorescence 
measurements and FRET ratio calculations were performed as described above.   
3.1.7 Nano-drop™ measurement method 
Firstly a blank measurement was made, this blanking was done with either DI water or the 
solution in which the sample to be tested was in.After blanking, a 2µl sample was placed on 
the pedestal. The pedestal was lowered and the Nano-drop™ was used to obtain readings. 
Xenon light which measures absorbance at 260 nm for DNA and at 280 nm for protein 
provided the light source for this spectrometer.  
3.2 Mammalian cell culture system 
3.2.1 Cell line and maintenance 
CHO-S cells (Invitrogen) were maintained in suspension in CD-CHO medium (Invitrogen) and 
supplemented with 2 mM L-Glutamine and 10 mL/L 100x hypoxanthine/thymidine 
supplement (both Invitrogen). This mixture is referred to as growth medium from here on. 
The cells were sub-cultured every 4 days at a seeding density of 2x105 cells/mL. They were 
maintained in 250 mL Erlenmeyer flasks in a working volume of 50 mL. They were kept in a 
cell incubator at 37oC in a humidified atmosphere of 5% CO2, on an orbital shaking platform 
(Thermo) rotating at 125rpm.  
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3.2.2 Cell density and viability measurements 
For cell density and viability measurements, 1 mL of sample was removed from each 
culture. This was diluted with the appropriate amount of Trypan blue and injected into an 
improved Neubauer haemacytometer. The sample was assessed using light microscopy at 
10x magnification. The number of viable and dead cells in the middle and the four corner 
large squares of the central area of the counting grid were counted. To obtain the cell 
density in cells/mL, the cell count obtained in the previous step was multiplied by the 
dilution and the result was divided by the total volume counted (each square has a surface 
area of 1 mm2 and depth of 0.1 mm). The cell density (in 104 cells/mL) is given by equation 
(6). The integral viable cell concentration is a product of the time and cell concentration 
over that time.  
 
              
                     
                 
     
        
  
                               (6) 
3.2.3 Intracellular metabolite measurements 
To measure the intracellular concentrations of glucose and glutamine, a 2 mL sample was 
removed from a batch growth curve once daily. This was centrifuged for 5 minutes at a 
speed of 800 rpm. The supernatant was removed and the sample was re-suspended in 3 mL 
ice cold PBS and centrifuged at the same speed and time to wash the cells. The supernatant 
was again removed and the pellet was re-suspended in 3mL ice cold PBS. This was then 
sonicated five times for three minutes each time at a pulse of 15 seconds on and 15 seconds 
off. The cell extracts were then frozen and the metabolite assays were run on these samples 
as described below.  
 
3.2.3.1 Glucose assay 
The Amplex® Red Glucose/Glucose Oxidase Kit (Invitrogen) was used to measure 
intracellular glucose concentration. The standards were made as per the manufacturer’s 
guidelines (0-100 mM) and the glucose powder was dissolved in 1X reaction buffer. The 
intracellular concentration of each sample was calculated using equation (7) below.  For 
CHO cells, the single cell volume was calculated using a cell diameter of 12 μM (Han et al., 
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2006). The absorbance of the samples was measured using a microplate reader at a 
wavelength of 560 nm.  
 
                            
                    
                                                             
                 (7) 
  
 
3.2.3.2 Glutamine assay 
The EnzyChromTM Glutamine Assay Kit (Cambridge Bioscience) was used to measure the 
intracellular glutamine concentration.  The standards and various reagents were made as 
per the manufacturer’s instructions. First, a 2 mM glutamine standard was made by mixing 5 
µL of 100 mM standard with 245 µL of distilled water. This premix was then diluted with 
different amounts of distilled water to give standards of 2 mM, 1.2 mM, and 0.6 mM 
glutamine. A standard with no glutamine was also prepared. The optimal dilution was found 
to be 1:2 for these samples to fall within the standard range of 0 and 2mM. Since the 
EnzyChromTM Glutamine Assay Kit relies on a coupled enzymatic reaction, additional 
standards were used to correct for the presence of intracellular glutamate in these samples. 
To do this a sample blank control was also added in a separate well.  The absorbance was 
read at 565 nm on a microplate reader.  
3.3 Mammalian cell transfection 
3.3.1 Kill curves 
Two antibiotics were used as selection pressures in this work. Zeocin (Invivogen) was used 
to select for the plasmid containing the glucose or glutamine biosensors and neomycin 
(G418) (Invivogen) was used for the plasmid containing the scFv genes. The concentration 
required for selection (the lowest concentration required to kill non-transfected cells) was 
determined using a kill curve.  
 
Cells were seeded at a seeding density of 2x105 cells/mL in a 6-well plate.  For the Zeocin kill 
curve, non-transfected CHO-S cells were used and the concentration of Zeocin varied from 
200 to 1000 µg/mL.  For the G418 kill curve, the concentration was varied between 0.25 and 
10 mg/mL. This kill curve was performed using CHO cells expressing the glucose or 
  61 
glutamine biosensor and in the presence of 400 μg/mL Zeocin.  In both cases, CD-CHO was 
used as the base medium. The selective medium was changed every 4 days and the 
percentage of surviving cells was assessed via visual examination using light microscopy.  
The lowest concentration of antibiotic that killed the cells was selected for further 
experiments. 
3.3.2 Transfection  
CHO-S cells were maintained under the aforementioned conditions (37°C, 5% CO2, 125 rpm) 
for 12‒24 hours prior to transfection to ensure the cells were actively dividing at the time of 
transfection. The TransIT-PRO™ transfection kit (Mirus Bio) was used to transfect CHO-S 
cells. The TransIT-PRO™ and PRO™ reagents were warmed to room temperature and 
vortexed before use. The CHO-S cells were counted using the Trypan blue dye exclusion 
method, from which a working volume of 20 mL of cells at a concentration of 106 cells/mL 
was prepared in an Erlenmeyer 125 flask. The DNA for transfection was prepared by 
combining 2 mL of warm CD-CHO medium, 20 µg of plasmid DNA, and 20 µL of Trans IT 
Pro™ in a 50mL tube. The tube was mixed gently; 10 µL of ProBoost™ solution was added 
and the solution was mixed again. This mixture was incubated at room temperature for 30 
minutes to allow time for the complexes to form. Following incubation, the complexes were 
added to the cells and shaken gently for 1 minute at 125 rpm on a shaking platform. The 
resulting mixture of cells and DNA was plated into 5 of the 6 wells on a 6-well plate at a 
volume of 2 mL per well. The final well was used as a negative control where the solutions 
without DNA were added. The plates were incubated for 4 days without shaking, then 
transferred to a shaking platform (125 rpm) and 400 µg/mL of zeocin or 0.50 mg/mL of 
neomycin was added for selection of transfected cells. The medium was changed every four 
days (adding antibiotic each time) until the cells in the control well had died. Once a stable 
cell line was obtained the percentage of antibiotic was reduced to 10% and this was added 
every time the specific cells were sub-cultured.  
 
3.3.2.1 Quantitative polymerase chain reaction (qRT-PCR) 
The expression of the FRET biosensors by the transfected cells was further confirmed by 1-
step quantitative reverse-transcription PCR. Total mRNA was isolated from 5 mL of cell 
culture using the peqGold RNA S-line extraction kit (Peqlab, UK) according to the 
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manufacturer’s instructions.  The RNA concentration was determined using the Nano-drop™ 
1000 (Thermo Scientific). Primers with complementarity to the CFP/YFP gene were 
synthesized by Invitrogen (see Appendix A). Gradient PCR reactions and agarose gel 
electrophoresis were used to select primer pairs that gave a single product of the correct 
size at an annealing temperature of 62.7oC.  A 1-step PCR was used, with an initial 
denaturation for 7minutes at 98oC followed by 35 cycles for 10 s at 98oC and 1 minute at 
62.7°C as a combined annealing/elongation step. The results were analyzed using the 
Mastercycler ep Realplex software (Eppendorf), which determined Ct values with a 
threshold of 100 (arbitrary fluorescence units).  
3.4 In vivo calibration curves 
To perform in vivo calibration curves duplicates of batch cell cultures (E250 flask with a 
working volume of 50mL) were set up using cells transfected with either the glucose or 
glutamine biosensor. The cells were thawed and sub-cultured three times before use. 
Fluorescence measurements were conducted using culture samples in a 6-well plate. Every 
24 hours, a 2 mL sample was removed from the flask and pelleted by centrifugation at 800 
rpm for 5 minutes at 4oC. This cell pellet was re-suspended in 2 mL of ice cold PBS and the 
resultant mixture was pipetted into a 6-well plate. This was placed in the Tecan™ 
fluorescent plate reader and blue and yellow fluorescence measurements were taken as 
described above. Part of the sample was then used for viable cell concentration 
determination using the Trypan blue exclusion method as described above. To be able to 
correlate the fluorescent ratio to intracellular glucose and glutamine measurements, the 
rest of the sample was sonicated on ice to release the intracellular metabolites, and the 
intracellular glucose or glutamine concentration was determined using the aforementioned 
assay kits.   
3.5 Batch and Fed-batch cell cultures 
Batch CHO cell cultures were maintained in duplicates for 11-12 days in 250 mL Erlenmeyer 
flasks with a working volume of 50 mL, at a seeding density of 2x105 cells/mL. Samples were 
removed at 24 h-intervals to determine the viable cell concentration using the Trypan blue 
dye exclusion method and to measure FRET ratios and intracellular metabolite 
concentrations as described above. The fed-batch CHO cell cultures were conducted in 
  63 
duplicates in 250 mL Erlenmeyer flasks containing 50 mL of CD-CHO but with additional 
supplementation of glucose or glutamine on day 6 of the cell culture to bring the 
extracellular concentrations of these metabolites to 36 mM and 4 mM. Two control cultures 
were set up, which were fed with the same volume of filtered water instead of nutrients on 
day 6.  
3.6 BioLector™ evaluation 
The BioLector™ (m2p-labs) allows measurements of biomass and FRET automatically. The 
machine was set to take measurements every 300 minutes, shaking at 1000 rpm at 5% CO2 
at 37oC. Gain values for the biomass were determined using a calibration curve. The value of 
the gain was fixed when a single measurement gave a reading below 1000 U for the highest 
concentration used. The gain for the biomass was set at 41 whilst the gains for the yellow 
and blue fluorescence filters were 51.  
3.6.1 Fed-batch cell culture using the BioLector™ 
A fed-batch study was undertaken using a 48-well micro-titre plate. Three feeds, CHO Feed 
1, 2, and 3, were purchased from Irvine Scientific (CA. USA). CHO cells expressing the 
glucose or glutamine biosensor were seeded at a density of 2x105 cells/mL.  The cells were 
fed 150 μL of the feeds on days 3, 6 and 9 with triplicates for each experimental condition. 
This represents 10% of the well volume as per the manufacturer’s guidelines. The cultures in 
the final two columns of the plate were not fed to include a batch culture comparison. 
During culture, daily samples were taken for determining viable cell concentration as before.  
 
3.7 Glutamine di-peptide sources 
Various glutamine sources were used in this investigation, two different di-peptide sources 
(Life Technologies) were used, Ultraglutamine I (alanyl-L-glutamine) and II (L-glycyl-L-
glutamine) as well as L-glutamine (Invitrogen, UK) which was used for media 
supplementation. Five concentrations of these glutamine sources (2, 4, 6, 8 10 mM) were 
added in CD-CHO medium supplemented with 10 mL/L hypoxanthine/thymine. Cells 
transfected with the glutamine biosensors were grown in triplicate cultures in 48-well 
micro-titre plate in the BioLector™ at a shaking speed of 1000 RPM at 37oC, 5% CO2 with 
readings of biomass concentration and FRET measurements every 5 hours. 
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3.8 Construction of scFv- and biosensor-producing cell lines 
3.8.1 scFv vector design 
The genes for the two scFvs Hubc-1 and MFE23 were kindly provided by Dr Mahendra 
Deonarain.  The sequences were PCR amplified from an E coli expression vector using 
Phusion DNA polymerase (New England Biolabs). The forward primer incorporated a Kozak 
consensus sequence and a CHO signal sequence followed by 22 base pairs of the sequence 
identity to the scFv in question. The reverse primer had homology to the C-terminal 6x 
histidine tag and thus was the same regardless of which scFv was cloned. The primers were 
used in a PCR amplification reaction with the following program: denaturation for 7 minutes 
at 95°C: 5 cycles of 30s at 95°C, 30s initial annealing at 55°C, and 45s elongation at 72°C, 
followed by 20 cycles of 30s at 95°C, 30 s at 63°C, then a final elongation step for 5 minutes 
at 72°C then the PCR machine was let to cool down to 4°C. . The PCR products were cloned 
using BamHI and HindIII restriction enzymes into the corresponding sites of pCDNA3 
mammalian expression vector (Invitrogen). The plasmid was constructed using E.coli as a 
host organism and, once the appropriate sequence was confirmed by DNA sequencing, a 
plasmid maxiprep (Qiagen) was used to prepare sufficient DNA for CHO cell transfection.  
3.8.2 scFv transfection in the BioLector™ 
The transfection protocol described above was modified to allow us to transfect the scFv 
vectors into cell lines already expressing one of the two biosensors using the BioLector™. 
The DNA and transfection reagent mixture was prepared as described previously and was 
mixed with an appropriate volume of cell culture growing in fresh medium. Following this, 
the mixture was plated into a 48-well micro-titre plate and placed in the Biolector™. The 
BioLector™ was set at 200 rpm (lowest the BioLector™ can be set) for three days to allow 
the cells to recover from the transfection and the shaking speed was increased to 1000 rpm 
at this point the antibiotic selection pressure was also added.  The 48-well micro-titre plate 
had 10 cultures per scFv per biosensor, i.e. for each cell line (CHO with the glucose or 
glutamine biosensor) there were 10 cultures that were transfected with the Hubc scFv and 
10 cultures that were transfected with the MFE 23 scFv. The cells were progressed to E125 
flasks when they reached 1000 biomass units (0.50 mg/mL of G418 was added) and then 
bulked up. After 3 subcultures, the scFv concentration in the supernatant was determined 
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using the Nano-drop™. FRET measurements were taken every 5 hours during the time the 
cells were in the BioLector™. 
3.8.3 Fed-batch cell cultures of the top 6 transfected cells lines 
The top 6 scFv-producing cell lines based on product concentrations at subculture were 
chosen to carry out a fed-batch cell culture study. Fed-batch cultures were set up in 
duplicates in E500 flasks to a working volume of 100 mL. These flasks were fed 15% v/v feed 
C (Invitrogen) on days 2, 4, 6, 8, 10 and 12 as per the manufacturer’s instructions. Culture 
samples for FRET measurements were taken daily and were analysed using the Tecan™ 
fluorescent plate reader.  The cell concentration and viability were determined using the 
Trypan blue dye exclusion method. Supernatant samples were also removed to determine 
the scFv concentration using the Nano-drop™. 
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Chapter 4. FRET biosensors: In vitro 
and in vivo testing 
Growing cell cultures need a well-regulated environment and a food supply in order to grow 
and produce biomass and protein products. Testing of the environment is based on samples 
being removed from the fermentation broth and analysed (often using enzymatic assays). 
This is ineffective as it takes time during which the fermentation process in the bioreactor 
continues, so the information frequently fails to provide the researchers with a realistic 
picture of conditions in the reactor. Real-time monitoring the cell culture environment is 
usually divided into two methods, either using in situ probes (Mazarevica et al., 2004) or 
automated online systems. Probes are put in the bioreactor and therefore do not require 
sampling. The automated method relies on sampling and an analyser. One method is the YSI 
flownamics SEG-FLOW, a biochemistry analyser that allows automated online analysis. This 
machine firstly draws samples from 1-8 bioreactors and takes measurements of 
metabolites. The amount of required nutrient can then be calculate and fed to the culture. 
In situ sensors offer several advantages such as elimination of sampling, reduced risk of 
contaminations and absence of reagents costs compared with batch analysers. Also with the 
probes in mind there is a question about the sterilization approaches (Mazarevica et al., 
2004). This is important if a biological component is present on the probe, in the case of a 
contaminant. Online monitoring allows real-time control of fermentation and cell culture 
processes. Online glucose and/or glutamine measurement in the process allows for 
optimization of the feed rate, which increases production yields for growing cell cultures 
that produce therapeutic proteins. 
 
Measuring cell health and metabolites has a few advantages. Firstly, it can reduce risk, 
increase operators’ confidence level and provide more consistent results. Online detection 
of abnormal consumption rates with the help of intracellular metabolite concentrations 
would allow operators to terminate bad batches of cells at an early stage. Glucose is the 
carbon and energy source for the organism, hence it is very important to monitor this 
metabolite. Feedback control of glucose concentrations would allow fixed, low 
concentration of glucose to be fed in a fed-batch bioreactor. This cannot be done with 
  67 
periodic or manual feeding, which often leads to nutrient depletion or accumulation of 
substrates or metabolites to inhibitory levels (Zhou et al., 1996). Furthermore fixing the 
glucose concentration at a low value has a potential to increase the quality of the 
therapeutic product by reducing uncontrolled glycation (Yuk et al., 2006) and improve 
efficiencies of nutrient utilization (Maranga and Goochee, 2006). 
 
Glutamine supports the growth of cells that have high energy demands and synthesize large 
amounts of proteins and nucleic acids. It is an alternative energy source for rapidly dividing 
cells and cells that use glucose inefficiently. It breaks down to ammonium, which is very 
toxic to cells. It has been shown by Maranga and Goochee, (2006) that a low concentration 
of glucose and glutamine during a fed-batch system had significant effect on cellular 
metabolism leading to an increased efficiency of nutrient utilization, decreased by product 
synthesis. This chapter will detail the evaluation and testing of FRET biosensors as tools for 
testing and predicting the intracellular glucose and glutamine concentrations. 
 
4.1 Development and evaluation of biosensor-producing cell lines 
The next section will focus on the steps taken to decide upon suitable candidate biosensors 
and the subsequent transfections and testing of these biosensor and biosensor transfected 
cell lines. Then this section will go on to explain the results obtained from the in vitro and in 
vivo calibration of these biosensor transfected cell lines. Finally the use of in vivo calibration 
curves for possible predictive metabolite measurements will be evaluated and discussed.    
 
4.1.1 CHO-S growth profile 
Figure 13a shows the CHO-S cells growth curve with the associated the integral viable cell 
concentration (IVCC) in Figure 13b. These cells were grown in a batch cell culture as detailed 
in section 3.2.1.  Figure 13a shows that the CHO-S cells have a peak concentration of 7.02 x 
106 cells/mL, whilst Figure 13b highlights the IVCC. The exponential phase has a growth rate 
of 0.62 h-1 as worked out by using the following equation: 
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Figure 13a: A typical batch culture growth curve for CHO-S cells 
The above figure shows the lag phase for day 0-1, the exponential growth 
phase from days 2-5, a stationary phase from days 5-6 and the decline/death 
phase from 7 onwards. N=4 biological replicates, error bars represent the 
standard deviation.  
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Figure 13b: The IVCC as calculated from the growth curve for CHO-S cells. 
The corresponding IVCC from the above growth curve showing the 
characteristic curve and increase.  N=4 biological replicates. , error bars 
represent the standard deviation. 
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4.1.2 Glucose and glutamine biosensor  
The next experiment was undertaken to gain an understanding of the intracellular 
concentration range of glucose and glutamine encountered over the course of the cell 
culture. This is an important fact to know as the choice of biosensor is based on the linear 
range that best matches the intracellular concentration ranges displayed. This was done by 
sampling daily during a batch cell culture of CHO-S cells. Glucose was measured with the use 
of a commercially available kit, Amplex Red™, whilst intracellular glutamine was measured 
with the Enzychrome™ kit. The results below show the intracellular glucose and glutamine 
levels within CHO-S cells during this batch growth curve (Figure 14).  
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Figure 14: Intracellular metabolite concentration assay results. 
Intracellular glucose concentrations as obtained by the Amplex red™ glucose 
assay (red line). Intracellular glutamine concentrations as obtained by the 
EnzyChrome™ kit (blue line). Samples obtained from a batch growth curve of 
CHO-S cells during a cell culture. N=4 biological replicates, error bars represent 
the standard deviation. 
 
 
 
Figure 14 shows that the intracellular concentration range of glucose to be between 0.4 and 
23mM whilst the glutamine concentration ranges from 0.05 to 25 mM.  The next step was to 
select biosensors for glucose and glutamine capable of providing a linear output over this 
concentration range. Two candidate glucose biosensors were identified from the literature 
(Deuschle et al., 2005) and one glutamine biosensor (Yang et al., 2010). The first glucose 
biosensor (FLIPglu-600µ-Delta11aphrodite) measures a linear concentration range of 
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glucose from 0.1 to 10 mM with a Kd of 600μM, whilst FLIPglu-3200µ-Delta13 measures 
linear glucose concentrations from 0.01 to 100mM with a midpoint (Kd ) of 3200μM.  The 
glucose plasmids were kindly supplied by Professor Wolf Frommer from the Carnegie 
Institution for Science, Stanford University. The glutamine biosensor (D157N) was 
generously provided by Dr Uwe Ludewig at the Hohenheim University (Yang et al., 2010). It 
has a Kd of 6.9µM and measures a linear range of glutamine between 0.1-20mM. These two 
glucose biosensors were chosen for the below in vitro investigations as they measure the 
correct range of glucose measurements (Figure 14) which falls in the range for the CHO 
cells. Also other biosensors did not have as large a FRET ratio change between zero glucose 
and saturation so they were excluded. The glutamine biosensor was chosen as it measures 
the correct range for glutamine based on the intracellular range. 
 
The behaviour of the purified protein was assessed and compared against previously 
published data. This was done by measuring a titration curve of the purified protein against 
a range of glucose standards in a 96-well plate. The fluorescence emission for blue and 
yellow wavelengths when excited with blue light were collected and divided to obtain the 
FRET ratio for each concentration used. The graphs below highlight that both the FLIPglu-
600µ-Delta11aphrodite and FLIPglu-3200µ-Delta13 biosensor behaved as previously 
reported and their respective Kd values were in agreement with previously published work 
(Figures 15-17). Figure 15 shows the linear range of measurement (0.1mM-10mM) for the 
biosensor is similar, but not identical to that reported in the literature (reference). This 
Figure also shows that the unique relationship between FRET ratio and glucose 
concentration highlighted by the orange box. The other numbers are excluded; the Log 4 
µM was also excluded as it was not a unique value for the relationship between glucose 
concentration and FRET ratio. This can also be said of Log 1µM. Table 8 shows that the 
highest R2 is reached between the concentration of 2-3.8 Log glucose (µM) for both the 
results obtained from Frommer lab and the data this experiment yielded. Figure 16 also 
shows the linear range is similar for the FLIPglu-3200µ-Delta13 glucose biosensor. This is 
further seen with the Kd comparison in Figure 17, where there is no significant increase 
between the data from the literature and the data collected here.  In Figure 16 it must also 
be noted that after 3.5 Log glucose (µM) the similarity is decreased with the data from 
Frommer lab increasing whilst the data from this study reaches a plateau. The experimental 
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set up in this work used filter sets of 538 ±25(YFP) and 460 ±10 (CFP) whilst Frommer lab 
used 528 ±12 (YFP) /480 ±12 (CFP) for the glucose biosensorsTherefore the experimental set 
up used for this work are comparable, but not identical to those used by the literature. 
Table 9 shows that the highest R2 is reached between the concentration of 2.5-3.5 Log 
glucose (µM) for both the results obtained from Frommer lab (R2= 0.916) and the data this 
experiment yielded (R2= 0.882). This table shows that the best fit for a linear relationship is 
between these two concentrations.   
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Figure 15: The titration curve for the FLIPglu-600µ-Delta11aphrodite 
glucose biosensor.  
The highlighted box represents the linear range for glucose measurements 
which is 0.1mM to 10mM. N=5 biological replicates, error bars represent the 
standard deviation.   
*https://dpb.carnegiescience.edu/sites/dpb.carnegiescience.edu/files/labs/fro
mmer/nanosensors/monosaccharide/FLIPglu600uD11%20Aphrodite.html. The 
points for Frommer lab were digitized using Getdata Graph Digitizer v2.26.  
 
Table 8: Comparing regression curves for a range of glucose concentrations based 
on data from Figure 15.  
The yellow areas highlight that the highest R2 is observed for concentrations of 2-3.8 
Log Glucose (µM) for both Frommer lab and our data.  
 
 
FLIPglu-600µ-Delta11aphrodite Log Glucose (µM) Equation of line R2 
Frommer lab 1-4 y = -0.3634x + 3.5376 0.871 
Frommer lab 2-3.8 y = -0.4039x + 3.6677 0.941 
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Our data 1-4 y = -0.2697x + 3.2353 0.801 
Our data 2-3.8 y = -0.3963x + 3.6349 0.874 
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Figure 16: The titration curve for the FLIPglu-3200µ-Delta13 glucose 
biosensor.  
The linear range is highlighted by the yellow box. N=5 biological replicates, 
error bars represent the standard deviation. 
*https://dpb.carnegiescience.edu/sites/dpb.carnegiescience.edu/files/labs/fro
mmer/nanosensors/monosaccharide/FLIPglu600uD13%20curves.html.The 
points for Frommer lab were digitized using Getdata Graph Digitizer v2.26, 
then converted into FRET ratios based on the following equation: Saturation = 
(ratio-ratioapo)/(ratiosat-ratioapo). Where sat = saturation and apo =unbound 
state 
 
Table 9: Comparing regression curves for a range of glucose concentrations based 
on data from Figure 16.  
The yellow areas highlight that the highest R2 is observed for concentrations of 2.5-
3.5 Log Glucose (µM) for both Frommer lab and our data.  
 
 
 
FLIPglu-3200µ-Delta13 Log Glucose (µM) Equation of line R2 
Frommer lab 1-4 y = 0.1722x + 2.0552 0.8421 
Frommer lab 2.5-3.5 y = 0.2197x + 1.7898 0.916 
Our data 1-4 y = 0.0654x + 2.1186 0.780 
Our data 2.5-3.5 y = 0.1266x + 1.9681 0.882 
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Figure 17: Kd comparison for the FLIPglu-600µ-Delta11aphrodite and 
FLIPglu-3200µ-Delta13 biosensors.  
In blue is the data this study obtained vs. the previously published data in the 
red. Showing the close agreement of data. N=5 biological replicates, error bars 
represent the standard deviation. 
 
As Figure 14 shows, it was found that the concentration range of intracellular glucose to be 
between 0.4 -23 mM, however, with the exception of the early days, average intracellular 
glucose concentration falls between 0.4-6 mM. Therefore this range falls into the linear 
range for the FLIPglu-600µ-Delta11aphrodite biosensor. This biosensor also has a greater 
signal change between the unoccupied and fully occupied form.  Therefore, the FLIPglu-
600µ-Delta11aphrodite biosensor was chosen for the remainder of the study. 
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Figure 18:  a) Titration curve for the D157N glutamine biosensor. b) The 
titration curve for Figure 18a showing the smaller side of the scale  
The X-axis being the various glutamine standards used with the Y-axis 
highlighting the various FRET ratios calculated based on the yellow wavelength 
divided by the blue wavelength. The highlighted box represents the linear 
range for glutamine measurements. N=5 biological replicates, error bars 
represent the standard deviation. 
* The points for Yang et al.,2010 were digitized using Getdata Graph Digitizer 
v2.26. 
 
Table 10: Comparing regression curves for a range of glutamine concentrations 
based on data from Figure 18a.  
The highest R2 is observed for concentrations of 0-1.5 mM for both Yang et al., 2010 
and our data.  
 
D157N Glutamine Concentration  (mM) Equation of line R2 
Yang  et al., 2010 0-1.5 y = 0.1871x + 4.9759 0.9978 
A 
B 
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Yang et al., 2010 0 -3 y = 0.7396x + 4.5917 0.8455 
Our data 0-1.5 y = 0.0454x + 4.9363 0.8682 
 
Our data 0 -3 y = 0.2808x + 4.4716 0.5164 
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Figure 19: Kd comparison for the D157N glutamine biosensor.  
The blue represents the data obtained vs. the previously published data in the 
red. This shows the agreement of results. N=5 biological replicates, error bars 
represent the standard deviation. 
 
The glutamine biosensor this work undertaken here used filter sets of 538 ±25 (YFP) /460 
±10 (CFP) whilst Yang el at.,2010 used 528 ±12 (YFP) /475 ±12 (CFP). Figure 18 displays the 
results from the titration curves obtained with the glutamine biosensor, whilst Figure 19 
confirms that the similar Kd to that of the literature was obtained (Yang et al., 2010). The 
difference in Kd in Figures 17 and 19 is 4% and 3%, respectively.  This is not statistically 
different. This difference has no effect on the ability of the biosensors to function as seen in 
Figure 15 and Figure 18, the results from literature and data from this thesis show 
agreement. Table 10 highlights that the strongest linear relationship is seen between 
glutamine concentrations of 0-1.5mM. This is true for the data published by Yang et al., 
2010 (R2 = 0.99) and our data (R2= 0.87). Figure 18 shows that the correct curve was 
obtained, the points were mostly below that of Yang et al. (2010). This may have been due 
to the difference in experimental set up. Yang et al. used an excitation filter of 433nm ±12 
with an emission of 475nm ±12 for their blue wavelength, whilst this investigation used 
430nm ±35 and 465nm ±35. This suggests the calculated FRET ratios may have been lower 
due to the higher blue fluorescence measurements. This reason could also be why there is a 
discrepancy in the linear range between the literature and this study.  
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4.1.3 Biosensor stability study  
The next stage was to measure the stability of the biosensor over time in vitro. Purified, 
dialysed protein was incubated at three temperatures: 4oC, room temperature 
(approximately 24oC) and 37oC.  Samples were removed over 5 days using 6 different 
glucose standards to measure the FRET ratios daily to assess the changes in FRET ratio as a 
consequence of protein stability.  The results are below in Panels A-C of Figure 20. 
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Figure 20:  In vitro glucose biosensor stability  
Panels A-C show the various FRET ratios obtained for each separate glucose 
standard over 5 days. Panel A Is 4oC, Panel B is the FRET ratios from room 
temperature and Panel C is from the 37oC test. N=3 technical replicates, error 
bars represent the standard deviation. 
 
As previously mentioned the linear range of measurement for this glucose biosensor is 
between 10 and 10,000µM, either side of this range saturation is reached.  Panel A shows 
that this linearity is seen from 100 to 500µM after which saturation is reached. In all cases, 
as the days increase, the FRET ratios decrease and the ability of the protein to act like a 
biosensor appears to be lost. This happens much more quickly at higher temperatures.  At 
37°C the biosensor does not function properly even on day 1, whereas at room temperature 
and 4°C this process takes until day 3.   
 
The above test was also repeated for the glutamine biosensor protein, the results for which 
are in Figure 21. Panel A shows the results at 4oC on day 1 and show a similar FRET ratio. 
Following this, days 3, 4 and 5 display an erratic FRET ratio. This would suggest the linear 
range is not kept at this temperature. Panel B also shows decrease in FRET ratio while Panel 
C shows that the linear range that this study measured was kept for all five days. This would 
suggest the biosensor has kept its ability to function as a biosensor.  
 
 
C 
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Figure 21: In vitro glutamine biosensor stability  
Panels A-C show the various FRET ratios obtained for each separate glutamine 
standards over 5 days. Panel A is for 4oC, Panel B is the FRET ratios at room 
temperature and Panel C is from the 37oC test. N=3 technical replicates, error 
bars represent the standard deviation. 
 
 
C 
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4.1.4 Interference studies  
The next in vitro test was to determine if other molecules that might be present in high 
intracellular concentrations interfere with the ability of FLIPglu-600µ-Delta11aphrodite 
biosensor to bind glucose and the ability of D157N to bind glutamine. The binding domain 
for the glucose biosensor is termed the glucose/galactose periplasmic binding protein and, 
as the name implies, it is able to bind galactose. However, there is very little galactose in CD-
CHO medium (Debra at Life Technologies, catalog number: 10743-029) and, therefore, this 
is not a problem in this system. However, after transport into the cell, glucose will be 
phosphorylated to glucose-6-phosphate (G-6-P) (Aiston et al., 2004). G-6-P has a similar 
structure to glucose and hence might bind to the biosensor. To test this, 1mM of G-6-P was 
added (the intracellular concentration in CHO cells, Williamson et al. 1971) to the purified 
biosensor in the presence of glucose within the range that had previously been tested 
(Figure 14) and the FRET ratio measurements were repeated. Figure 21 shows that the 
addition of G-6-P had no impact on the FRET ratios measured. This suggests that the FLIPglu-
600µ-Delta11aphrodite glucose biosensor in vivo will not experience interference from any 
G-6-P present.   
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Figure 22: G-6-P binding test on purified glucose protein.  
The blue bars are the results of the samples that contained the glucose 
standards and the purified protein whilst the red bars indicate the results of 
the glucose standards with the purified protein and the G-6-P. Showing the 
addition of G-6-P has no effect of the typical FRET ratios. N=4 technical 
replicates, error bars represent the standard deviation. 
 
The specificity of the glutamine biosensor for glutamine in the presence of various other 
amino acids and glutamine-containing di-peptides was also explored. This was especially 
important given previously published work by Yang et al. (2010) which suggested that this 
biosensor was able to bind to other amino acids and produce a FRET signal. They noted that 
large positive FRET changes were observed in response to cysteine, histidine and arginine 
and negative FRET changes with addition of glutamate, lysine and aspartate. Their work, 
however, did not measure the changes during a competition assay; they instead added each 
amino acid singly and measured the resulting FRET change. The fidelity of the signal in the 
face of competing substrates is of greater interest for the system under development, so a 
competition assay using purified protein, 1mM glutamine and the maximum physiologically 
relevant levels of intracellular amino acid reported in the literature (Hansen and Emborg, 
1994) was undertaken. For cysteine unpublished data from Kontoravdi was used as a 
reference.   Table 11 shows the various concentrations for these amino acids selected.  
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Table 11: Concentrations of amino acids used in the competition study.  
The maximum intracellular amino acid concentrations were used. All 
concentrations apart from cysteine were obtained from Hansen and Emborg, 
1994. For cysteine unpublished data from Kontoravdi was used as a reference.  
 
Amino Acid Physiological range Concentration used 
Alanine 9.4-10.7 mM 10mM 
Arginine 0-2.3 mM 3 mM 
Asparagine 1.1-18.7 mM 20 mM 
Cysteine † 0.5-5 mM 5 mM 
Glutamate 2.6-4.6 mM 5 mM 
Glutamine 0.3-0.9 mM 1 mM 
Glycine 4.4-8.4 mM 9 mM 
Histidine 0.3-0.6 mM 0.5 mM 
Isoleucine 0.5-0.8 mM 1 mM 
Leucine 0.2-0.5 mM 0.5 mM 
Lysine 0.2-0.6 mM 0.5 mM 
Phenylalanine 0.6-0.8 mM 1 mM 
Serine 0.5-1 mM 1 mM 
Threonine 0.9-3.5 mM 4 mM 
Tyrosine 0.03-0.5 mM 1 mM 
Valine 0.6-1.2 mM 1 mM 
 
 
Figure 23 suggests that most of the amino acids tested do not affect the ability of the 
glutamine biosensor to bind glutamine since the maximum amount of difference in the 
measured FRET ratio is approximately 20%. Of the amino acids reported in Yang et al., 2010 
which gave an increase in FRET, these results show alanine and cysteine produce a higher 
FRET change. An amino acid that is structurally similar to glutamine, asparagine, did not 
produce a high FRET signal. Decreased FRET ratios were observed for aspartate, glutamate, 
glycine, threonine, valine and phenylalanine meaning that these amino acids interfered with 
the ability of the biosensor to bind glutamine. It is hypothesized that since glycine, 
threonine, and valine are small amino acids they are small enough to enter the binding 
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domain and may stop or hinder the binding of glutamine. They are not able to cause a 
conformational change (i.e. produce a FRET signal) but this may indicate a competitive 
binding mechanism.  
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Figure 23: Amino acid interference study. 
The line shows the FRET ratio achieved with addition of only glutamine. The 
bars show the results of the various amino acids and the addition of glutamine 
had on the FRET ratio. Where A = alanine, C= cysteine, D= aspartate, E= 
glutamate, F= phenylalanine, G= glycine, H= histidine, I= isoleucine, K= lysine, 
L= leucine, N= asparagine, Q= glutamine, R= arginine, S= serine, T= threonine, 
V= valine, Y= tyrosine. N=3 technical replicates, error bars represent the 
standard deviation. 
 
 
It was also of interest to test interference of glutamine-containing dipeptides on the ability 
of the biosensor to bind glutamine. Ultraglutamine is an extremely stable dipeptide form of 
glutamine used as an alternative to glutamine in cell culture 
(http://bio.lonza.com/uploads/tx_mwaxmarketingmaterial/Lonza_BenchGuides_TechSheeU
ltraGlutamine_Supplement_200_mM.pdf). Figure 24 suggests that the addition of either 
ultraglutamine I (alanyl-L-glutamine) or II (L-glycyl-L-glutamine) did not change the 
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measured FRET ratio. Taking 15mM as an example adding UI decreased the FRET by 8% 
whilst adding UII resulted in an 11% decrease. A maximum of 9% difference was seen in any 
of the concentrations used with an average of 4% difference between the samples of any 
same concentration.  This would suggest that the glutamine biosensor is specific for 
glutamine even in the presence of the glutamine containing dipeptides.  
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Figure 24: Ultraglutamine I and II binding test.  
The blue bars indicate the samples that had the glutamine standards as well as 
the purified protein. The red bars show the samples that contained the 
glutamine standards plus the purified protein and the Ultraglutamine I 
dipeptide source. The green bar is the results from the Ultraglutamine II 
treated samples. This highlights that fact that neither glutamine source had 
any effect on FRET ratios. N=4 technical replicates, error bars represent the 
standard deviation. 
 
4.1.5 Expression study 
To confirm the presence and expression level of the glucose and glutamine biosensor in the 
biosensor-transfected cells, a qRT-PCR analysis was performed. RNA was extracted from 10 
million cells taken from the mid exponential phase (day 4) of a batch cell culture. A positive 
control of the housekeeping gene -actin was included in order to ensure that the PCR 
reaction was working. Figure 25 suggests that the glucose biosensor is present in that the 
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mRNA is being produced, whilst Figure 26 suggests that the glutamine biosensor is also 
present.  
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Figure 25: The qRT- PCR results for the glucose biosensor  
The results from the glucose biosensor transfected CHO cells vs. the 
housekeeping gene β actin and the parental cell line. This shows the high 
mRNA levels present in the transfected cell line. N=3 technical replicates, error 
bars represent the standard deviation. 
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Figure 26: The qRT-PCR results for the glutamine biosensor  
The results from the glutamine biosensor expression found in transfected CHO 
cells vs. the house keeping gene β actin and the parental cell line.. This shows 
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the high mRNA levels present in the transfected cell line. N=3 technical 
replicates, error bars represent the standard deviation. 
 
To determine the point at which a FRET signal is detected, stable and reproducible, cells 
were sub-cultured every 4 days and the FRET ratio was measured at the point of subculture. 
This was repeated for 8 sub-cultures (Figure 27). The results show that after the third sub-
culture the FRET ratio becomes stable and the signal is maintained. This suggests that these 
cells need to be sub-cultured a minimum of three times after thawing before the FRET ratio 
is stable.  
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Figure 27: Stability of expression of the glucose biosensor 
The sub-culture number against the FRET ratios for the CHO-S transfected with 
the glucose biosensor. A reproducible FRET ratio is reached from the third sub-
culture until the sixth. N=3 biological replicates, error bars represent the 
standard deviation.. 
 
The same investigation was conducted on CHO cells expressing the glutamine biosensor. 
Figure 28 suggests that after the third sub-culture the cells produce a repeatable FRET ratio. 
Once the 7th sub-culture is reached the culture should be disposed of and a new vial 
thawed from the cell bank to ensure that the cells do not undergo genetic shifts (Wenger et 
al., 2004).  
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Figure 28: Stability of expression of the glutamine biosensor  
The sub-culture number against the FRET ratios for the CHO-S transfected with 
the glutamine biosensor. A reproducible FRET ratio is reached from the third 
sub-culture until the sixth. N=3 biological replicates, error bars represent the 
standard deviation. 
 
 
It was also of interest to understand the metabolic burden of biosensor expression on the 
cells. The growth curve of the biosensor-transfected cell lines was therefore compared with 
that of the non-transfected cells to evaluate the impact of biosensor expression on cell 
growth. The cells were grown in batch cell cultures and samples were taken daily for Trypan 
blue dye exclusion counts of cell concentration and viability. Figure 29a shows the growth 
trend for both cell lines is similar, both showing the highest concentration of cells at day 6. 
The peak concentration of cell reached for the non-transfected cells, however, is higher 
than that of the transfected cell lines, as can be expected for cells expressing a recombinant 
protein. The non-transfected cells have a peak concentration of 7.02 x 106 cells/mL, while 
the glucose biosensor transfected cells have a peak of 5.03 x 106 cells/mL, which represents 
a decrease of 28%. The IVCC is shown in Figure 29b and again is higher for non-transfected 
cells.   
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Figure 29a: A typical batch culture for CHO-S cells and CHO cells with the 
glucose biosensor.  
The blue line shows the lag, exponential growth, stationary and death phases for 
CHO cells with the red line showing the same phases for the CHO-S cells with the 
glucose biosensor. A decrease in cell concentration is seen in the transfected cell 
line. N=3 biological replicates, error bars represent the standard deviation. 
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Figure 29b: The IVCC for the CHO-S and CHO-S cells expressing the glucose 
biosensor 
The IVCC from the above growth curve for the CHO-S cells and the cells with 
the glucose biosensor. Shows the decrease in cell concentration is reflected in 
the reduced IVCC. N=4 biological replicates. , error bars represent the standard 
deviation. 
 
Figure 30a  shows that the growth pattern of the glutamine biosensor-expressing cell line 
was similar to that of non-transfected CHO-S cells, but that the latter had a higher peak 
reaching 7.11 x 106 cells/mL compared to 4.89 x 106 cells/mL for the glutamine biosensor-
  88 
expressing cell line. The impact on growth is seen in Figures 29b, the IVCC was greatly 
affected and the burden on the cells is clear. The glucose biosensor transfected cells had a 
lower IVCC, 50% lower whilst the glutamine biosensor decreased the IVCC by 40% when 
compared to the non-transfected CHO-S cells.. The IVCC displayed by these two cell lines is 
shown in Figure 30b. Up to day 5 it is comparable for the two cell lines, after which it 
increases considerably for the CHO-S cell line. Both transfected and non-transfected cells 
reach their maximum concentration at day 6. This shows that the stationary phase begins at 
the same time for the two cell lines under batch culture. The above difference in cell 
concentration and IVCC is also seen in the growth rates during the exponential phase. The 
non-transfected cells have an exponential growth rate of 0.62 day-1 and the glucose 
biosensor transfected CHO-S cells have an exponential growth rate of 0.60 day-1. Whilst the 
difference in the exponential growth rate of glutamine transfected CHO-S cells is more 
pronounced with 0.52 day-1 when compared to the non-transfected. This impact may be 
attributed to the extra burden of producing the biosensor.  
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Figure 30a: A typical batch growth curve for CHO-S cells and CHO cells 
expressing the glutamine biosensor.  
The graph highlights the four phases of growth and the lower cell 
concentration of the CHO-S cells with the glutamine biosensor. N=3 biological 
replicates, error bars represent the standard deviation. 
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Figure 30b: The IVCC for the CHO-S and CHO-S cells with the glutamine 
biosensor. 
The IVCC for the non-transfected CHO-S cells and the cells expressing the 
glutamine biosensor. This shows the decrease in IVCC for the CHO-S cells 
expressing the glutamine. N=3 biological replicates, error bars represent the 
standard deviation. 
 
4.2 In vivo biosensor calibration 
To assess the possible relationship between the FRET ratio and a changing intracellular 
glucose and glutamine concentrations in vivo calibration curves were produced. With 
respect to the glutamine biosensor a FRET signal is observed when the glutamine ligand 
binds the periplasmic binding domain, which causes a conformational change in the ECFP 
and EYFP. This conformational change leads to the FPs coming into a close orientation so 
that the dipoles are aligned and a transfer of energy takes place. This is manifested by an 
increase in FRET ratio. Conversely, when there is no glutamine present, the FPs are far apart 
and no FRET signal is observed. The glucose biosensor has a different method for FRET 
detection, Figure 31a shows that an increase in the FRET ratio is coupled to a decrease in 
the intracellular glucose concentration and vice versa for a large part of the growth curve in 
vivo, in particular between days 4 and 8 of the batch cell culture. 
 
 The FRET ratios from the initial days are inaccurate and difficult to measure because of the 
small number of cells and thus an accurate relationship cannot be formulated. Also when 
the ratios are out of the calibration range the numbers cannot be used in any patterns or 
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trend formulations. From day 9 to 11 the FRET ratio is also erratic, possibly due to decreased 
cell viability and increased light scattering by debris from lysed cells. Therefore days 4-8 of a 
batch culture (Figure 31b) represent the best window to measure the FRET ratios under the 
conditions tested and correlate this to the intracellular glucose concentration measured. 
Figure 31c is the in vivo calibration curve resulting from the intracellular glucose 
concentrations (Figure 31a) and corresponding FRET ratios (Figure 31b). Figure 31c shows an 
R2 of 0.96 is observed which shows that this is a very close linear relationship. This figure 
also allows us to possibly be able to predict the intracellular glucose concentration in cells 
using the FRET ratios of these cells. This is a step in the direction of using these biosensors 
as a tool for online metabolite readings.  
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Figure 31a: In vivo calibration curve for CHO cells with the glucose biosensor 
Where the FRET ratios are in red against the intracellular glucose 
concentrations in blue. This shows that decreasing intracellular concentration 
over time against the increasing FRET ratio.  N=2 biological replicates, error 
bars represent the standard deviation. 
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Figure 31b: Closer look at days 4-8 for the in vivo calibration curve for CHO 
cells with the glucose biosensor.  
The expected relationship of decreasing intracellular glucose concentration 
and increasing FRET ratios is seen between days 4 and 8. N=4 biological 
replicates, error bars represent the standard deviation. 
 
0 1 2 3 4 5 6
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
8.0
y=-1.2327x + 8.0341
R2= 0.9616
Glucose concentration (mM)
F
R
E
T
 R
a
tio
 5
2
0
/4
6
5
n
m
 
Figure 31c: Glucose biosensor In vivo calibration curve for days 4-8  
As calculated from Figure 31b, showing the linear relationship between FRET 
ratio and intracellular glucose concentration with a R2 of 0.9616. Vertical error 
bars represent the standard deviation for the FRET ratio on the y axis and 
horizontal error bars represent the glucose concentration on the x axis. 
 
 
Table 12: Comparing regression curves for a range of days based on data from 
Figure 31a.  
The yellow area highlights that the highest R2 is observed for days 4-8. 
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Glucose biosensor Range (days) Equation of line R2 
 3-8 y = -1.3251x + 8.1918 0.9516 
 4-7 y = -1.1784x + 7.7984 0.9555 
 4-8 y = -1.2327x + 8.0341 0.9616 
 
 
Figure 32a shows the intracellular glutamine concentration and the corresponding FRET 
ratio over cell culture time. As explained in the glucose section, the initial days show a small 
FRET ratio due to the low cell number. Similarly, between days 9-12 the FRET ratio 
fluctuates greatly due to the cell debris present because of cell death. The FRET ratios for 
these days were therefore deemed unreliable. The interval between days 4 and 8 is the 
usable window for this type of batch experiment. As table 12 shows the highest linear 
relationship is observed for days 4-8 with a R2 of 0.9616. The R2 values for the range of days 
displayed in table 9 are similar, so the range of 4-8 was chosen as this was the maximum 
possible range to use. The linear relationship between FRET ratio and intracellular glutamine 
concentration is clearly displayed in Figure 32b where the decrease in glutamine levels and 
the decrease in FRET ratio are observed. This linear association is further highlighted with 
the in vivo calibration curve where R2 of 0.87 in Figure 32c is seen. Whilst it can be seen that 
the linear relationship is not as obvious as Figure 31c. This may be due to some sort of 
competitive inhibition (e.g. by other amino acids) on the glutamine biosensor, which may 
decrease the strong linear relationship.  As table 13 reveals days 4-7 has the highest R2  and 
confirms this range of days to be the best for linear measurements to be taken. 
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Figure 32a: In vivo calibration curve for CHO cells with the glutamine 
biosensor  
Where the FRET ratios are in red against the intracellular glutamine 
concentrations in blue. This shows that decreasing intracellular concentration 
over time against the decreasing FRET ratio.  N=2 biological replicates, error 
bars represent the standard deviation. 
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Figure 32b: Closer look at days 4-8 for the in vivo calibration curve for the 
CHO-S cells with the glutamine biosensor.  
The expected relationship of decreasing intracellular glutamine concentration 
and decreasing FRET ratios is seen between days 4 and 8. N=4 biological 
replicates, error bars represent the standard deviation. 
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Figure 32c: Glutamine biosensor In vivo calibration curve for days 4-8  
As calculated from Figure 32b, showing the linear relationship between FRET 
ratio and intracellular glutamine concentration with an R2 of 0.8794.  
Vertical error bars represent the standard deviation for the FRET ratio on the y 
axis and horizontal error bars represent the glucose concentration on the x axis. 
 
Table 13: Comparing regression curves for a range of days based on data from 
Figure 32a.  
The yellow area highlights that the highest R2 is observed for days 4-7. 
 
Glutamine biosensor Range (days) Equation of the line R2 
 3-8 y = 0.1614x + 1.4715 0.0576 
 4-7 y = 1.8923x - 0.3323 0.8794 
 4-8 y = 1.4948x + 0.2881 0.7566 
 
 
4.3 Quantitative predictive capability of biosensor signal 
To show that the observed changes in FRET were a consequence of the changing 
intracellular glucose and glutamine concentration, a fed-batch cell culture study was 
instigated. The fed-batch cultures were fed with a bolus addition of glucose on day 6 (peak 
day for growth in previous experiments) to bring the extracellular concentration up to 
36mM and glutamine on day 6 to bring the extracellular concentration up to 4mM, while 
batch cultures were given an equal volume of double distilled water (ddH20).  Figure 33a 
shows a typical growth curve for both batch and fed-batch cultures. The results indicate the 
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addition of the extra glucose on day 6 increased the growth curve by one day as compared 
to the batch cultures. The IVCC is shown in Figure 33b and this corroborates the increased 
cell concentrations, as the IVCC reached from the fed-batch flask is 33% higher than the 
batch grown cells.  Figure 33b shows that the fed-batch has a higher IVCC approximately 
60% greater than the batch cell cultures.  The increased cell concentrations and IVCC are 
seen in the difference in growth rates during the exponential phase. Whilst the Batch test 
has a growth rate of 0.58 day-1, the fed-batch culture has an increased growth rate during 
the exponential phase reaching 0.64 day-1. Figure 33c shows the corresponding FRET ratio 
changes.  Upon addition of glucose on day 6 the FRET ratio decreased, which as explained 
above is a direct result of the change in intracellular glucose concentration.  
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Figure 33a: Batch vs. fed batch test on CHO cells expressing the glucose 
biosensor.  
The blue points represent the fed-batch study which shows an increase in cell 
concentration once feed on day 6. While the red points correspond to the 
batch cell cultures that display a typical growth curve. N=2 biological 
replicates, error bars represent the standard deviation. 
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Figure 33b: IVCC for the batch vs. fed batch CHO cells with the glucose 
biosensor 
The batch in red against the fed-batch cell cultures in blue. The difference in 
cell concentration is reflected in the large increase in IVCC of the fed-batch 
culture of the CHO cells expressing the glucose biosensor. N=2 biological 
replicates. , error bars represent the standard deviation. 
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Figure 33c: Change in FRET ratio as a consequence of feeding on day 6 
The decrease in FRET as a result of feeding on day 6 is seen in blue, whilst a 
typical batch FRET ratio profile is seen in red. N=2 biological replicates, error 
bars represent the standard deviation. 
 
Figure 34a illustrates a batch vs. a fed-batch growth curve with CHO cells transfected with 
the glutamine biosensor and it is clear that due to the feed at day 6 a higher cell 
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concentration is reached which correlates to a higher IVCC of 25% (Figure 34b).  The 
difference in the exponential growth phase of these two tests shows the impact of the fed-
batch. The batch has a growth rate of 0.60 day-1 whilst the fed-batch has an increased 
growth rate of 0.63 day-1. Daily samples were taken from these fed-batch cultures and FRET 
ratios obtained. Figure 34c shows us that upon addtion of glutamine on day 6 there is an 
increased FRET signal. These experiments highlight that these biosensors are useful for 
measuring changes in intracellular glucose and glutamine concentrations.  
 
 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
0
2.0×106
4.0×106
6.0×106
8.0×106
1.0×107
1.2×107
Batch
Fed batch
Day
C
o
n
c
e
n
tr
a
tio
n
 (
c
e
lls
/m
L
)
 
 
Figure 34a: Batch vs. fed batch test on CHO cells expressing the glutamine 
biosensor.  
The blue points represent the fed-batch culture which shows an increase in cell 
concentration once feed on day 6. While the red points correspond to the 
batch cell cultures that display a typical growth curve. This shows the decrease 
in cell concentration of the batch culture as compared to the fed-batch.  N=2 
biological replicates, error bars represent the standard deviation.  
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Figure 34b: IVCC for the batch vs. fed batch CHO cells with the glutamine 
biosensor.  
The batch in red against the fed-batch cell cultures in blue. The difference in 
cell concentration is reflected in the large increase in IVCC of the fed-batch 
culture of the CHO cells expressing the glutamine biosensor. N=2 biological 
replicates, error bars represent the standard deviation. 
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Figure 34c: Change in FRET ratio as a consequence of feeding on day 6 
The increase in FRET as a result of feeding on day 6 is seen in blue, whilst a 
typical batch FRET ratio profile is seen in red. N=2 biological replicates, error 
bars represent the standard deviation. 
 
 
The ability of this system to predict the intracellular glucose and glutamine concentration 
based on FRET ratio measurements was also measured.  The calibration curve in Figure 31c 
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was used to convert the FRET ratio to intracellular glucose concentration (mM) and Figure 
32c for the glutamine concentration (mM). The result was compared with the actual 
concentration as measured by the enzymatic assay (Figure 14).  Both Figures show a 
comparable pattern; days 4, 5 and 6 show a decrease in the actual and predicted glucose 
and glutamine concentration. As a result of feeding the glucose and glutamine 
concentrations increase on day 7 and as these metabolites are used the final day (8) shows a 
decrease once more. Figure 35a shows that at every point apart from day 8 the predicted 
glucose concentration is higher, there is a 20% error for days 4 and 5 and a 10% difference 
at day 7. Figure 35b shows a 28% maximum difference on days 4 and 5. Days 4 and 5 for 
both Figures show the largest percentage difference. It is clear that using the FRET ratios it is 
possible to predict the changes in intracellular glucose and glutamine with a moderate 
amount of accuracy.   
3 4 5 6 7 8 9
2
3
4
5
6
Actual glucose
concentration
Predicted glucose
concentration based on
FRET ratios
Day
In
tr
a
c
e
llu
la
r 
G
lu
c
o
s
e
 c
o
n
c
e
n
tr
a
ti
o
n
(m
M
)
 
Figure 35a: Using FRET for predicting intracellular glucose concentrations in a 
fed batch culture 
The blue line represents the actual intracellular glucose concentrations as 
measured by the Amplex red™ glucose assay. The Red line is the predicted 
concentrations based on FRET ratios. This shows that using FRET ratios it is 
possible to predict accurately the glucose concentrations even in a fed-batch 
culture.  N=2 biological replicates, error bars represent the standard deviation 
(blue line), error bars for predicted glucose concentration were calculated 
using 95% CI values. 
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Figure 35b: Using FRET for predicting intracellular glutamine concentrations 
in a fed batch culture 
The blue line represents the actual intracellular glutamine concentrations as 
measured by the Enzychrome™ assay. The Red line is the predicted 
concentrations based on FRET ratios. This shows that using FRET ratios it is 
possible to predict accurately the glutamine concentrations even in a fed-batch 
culture.  N=2 biological replicates, error bars represent the standard deviation, 
(blue line), error bars for predicted glucose concentration were calculated 
using 95% CI values. 
 
 
4.4 Conclusions 
The aim of this work was to develop two biosensors that would allow the measurement of 
intracellular glucose and glutamine concentrations in Chinese Hamster Ovary cells in a non-
invasive way. Ideally, the sensor should be genetically encoded (so the biosensor is 
constantly produced), not interfere with normal cellular processes, and give a quantifiable 
signal, rather than just indicate the presence/absence of a metabolite.  For these reasons, 
Förster resonance energy transfer protein-based biosensors were chosen. These allow non-
destructive measurements of any metabolite to which the binding domain is sensitive. They 
are also genetically encoded and allow online measurements provided that the right tools 
are available. Two potential glucose biosensors FLIPglu-600µ-Delta11aphrodite and FLIPglu-
3200µ-Delta13 were identified in the literature.  These were evaluated in vitro to determine 
their Kd and linear range of measurement. The data produced suggested that the FLIPglu-
600µ-Delta11aphrodite biosensor was more suited to measuring the intracellular 
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concentrations of glucose as encountered in CHO cells during batch cell culture in CD-CHO 
medium.  One glutamine biosensor was identified D157N and as above this was evaluated in 
vitro to determine their Kd and linear range of measurement. The specificity of FLIPglu-
600µ-Delta11aphrodite for glucose in the presence of G-6-P, a structurally similar 
metabolite, was also tested.  The results indicated that the interference by this metabolite 
was minimal. The amino acid interference test for the glutamine biosensor was conducted 
as a result of previous work, which highlighted there may by a difference in FRET ratios 
based on addition of other amino acids. However, these results suggest that interference by 
other amino acids is limited. This section also tested glutamine binding with the addition of 
two different sources of dipeptides and again there was no difference in the FRET ratio with 
the addition of these sources. Two stable CHO cell lines expressing the biosensors were 
created and expression was confirmed by qRT-PCR. An in vivo calibration was constructed 
by simultaneous measurement of the FRET ratio and the actual intracellular glucose and 
glutamine concentration by enzymatic assay.  The data suggested that the biosensor 
readings would have a limited range during which they accurately reflect the intracellular 
glucose concentration.  During the initial days the cell number was too low so the FRET ratio 
would not be accurate and between days 9-11 the cell debris in the culture medium would 
not allow a reliable FRET ratio as the ratios were too unpredictable.  
 
These findings suggest that the FRET signal is best correlated with the intracellular 
concentrations between 1 and 5 mM for glucose and 0.3 and 2 mM for glutamine. These 
ranges correspond to the exponential, stationary, and early decline phases of the culture of 
these cell lines, which are the most important in terms of elucidating metabolic 
requirements in a bioprocessing context. This meant that when performing a batch cell 
culture of this particular cell line in shake flasks in CD-CHO medium, days 4-8 for the glucose 
transfected cell and days 4-7 for the glutamine transfected cells (mid-exponential phase) 
were the ones for which non-invasive measurement would be possible. The data from these 
days were used to construct the calibration curve. Finally, a proof-of-concept study using a 
fed-batch culture showed that the FRET ratio could be used to predict the intracellular 
concentration of metabolites within 28% maximum difference, which highlights that these 
biosensors can be used for quantification as well as a tool for measurement.  
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Chapter 5. Bioprocess and BioLector™ 
Chapter 4 demonstrated that the selected biosensors give correlations and trends with 
respect to glucose and glutamine level and could be used to predict concentrations of these 
metabolites in vivo within 30%. These results, however, are from shake-flask studies. It 
would be interesting to compare them to what happens at a smaller scale. To save labour 
and money low volume assays are used. These allow much more work to be done and  more 
data to be collected in a short amount of time.  Due to their automated nature this cuts 
down on labour costs. One such system is the BioLector™ micro fermentation unit from 
m2p-labs.  
 
Firstly the cultivation parameters must be defined. For the BioLector™ investigations a 
temperature of 37oC was used as well as 5% CO2 and a shaking speed of 1000rpm. To set up 
the gain, an inoculated micro-titre plate containing CHO cells with the two biosensors was 
used. Various gains were tested as detailed in the methods and materials section. For the 
biomass, yellow and blue fluorescence calibration curves the same method was repeated. 
The optical set up in the BioLector™ for the blue filter was an excitation of 420nm and an 
emission of 470nm while the yellow filter had an excitation of 420nm and an emission at 
532nm. Figure 36 shows an example calibration curve from these tests. Various gains were 
tested (40-50 for biomass and 40-55 for the filters); the gain for biomass was set to 41, with 
gains for the yellow and blue wavelengths set at 51. These gains were chosen as the highest 
concentration of cells gave a light scattering intensity of less than 1000U. This method was 
also used for the blue and yellow fluorescence using a different tab on the software analysis 
tool for the readings on the BioLector™.  
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Figure 36: Example calibration curve used for biomass estimation in the 
BioLector™.  
The concentration against the biomass is shown, where an exponential 
increase is seen. N=3 technical replicates, error bars represent the standard 
deviation 
 
5.1 Growth profile  
The first step was to assess cell growth in the BioLector™ scaled down system. Figure 37a 
shows this for the non-transfected CHO-S cells. This Figure compares the growth in shake 
flasks and the BioLector™.   
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Figure 37a: Batch growth curve for CHO-S in a flask and the BioLector™ 
The batch growth curve shows an increase in cell concentration for CHO-S cell 
grown in the BioLector™. N=4 biological replicates, error bars represent the 
standard deviation.  
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The peak concentration reached in the BioLector™ is higher at 8.2 x 106 cells/mL, compared 
to 7.02 x 106 cells/mL reached in the flask. The whole growth curve shifted to the right with 
the cells in the BioLector™ growing for an additional 5 days. This change in IVCC may be 
attributed to the difference in culture conditions between the BioLector™ and the flask 
level. There may be differences in the oxygen transfer rates as the filter lid of the flask is 
different to the filter sheet placed over the cultures of the micro titre plate in the 
BioLector™.  There may also be differences in growth as the shaking speeds are different, in 
the flask a shaking speed of 125rpm is used whilst the BioLector™ uses 1000rpm. Below the 
IVCC is seen, and it is clear that the cells grown in the BioLector™ have a much higher IVCC 
as a result of the cells growing to a higher concentration and for a longer period of time. The 
above data would suggest that the cells grown in the BioLector™ have a better growth rate 
but in the exponential phase the growth rate is lower when compared to the CHO-S cells 
grown in the flasks. The CHO-S cells in the BioLector™ have a growth rate of 0.37 day-1 
comparing this to 0.62 day-1 for the CHO-S cells in the flasks 
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Figure 37b: IVCC for the CHO-S cells grown in batch in the flask and 
BioLector™ 
The increase in cell concentration is reflected in the higher IVCC. N=4 biological 
replicates, error bars represent the standard deviation.  
 
 
 
Figures 38a and 38b highlight the growth curve and IVCC of the CHO cells transfected with 
the glucose biosensor grown in the BioLector™ vs. the non-transfected CHO-S cells. As with 
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the transfected cells cultured in flasks, the cells grown in the BioLector™ also have a burden 
placed on them with respect to IVCC. In flasks the IVCC was reduced by 50% whilst in the 
BioLector™ this reduction is 33%. The peak in the Figure below is on day 6 (5.94 x 106 
cells/mL) as was the peak in the same cells in the flask (5.03 x 106 cells/mL).  The 
exponential phase growth rate for these two cultures however shows a less pronounced 
difference. The CHO-S cells transfected with the glucose biosensor in the BioLector™ have a 
growth rate of 0.34 day-1 with the un-transfected CHO-S cells grown in the BioLector™ 
having a growth rate of 0.37 day-1.  
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Figure 38a: Batch growth curve for CHO-S transfected with the glucose 
biosensor and CHO-S cells in the BioLector™  
The batch growth curve shows an increase in cell concentration for CHO-S cells 
grown in the BioLector™ whilst the glucose biosensor transfected cells display 
a decrease in cell concentration. N=4 biological replicates, error bars represent 
the standard deviation.  
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Figure 38b: IVCC for CHO-S cells and CHO-S cells expressing the glucose 
biosensor in the BioLector™ 
CHO-S cell transfected with the glucose biosensor show a decreased IVCC as 
confirmed by the decreased cell concentration. . N=4 biological replicates, 
error bars represent the standard deviation. 
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Figure 39a: Batch growth curve for CHO-S transfected with the glutamine 
biosensor and CHO-S cells in the BioLector™  
The batch growth curve shows an increase in cell concentration for CHO-S cells 
grown in the BioLector™ whilst the glutamine biosensor transfected cells 
display a decrease in cell concentration. N=4 biological replicates (blue), error 
bars represent the standard deviation.  
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A similar trend is seen with the CHO cells transfected with the glutamine biosensor (Figures 
39a and b). The burden here is more than in flasks, reaching 50% lower IVCC when 
compared to 40% in the flask. The peak is on day 7 whilst the CHO-S cells transfected with 
the glutamine biosensor in the flask peaked at day 6 (Figure 29a). The above burden effect is 
seen in the growth rates for the above two tests. During the exponential phase the growth 
rate for the glutamine sensor transfected cells is 0.28 day-1, compared to higher non-
transfected with 0.37 day-1. However the CHO-S data in the BioLector™ needs higher sample 
numbers for a clear conclusion to be drawn for Figures 38 and 39. This is because the CHO-S 
cells in this particular case may have shown a delayed growth but more sample numbers 
would show a more complete growth pattern and this delay may be addressed.  
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Figure 39b: IVCC for CHO-S cells and CHO-S cells expressing the glutamine 
biosensor in the BioLector™ 
CHO-S cell transfected with the glutamine biosensor show a decreased IVCC as 
confirmed by the decreased cell concentration. N=4 biological replicates, error 
bars represent the standard deviation. 
 
 
 
Figures 40a (IVCC for CHO cells expressing the glucose biosensor) and 41a (IVCC for the 
CHO-S expressing the glutamine biosensor) show this burden effect. Comparing these 
growth curves with those obtained from shake flasks, the growth curve in Figure 40a is 
similar with the peaks at the same day 6. The red line is consistently higher, which is 
reflected in the IVCC (Figure 40b) that is higher in the cells grown in the BioLector™ by 37%.
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Figure 40a: Flask and BioLector™ growth curve comparison for CHO-S cells with 
the glucose biosensor. 
The growth curve in the BioLector™ shows a higher cell concentration over the 
flask growth curve. N=4 biological replicates, error bars represent the standard 
deviation.  
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Figure 40b: IVCC for CHO-S cells expressing the glucose biosensor in the flask 
and BioLector™  
The higher cell concentration is confirmed with a higher IVCC for the 
BioLector™ grown CHO-S cells with the glucose biosensor compared to the 
flask growth curve. N=4 biological replicates, error bars represent the standard 
deviation. 
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Figure 41a: Flask and BioLector™ growth curve comparison for CHO-S cells with 
the glutamine biosensor 
The two growth curves show a similar cell concentration and growth profile. N=4 
biological replicates, error bars represent the standard deviation.  
 
Figure 41a shows the growth curves for CHO cells transfected with the glutamine biosensor 
in the flask and the BioLector™. The growth curves are similar with the peaks differing by 
one day; the cell concentration at these peaks is also very similar. This similarity is also seen 
in the IVCC (41b).  This suggests that growth in the BioLector™ alleviates the burden of 
expressing the glutamine biosensor. 
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Figure 41b: IVCC for CHO-S cells expressing the glutamine biosensor in the 
flask and BioLector™ 
The similar cell concentration is confirmed with a very similar IVCC for both 
scales of growth curves. N=4 biological replicates, error bars represent the 
standard deviation. 
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Figures 42 and 43 show that the growth curve determined with the Trypan blue dye 
exclusion method in blue and the expected growth curve based on the biomass readings in 
red are very close up until day 6 for the glucose biosensor-producing cells (Figure 42) and 
day 8 for the glutamine biosensor-producing cells (Figure 43). The difference between the 
two cell lines is due to the threshold of 5.00 x 106 cells/mL being reached on day 6 by the 
former (Figure 42) and day 7 by the latter (Figure 43). This is the threshold up to which 
biomass readings can be predictive of cell concentration. The peak cell concentration for 
CHO cells expressing the glucose biosensor was reached on day 6 (Figure 42) whilst for the 
cells expressing the glutamine biosensor the maximum cell concentration was reached at 
day 7 (Figure 43). However, after that time the estimated cell concentration based on the 
biomass readings from the BioLector™ continues to rise whilst the cell count data shows 
that cells actually reach stationary and enter the decline phase. One of the limitations of the 
BioLector™ is that biomass concentration is estimated via optical density measurements.  
This cannot account for cell viability and thus the correlation of optical density with viable 
cell concentration becomes unreliable at later stages of culture. 
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Figure 42: Estimated growth curve and actual growth curve for glucose 
biosensor transfected cells in the Biolector™ 
The estimated growth curve based on biomass readings shows a constant 
increase, this is due to the biomass readings not being able to account for cell 
debris and cell death during the decline phase of growth. A threshold of 5.00 x 
106 cells/ml is observed.  N=4 biological replicates, error bars represent the 
standard deviation (blue line). Error bars for estimated growth were calculated 
using 95% CI values. 
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Figure 43: Estimated growth curve and actual growth curve for glutamine 
biosensor transfected cells in the Biolector™ 
The estimated growth curve based on biomass readings shows a constant 
increase, this is due to the biomass readings not being able to account for cell 
debris and cell death during the decline phase of growth. Again a threshold of 
5.00 x 106 cells/ml is observed.  N=4 biological replicates, error bars represent 
the standard deviation (blue line). Error bars for estimated growth were 
calculated using 95% CI values. 
 
5.2 Case study 1- Glutamine sources test 
The BioLector™ was set to take measurements every 300 minutes, shaking at 1000 rpm at 
5% CO2 at 37
oC. Gain values for the biomass were determined using a calibration curve. The 
value of the gain was fixed when a single measurement gave a reading below 1000 U for the 
highest concentration used. The gain for the biomass was set at 41 whilst the gains for the 
yellow and blue fluorescence filters were 51.  
 
The first investigation focused on using various glutamine sources to assess their effect on 
the growth and metabolism of CHO-S cells transfected with the glutamine biosensor. Two 
different di-peptide sources were used, Ultraglutamine I (alanyl-L-glutamine) and II (L-glycyl-
L-glutamine), as well as molecular glutamine at a range of concentrations from 2 mM up to 
10 mM in CD-CHO medium supplemented with 10 mL/L hypoxanthine/thymine. These 
different glutamine sources were used as it has been shown they can increase cell 
concentrations when compared to glutamine alone (Christie and Butler, 1994). It was also of 
interest to show if the di-peptide coupling would have an advantage in terms of cell 
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concentration increases as it has been shown the di-peptides are a more stable form of 
glutamine (Christie and Butler, 1994). These investigations were conducted in the 
BioLector™ to assess whether the small scale would allow FRET readings to be used as a tool 
for the assessment of increases and decreases in intracellular metabolite concentration.   
 
Glutamine is an essential amino acid required for cell growth. Once deaminated by the 
cells, it is used as an energy source, incorporated into protein, and used in nucleic acid 
metabolism. Figure 48a is the batch cell growth curve observed for the five different 
concentrations of molecular glutamine used and the effect on cell growth. 
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Figure 44a: Batch cell growth curves for CHO cells expressing the glutamine 
biosensor cultivated under five different concentrations of L-glutamine in the 
BioLector™.  
The highest viable cell concentrations come from the cultures supplemented 
with 4mM, 6mM and 8mM L-glutamine, while cultures supplemented with 
2mM and 10mM displayed the lowest concentrations. N=1 biological replicate.  
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Figure 44b: IVCC for the CHO cells expressing the glutamine biosensor 
cultivated under five different concentrations of L-glutamine in the 
BioLector™. 
The three cultures with the highest viabilities seen in Figure 44a (4mM, 6mM 
and 8mM) also show the highest IVCC. N=1 biological replicate. 
 
The results in Figure 44a are reflected in the IVCC shown in Figure 44b. They show that 6mM 
and 4mM seem to yield a higher IVCC with the highest concentration of glutamine (10 mM) 
yielding the lowest IVCC. This is shown in the 32% decrease for the IVCC of 10mM compared 
to 4 and 6 mM. The highest growth rate observed in the exponential phase is for the 6mM 
glutamine, reaching 0.33 day-1, this value is shared with 4mM with 0.33 day-1. The lowest 
growth rate is reached by the 8mM which is 0.29 day-1 and 10Mm which is also 0.29 day-1. 
This may indeed indicate that after a threshold of 6mM the uptake rate of glutamine will not 
increase, any more glutamine the cells are fed will cause no change in the IVCC.  Too little an 
amount of glutamine means there is not enough for metabolism and this may account for 
the lower cell density seen in Figure 44a. Adding more glutamine than needed, however, 
can also lead to the build-up of ammonia, as glutamine is broken down extracellularly faster 
than it is metabolized by the cells (page 16:  
https://www.atcc.org/~/media/PDFs/Culture%20Guides/AnimCellCulture_Guide.pdf). As 
mentioned by Hansen and Emborg “a high ammonia concentration leads to reduced cell 
growth rate, lowering cell density and reduced therapeutic protein production” (Hansen and 
Emborg, 1994).   
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Figure 44c shows the corresponding FRET ratios as calculated from the respective yellow 
and blue wavelength readings from the BioLector™. The cells grown in 8 mM glutamine 
show an initial increase in FRET ratio (positively correlated with glutamine concentration), 
followed by a decrease in FRET ratio, which indicates low glutamine levels. The 4mM, 6mM 
glutamine treated cells show consistently high FRET ratios, while the 10mM treated culture 
shows a much lower initial FRET then gradually increase over time, with a decrease coming 
after 150 hours. The green line representing the 2mM glutamine fed cells shows the lowest 
FRET ratios and hence the lowest glutamine concentration would be expected A similar 
pattern is noticed here where the FRET ratios decrease over time consistently with previous 
results in both the flask and BioLector™. This would make sense as over time the 
intracellular glutamine levels would decrease as this is metabolised and extracellular 
supplies run out. 
 
Figure 44b shows that the highest IVCC is that of the 4mM, 6mM and 8mM glutamine 
treated cells. These three also have the highest initial FRET ratios as seen in Figure 44c.  This 
would indicate that these cells had a higher beginning intracellular glutamine concentration; 
this may be an indication of why they also have the highest cell concentration seen in Figure 
44a. As the cell concentration decreases in Figure 44a so does the FRET ratio.  These findings 
may reveal that the cells with the highest initial intracellular glutamine levels are those that 
are able to give a higher cell concentration and thus the FRET ratios can be used in this 
context as a tool to reveal the cell lines with the highest initial intracellular concentrations.  
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Figure 44c: FRET ratios for the CHO cells expressing the glutamine biosensor 
cultivated under five different concentrations of L-glutamine in the 
BioLector™. 
These were calculated using the yellow wavelength divided by the blue 
wavelength as read from the BioLector™. The three highest viabilities also have 
the three highest initial FRET ratios, this indicates the highest initial intracellular 
glutamine concentrations. N=1 biological replicate.  
 
The following three graphs (Figures 45a, b and c) show the results for the batch growth 
curve, the IVCC and the FRET signal for CHO cells expressing the glutamine biosensor grown 
using different concentrations of Ultraglutamine I in place of glutamine as a supplement to 
CD-CHO medium. Figure 49a shows that supplementing with 6mM of Ultraglutamine I 
increases the cell concentration to a maximum of 8.0 x 106 cells/mL. The IVCC for the 4mM, 
6mM treated cells is also very similar. This represents a 30% increase over the maximum cell 
concentration obtained with 4 mM L-glutamine, which is the recommended concentration 
to use in cell culture by the manufacturer of CD-CHO, as well as the recommended 
concentration of Ultraglutamine I. The IVCC for this experiment is also similar to Figure 44b, 
however the 2mM Ultraglutamine I has a 10% higher IVCC than 2mM L-glutamine. The 
similarity is also shared with respect to the 10mM concentration giving the lowest IVCC. This 
high cell concentration trend is seen in the growth rates during the exponential phase. The 
6mM has the highest growth rate of 0.42 day-1 with the lowest growth rate belonging to the 
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10mM with 0.29 day-1. This would suggest that 6mM of Ultraglutamine I is the optimum 
concentration to get the highest growth and cell concentrations. Looking at Figure 45c a 
similar pattern is once again observed where the FRET ratios decrease over time possibly 
signalling a decrease in the glutamine concentrations. The FRET ratios for both the 8mM and 
10mM fall very sharply at days 7 and 8, respectively.  
The highest IVCC is seen with the 4mM and 6mM with the 8mM being a close behind. Figure 
45c shows that the highest initial FRET ratios belong to 4mM and 6mM. This trend is similar 
to what was concluded with the glutamine treated cells.  The FRET ratios also show a fall for 
all concentrations from day 6 onwards apart from the 6mM. This is reflected in the 
viabilities seen in Figure 45a where all the viabilities for all concentrations apart from 6mM 
fall. Indeed at day 6 the highest cell concentration is reached in Figure 45a, this is coupled to 
the highest FRET ratio reached for the 6mM. From this it may be inferred that a high FRET is 
linked to a high cell concentration, which is down to a high intracellular glutamine 
concentration. The FRET results may imply that this form of glutamine may be used more 
efficiently by the CHO-S cells. This may be due to a better uptake rate of this di-peptide. 
Indeed, ultranglutamine I (l-alanyl-glutamine) is more stable and far more water soluble 
than L-glutamine (Hassell et al., 1991). Dipeptides are usually transported faster than free 
amino acids, due to the intact and efficient dipeptide transport carrier they employ. 
Ultraglutamine I also reduces the build-up of toxic ammonia compared to glutamine (due to 
the latter's spontaneous conversion into pyrrolidone carboxylic acid and NH3), (Christie and 
Butler, 1999). 
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Figure 45a: Batch cell growth curves for CHO cells expressing the glutamine 
biosensor cultivated under five different concentrations of Ultraglutamine I 
in the BioLector™.  
The highest viable cell concentration is reached by the cultures supplemented 
with the 4mM and 6mM Ultraglutamine I, while cultures with 10mM 
Unltraglutamine I have the lowest viable cell density profile. N=1 biological 
replicate. 
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Figure 45b: IVCC for the CHO cells expressing the glutamine biosensor 
cultivated under five different concentrations of Ultraglutamine I in the 
BioLector™. 
The highest cell concentrations seen in Figure 45a also have the highest IVCC 
with 10mM having the lowest IVCC as the lowest cell concentration would 
suggest. N=1 biological replicate. 
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Figure 45c: FRET ratios for the CHO cells expressing the glutamine biosensor 
cultivated under five different concentrations of Ultraglutamine I in the 
BioLector™. 
These were calculated using the yellow wavelength divided by the blue 
wavelength as read from the BioLector™. The highest cell concentrations also 
have the highest initial FRET ratios, this indicates the highest initial intracellular 
glutamine concentrations. N=1 biological replicate. 
 
 
The next di-peptide was Ultraglutamine II and the associated results are presented in 
Figures 50 a-c. The highest cell concentration reached is once again from the 4 mM fed cells 
(4.0 x 106 cells/mL) however this is 33% less than the peak reached by the same 
concentration in ultraglutamine I and 20% less than 4mM glutamine feed cells. The highest 
viable cell concentration achieved is 4.2 x 106 cells/mL, which is almost half the maximum 
concentration reached with the use of Ultraglutamine I. This is reflected in the IVCC where 
four out of the five concentrations are below 5 x 1011 cells-h/L.  This is in contrast with the 
Ultraglutamine I where four out of five concentrations are between 7 x 1011 cells- h/L and 9 
x 1011 cells- h/L.  The growth rates during the exponential phase for Ultraglutamine II for all 
five concentrations shows much lower growth rates when compared to Uiltraglutamine I. 
The highest growth rates however for Ultraglutamine II are for 6mM with 0.22 day-1 and 
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4mM with 0.20 day-1. This shows that 4mM and 6mM is the most efficient concentrations to 
use for the highest growth rates.  
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Figure 46a: Batch cell growth curves for CHO cells expressing the glutamine 
biosensor cultivated under five different concentrations of Ultraglutamine II 
in the BioLector™.  
The highest cell concentration comes from the 4mM. However all 
concentrations are much lower that previous ones using Ultraglutamine I and 
L-glutamine. N=1 biological replicate. 
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Figure 46b: IVCC for the CHO cells expressing the glutamine biosensor 
cultivated under five different concentrations of Ultraglutamine II in the 
BioLector™. 
The highest viabilities seen in Figure 46a also have the highest IVCC. N=1 
biological replicate. 
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Figure 46c: FRET ratios for the CHO cells expressing the glutamine biosensor 
cultivated under five different concentrations of Ultraglutamine II in the 
BioLector™. 
These were calculated using the yellow wavelength divided by the blue 
wavelength as read from the BioLector™. The low viabilities are reflected in the 
low FRET ratios for all five different concentrations used when compared to 
Figure 45c. N=1 biological replicate. 
 
Figure 46c shows that FRET ratios from the Ultraglutamine II investigation. All 5 
concentrations show a steady decrease in FRET over time which indicates a decrease in 
glutamine. This steady decrease in FRET is coupled to the steady decrease in cell 
concentration seen in Figure 46a.  Also, the lower FRET ratios are reflected in the lower IVCC 
when compared with the Ultraglutamine I graphs. The above Figures suggest that this di-
peptide may not be as well used as the previous formulation, possibly because the 
metabolism rates have decreased due to a poor uptake of this feed. This is suggested by the 
average FRET ratio for Figure 46c being lower than the average FRET ratio for 
Ultraglutamine I Figure 45.  
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5.3 Case study 2- Feed test 
In a second case study, the effect of various commercially available feeds on glucose and 
glutamine utilisation were studied using both sets of CHO cells lines  expressing the glucose 
biosensor or the glutamine biosensor. Cells were grown in CD-CHO medium with 2 mM 
glutamine and 10 mL/L hypoxanthine/thymine supplement and the feeds in question, 
namely feed 1, 2 and 3, supplied by Irvine Scientific, USA, were added on days 3, 6 and 9. A 
batch control was included for each cell line. Figure 37a shows the results of the fed-batch 
growth curve of CHO-S cells expressing the glucose biosensor over the duration of the 
experiment.  These feeds were used as Irvine scientific has shown a great increase in cell 
concentrations with them and it was of interest to note if these increases in cell 
concentration could be monitored with the biosensors presented here. Feeds, 1,2 and 3 are 
proprietary formulations and as such the contents are unknown. However it may be 
postulated that they contain glucose/glutamine as well as vitamins and minerals. These 
feeds were used to determine if there is any difference in the FRET ratios or any patterns 
when correlated to cell concentrations.  
 
Feed 1 appears to produce a much larger increase in cell concentration over the batch 
condition and indeed more than the other feeds. A maximum concentration of 9.0 x 106 
cells/mL was reached, compared to 5.00 x 106 cells/mL without the addition of feed. This 
represents a 45% increase, which is significant. This very high cell density has been achieved 
by Irvine scientific where they obtained a maximum of 9.2 x  106 cells/mL  with CHO cells fed 
with feed 1 (http://www.irvinesci.com/uploads/technical-documentations/PB_94119-
BalanCD-CHO_Feed1_Rev1.pdf). The highest growth rate during the exponential phase 
belongs to feed 1 with 0.32 day-1, Feed 2 is next highest with 0.22 day-1  and the lowest is for 
feed 3. This shows that indeed feed 1 is the best feed to get the highest growth and cell 
concentrations. The three feeds also increased the growth profile by three days and in the 
case of feed 1 the cells survived until day 17. Irvine scientific have shown that using feed 3 a 
maximum cell concentration of 5.1 x 106 cells/mL can be obtained. This investigation 
obtained a maximum concentration of 4.6 x 106 cells/mL. The same company also report 
that their fed-batch curve lasted for 13 days whilst this investigation showed the fed-batch 
curve to last 14 days (http://www.noe.jx-group.co.jp/business/lifescience/pdf/pb_94118-
balancd-cho_feed3_rev.pdf).   
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Figure 47a: Fed-batch growth curve for glucose transfected CHO-S cells 
supplemented with the three feeds in the BioLector™ 
Feed 1 shows the highest cell concentration. Feeds 2 and 3 have similar growth 
curves. N=1 biological replicate. 
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Figure 47b: IVCC for glucose transfected CHO-S cells supplemented with the 
three feeds in the BioLector™ 
The highest IVCC belongs to feed1 with the other three IVCCs having a very 
similar curve. N=1 biological replicate. 
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Figure 47c: FRET ratios for glucose transfected CHO-S cells supplemented 
with the three feeds in the BioLector™ 
The lowest FRET ratio is for feed 1, which has the highest IVCC. As a result of 
feeding on day 3 a decrease in FRET is seen, this indicates an increase in 
intracellular glucose concentration. This is seen for feeds 2 and 3. This pattern 
is seen again after feeding on day 6.  N=1 biological replicate. 
 
Figure 47b depicts this difference in terms of the IVCC, which for feed 1 is 43% higher than 
all the other feeds and the batch. The IVCC for the other two feeds and the batch is very 
similar with only a 3% difference between them at any point. The difference between the 
batch and fed 2 and 3 is seen with the extended growth lasting for an additional 3 days. 
Whilst feeding with feeds 2 and 3 did not increase the maximum cell concentrations 
obtained it did however increase the length of the growth phase as a result of feeding.  
 
The FRET ratios are shown in Figure 47c, cells with feed 1 show that after feeding on days 3 
and 6 a decrease in FRET ratio is measured indicating an increase in intracellular 
concentration of glucose. It is also important to note that the values for the FRET ratios in all 
fed conditions are all lower than those for the batch; this indicates that the intracellular 
glucose concentration is consistently higher in the fed cells. This is in agreement with the 
fact that the feeds do contain glucose source as confirmed by Irvine scientific. This trend of 
  124 
decreasing FRET ratio after feeding is also supported by feeds 2 and 3. It is also important to 
note that after feeding on day 9 no further changes in FRET ratio result; this may be as a 
consequence of the cells entering apoptosis and a depletion in glucose.  
 
The lowest initial FRET ratio corresponds to cultures supplemented with feed 1 and this 
initially high intracellular glucose concentration translates to the highest IVCC as seen in 
Figure 47b. At days 3 and 6 the FRET ratio decreases for feed 1. However at day 9 the FRET 
ratio keeps on increasing which means a decreasing intracellular glucose concentration. This 
decrease is highlighted in Figure 47a when after day 9 the cell concentration falls as the 
glucose is being used and then depleted. Feeds 2 and 3 have similar FRET ratios which is 
reflected in the almost identical IVCC profile is Figure 47b. These results may indicate that 
using the FRET ratios and hence the intracellular glucose concentrations it may be possible 
to relate them to the IVCC and cell concentration.  
 
Graphs 48 a-c show the growth curve, IVCC and FRET ratios obtained from the same 
investigations with the CHO cells transfected with the glutamine biosensors. Feed 1 once 
again has the highest growth rate in the exponential phase with 0.34 day-1, followed by feed 
2 with a growth rate of 0.24 day-1. This shows that feed 1 is the best feed to use for highest 
growth rates; this is not cell line dependent as both the glucose and the glutamine 
transfected CHO-S cells have feed 1 being the most efficient. Feed 1 gives the highest cell 
concentration, however, this is less than the maximum concentration of cells reached with 
the glucose biosensor expressing cell line. This may be due to a larger burden put on the 
cells to produce the glutamine biosensor. This burden effect has been seen in Figure 29b, 
where the CHO-S cells transfected with the glutamine biosensor had a large decrease on the 
IVCC compared to the glucose transfected CHO cells in flasks. The peak concentration 
reached by the batch cells is very similar to that obtained when using feeds 2 and 3.  The 
high cell concentration obtained with feed 1 is again supported in Figure 48b where the 
IVCC is much higher than with the other feeds as well as for the -- 33% higher than the rest, 
in fact.  
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Figure 48a: Fed-batch growth curve for glutamine transfected CHO-S cells 
supplemented with the three feeds in the BioLector™ 
Feed 1 shows the highest cell concentration whilst, feeds 2 and 3 have similar 
growth curves. N=1 biological replicate. 
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Figure 48b: IVCC for glutamine transfected CHO-S cells supplemented with 
the three feeds in the BioLector™ 
The highest IVCC belongs to feed 1 with the other three IVCCs having a very 
similar curve. N=1 biological replicate. 
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Figure 48c: FRET ratios for glutamine transfected CHO-S cells supplemented 
with the three feeds in the BioLector™ 
The highest FRET ratio is for feed 1, which has the highest IVCC, this indicates 
the highest intracellular glutamine.  As a result of feeding on day 3 an increase 
in FRET is seen, this indicates an increase in intracellular glutamine 
concentration. This is seen for feeds 2 and 3. This pattern is seen again after 
feeding on day 6 and slight increase on feeding at day 9. The batch FRET ratios 
show a steady decrease over time which indicates a slow decrease in 
intracellular glutamine as expected.  N=1 biological replicate. 
 
Figure 48c shows the various FRET ratios observed.  The FRET ratios obtained with feed 1 
show that after feeding on days 3 and 6, the FRET ratio rises as expected, suggesting an 
increase in glutamine whilst consistently having a higher FRET ratio than the other two 
feeds. Feed 2 has a similar pattern, but after day 7 the FRET ratio drops dramatically and this 
may indicate a sudden depletion of glutamine. Feed 3 however seems to have an atypical 
FRET signal, feeding on day 3 increases the FRET ratio as expected, but feeding on days 6 
and 9 have no effect. As with the glucose biosensor transfected cells supplementation with 
feeds has prolonged the growth by two days for feeds 2 and 3 and six days for feed 1 when 
compared to the unfed cells. The batch cells have the lowest FRET ratios, suggesting the 
lowest overall intracellular glutamine concentration. This would make sense as it has been 
confirmed (Irvine scientific) that indeed these feeds do contain various amounts of 
glutamine as well.  
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From the above data it can be suggested that feed 1 has the highest amount of glutamine 
present when compared to feed 2 and 3. A higher glutamine concentration maybe coupled 
to a high cell concentration as shown by Figure 48c. This consistently high FRET ratio for 
feed 1 is coupled to a much higher IVCC and thus the highest cell concentration, whilst feeds 
2 and 3 have a similar average FRET ratio and a very similar IVCC. With these investigations 
it may be thought that using the initial FRET ratios as a tool for metabolite concentrations a 
possible link with high FRET ratios meaning high cell concentration is possibly seen. 
 
5.4 Conclusions 
CHO-S cells that were grown in the BioLector™ show a higher cell concentration and the 
culture lasts for 3 days longer. The corresponding IVCC seen in the BioLector™ is 38% higher. 
However, the specific growth rates between the cells grown in flasks and the BioLector™ 
show a difference. The specific growth rate during exponential phase for the CHO-S cells 
grown in the BioLector™ is 0.37 day-1, whilst at flask level this is 0.62 day-1.The cells 
transfected with the glucose and glutamine biosensors also show a difference in growth 
profile. Comparing the growth of these cells in the BioLector™ and flasks shows cultivation 
in the BioLector™ to increase the IVCC by 37% (glucose transfected cells) and no change to 
IVC (glutamine transfected cells).  As above, however, the specific growth rates during the 
exponential phase for the cells in the BioLector™ are consistently lower than the flask level, 
irrespective of which biosensor is being expressed. The next results indicate a possible 
threshold of 5.00 x 106 cells/ml as the cut off for the reliability of the biomass readings to be 
used as a predictive tool for viable cell density. This may be the result of the smaller volume 
leading to nutrient depletion at a faster rate and hence a decrease in cell concentration. 
Other groups have also reported problems with this aspect of the BioLector™ whereby the 
accuracy of the forward light scattering used for OD measurements is affected by large cell 
aggregates and cell debris which are present during the latter stages of cell culture 
(Amanullah et al., 2009).  
 
Case study one shows the results of various glutamine sources on CHO transfected with the 
glutamine biosensor in the BioLector™. Of the cells supplemented with L-glutamine, cultures 
with starting concentrations of 6mM and 4mM show the highest viable cell concentration 
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profiles. This high cell concentration is coupled to the highest specific growth rates during 
the exponential phase, with the 6mM having a specific growth rate of 0.33 day-1 and the 
4mM 0.33 day-1. This may indeed indicate that after a threshold of possibly 6mM the uptake 
rate of glutamine will not increase, any more glutamine the cells are fed will cause no 
change in the IVCC. Too little an amount of glutamine means there is not enough for 
metabolism and this may account for the lower cell density seen in Figure 34a. Adding more 
glutamine than needed however (10mM) can also lead to the build-up of ammonia, as it is 
broken down faster than it is metabolized by the cells.  6mM of Ultraglutamine I (alanyl-L-
glutamine) increased the maximum cell concentration by 30%; with the highest specific 
growth rate of 0.42 day-1 again the highest concentration (10mM) gives the lowest IVCC and 
the lowest specific growth rate in the exponential phase with 0.29 h-1. Ultraglutamine II 
shows lower cell concentrations and consequently lowest specific growth rates when 
compared to Ultraglutamine I and glutamine. Although the highest specific growth rate is 
for the 6mM with 0.22 day-1 and 4mM with a specific growth rate of 0.20 day-1.Case study 2 
indicates that feed 1 has a significant effect on growth profile of CHO transfected with the 
glucose biosensor. This feed has the highest specific growth rate during the exponential 
phase with 0.32 day-1 and the IVCC is 43% higher compared to feeds 2, 3 and the unfed cell 
line.  The glutamine transfected CHO cells show that feed 1 is again higher when compared 
to feeds 2 and 3. The specific growth rate is again the highest with 0.34 day-1 when 
compared to feeds 2 and 3 and the unfed conditions.  
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Chapter 6. Development of scFv 
producing cell lines and evaluation of 
cell line selection methodology 
The selection of high-producing mammalian cell lines is a crucial step in process 
development for the production of biopharmaceuticals. As described in Chapter 1, this is a 
time consuming and laborious task. One of the steps is the screening of the various cell lines 
this is time consuming, and is limited by the number of clones that can be feasibly handled. 
A few methods for automated cell line selection have been used. The ClonePix™ system is 
one such device.  To use this system the cells are dispersed within a semi-solid media and 
when they grow, colonies are formed. The secreted protein is captured by a fluorescently 
labelled antibody and using imaging software the user can analyse the productivity of 
individual colonies and pick the highest producers.  This system was used by Dharshanan et 
al. (2011) to screen and pick NS0 cells. They report that using this system it was possible to 
screen 1x 105 clones secreting humanized monoclonal antibodies and high producer clones 
were selected in just 7 days. So while this system is good for screening large numbers of 
cells and saves time, the authors say “other analyses are vital to determine the ‘actual’ and 
stable high producer clones” (Dharshanan et al., 2011).   
Another cell line selection method is the use of high-throughput flow cytometry (HT-FC). 
This method uses a fast sample loading technology called the HyperCyt™, with a two laser 
six parameter flow cytometer linked to data analysis software (Edwards et al., 2007). This 
method allows 40 wells to be measured per minute in 96-well plates (3 minutes) and 384-
well plates (12 minutes). The cells are coated with a label (different colour fluorescent 
markers), the level of laser scatter is measured an analysed. This labelling method is called 
multiplexing (Black et al., 2011), This method has been used by the same author for drug 
discovery and characterisation. This flow cytometry method is good for large populations of 
cells for screening. The BioLector™ may be a device that will allow automated FRET readings 
to be taken as the cells grow and produce the protein of interest. However, it is still an open 
question as to whether metabolite profiling can aid in the selection of high producing cell 
lines. For this purpose, a set of transfections were performed in which we monitored the 
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metabolic profile of the transfectants using the FRET biosensors alongside cell growth and 
protein productivity.  
To determine whether the choice of recombinant product affects the results, two different 
scFvs were transfected for this experiment. These were Hubc-1 and MFE23.  Hubc-1 is a 
fragment of the humanized form of BC-1, which is an anti-fibronectin monoclonal antibody 
(mAb) specific for ED-B-containing fibronectin (FN) molecules (Carnemolla et al., 1992). It 
has been shown by Lo et al. (2007) that a fusion protein composed of IL-12 (Interleukin -12 
is a pro inflammatory cytokine) and Hubc-1 (hubc1-IL12) shows anti-tumour activities in 
human tumour models. This highlights the use of this scFv as a potential vehicle for cancer 
therapy. MFE-23 is used in patients to target colorectal cancer through its high affinity for 
carcinoembryonic antigen (CEA), a cell-surface member of the immunoglobulin superfamily.  
The biosensors described previously in this thesis are used with this system to examine 
whether there is a correlation between the FRET ratios and increasing or decreasing scFv 
production. The biomass readings on the BioLector™ cannot be used as a tool to asses 
growth as it is not reflective of the actual growth as discussed in Chapter 5. Once a 
threshold of 1000 U has been reached the biomass will keep increasing exponentially as the 
OD measurements cannot distinguish between live cells and dying cells or cell debris. Thus, 
the OD measurements were complemented with daily cell counting.  It has already been 
established in the above chapters that the FRET ratios increase and decrease as a 
consequence of increasing or decreasing glucose or glutamine concentrations.  
6.1 Transfection of scFv-producing cell lines  
The aim of this investigation was to explore whether it was possible to use the BioLector™ 
to perform high-throughput metabolic profiling to screen for high-producing clones. Also, it 
was of interest to observe if the BioLector™ could be used as a tool for successful small-
scale transfection of the above scFvs in 48 well micro-titre plates.  Each combination of CHO 
cells expressing the glucose or glutamine biosensor transfected with either of the two 
products Hubc or MFE23 was plated into 10 wells. These cells were prepared and grown as 
detailed in 3.8.2. The cell lines depicted in purple were progressed on day 4 post-
transfection as this is when they were taken out of the BioLector™ based on the biomass 
reading. The green cell lines were progressed at day 5 or 6, whilst the blue lines were 
  131 
progressed on days 11, 12 and 13 (Figures 49-52). The following Figures show these three 
distinct groups of cell lines and the times they were progressed. These three sub-sets were 
chosen as it was seen two cell lines reached 1000U very early and these were the early cell 
lines. It is common practise that the early cell lines are progressed within the first few days. 
The next two cell lines took longer to reach 1000U these were termed mid and the final 
three cell lines took the longest to reach 1000U. These final three cell lines were called the 
late cell lines. 
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Figure 49: Biomass readings for CHO cells with Hubc and the glucose 
biosensor progressed in the BioLector™. 
Three groups of cell lines were found based on time of progression from the 
BioLector™. The two purple shapes represent the earliest cell lines that were 
progressed as they reached 1000 biomass U the fastest. The next two (green 
shapes) were termed the mid cell lines and the final three blue cell l were the 
late cell lines as it took them the longest to reach 1000 biomass U. 
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Figure 50: Biomass readings for CHO cells with the MFE23 scFv and the 
glucose biosensor progressed in the BioLector™. 
Three groups of cell lines were found based on time of progression from the 
BioLector™. The two purple shapes represent the earliest cell lines that were 
progressed as they reached 1000 biomass U the fastest. The next two (green 
shapes) were termed the mid cell lines and the final three blue cell l were the 
late cell lines as it took them the longest to reach 1000 biomass U. 
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Figure 51: Biomass readings for CHO cells with Hubc and the glutamine 
biosensor progressed in the BioLector™. 
Three groups of cell lines were found based on time of progression from the 
BioLector™. The two purple shapes represent the earliest cell lines that were 
progressed as they reached 1000 biomass U the fastest. The next two (green 
shapes) were termed the mid cell lines and the final three blue cell l were the 
late cell lines as it took them the longest to reach 1000 biomass U. 
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Figure 52: Biomass readings for CHO cells with the MFE 23scFv and the 
glutamine biosensor progressed in the BioLector™. 
Three groups of cell lines were found based on time of progression from the 
BioLector™. The two purple shapes represent the earliest cell lines that were 
progressed as they reached 1000 biomass U the fastest. The next two (green 
shapes) were termed the mid cell lines and the final three blue cell l were the 
late cell lines as it took them the longest to reach 1000 biomass U. 
 
6.1.1 scFv production  
Next the scFv production by each cell line was analysed. As discussed previously, each cell 
line was sub-cultured three times and then frozen down on the fourth day of the third 
subculture. At this time, the supernatant samples were also used for estimation of protein 
concentration by Nano-drop™. The next four graphs of Figure 53 are a representation of the 
results. The results below are the readout that the Nano-drop™ gave when samples were 
analysed under them. The method for the Nano-drop™ measuring device is detailed in the 
materials and methods in section 3.1.7.   
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Figure 53: The scFv concentration (g/L) as measured with the Nano-drop™ for 
the cell lines transfected in the BioLector™  
Panel A shows the cell lines that were designated as the highest producers 
(0.99-0.33g/L). Three late cell lines, two mid and one early make up the highest 
producers. The fastest growers are not the highest producers, which is in 
agreement with Porter et al., 2010.  Panel B shows the high/mid (0.23-0.18g/L) 
Here early and mid-cell lines dominate. Panel C details the mid/low (0.013-
0.06g/L) with mostly mid and early cell lines producers and finally Panel D 
show the lowest producers (0.03-0.02g/L) which has three late and one early 
cell line N=3 technical replicates, error bars represent the standard deviation 
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Currently, the most confluent cells are passed to next stages of cell line selection. These are 
the earliest and fastest growers. Previous work has shown that these are not necessarily the 
highest producers (Porter et al., 2010). Of the 8 fastest growing cell lines (the 8 purple cell 
lines), only one has made it through to the highest producers Panel (Figure 53 Panel A). 
Instead the cell lines that were progressed later (glutamine MFE 23 f, glucose MFE 23 e and 
g) dominate Figure 53 Panel A, along with two cell lines (glutamine Hubc d and glucose MFE 
23 d) progressed in the middle stage. So the fastest growing cell lines are not necessarily the 
highest producers in this study. Panel B shows a mixture of the early, mid and late cell lines 
with Panel C being predominately mid and early cell lines. To counteract Panel A we see that 
Panel D has only one of the early cell lines but three of the late cell lines. From this set of 
results it may in suggested that using the BioLector™ for selection may indeed be applicable 
but up to a certain point. It is possible to select cell lines based on a biomass number and 
different progression times. Successful transfections are possible and this will reduce the 
labour costs and time spent. Looking at the above Figures, especially Panel A in Figure 53, 
shows that of the early cell lines only one of them has placed in the possible highest 
producers. Whilst Panel D suggests that of the four cell lines that produced the lowest scFv, 
three of those were from the cell lines that were progressed earliest.  
 
6.1.2 FRET ratios for CHO cells (glucose) with the two scFvs 
FRET readings were taken at the same time as the biomass readings above. The FRET ratios 
for these are in the Figures below. Looking at Figure 53 Panel A, the transfection with the 
glucose biosensor and the Hubc scFv, the starting FRET ratio for Hubc a is 50% lower than 
Hubc b, after which the ratios for both cells lines are very similar and steady. This would 
indicate that the intracellular glucose concentration is also steady. Panel B shows that the 
highest FRET ratio is reached by Hubc C compared to Panels A and C. This means that during 
the first few days Hubc c has a lower intracellular glucose concentration compared to the 
rest. This Panel also highlights the decrease in FRET ratio from the early days, which may 
indicate glucose accumulation in the cells. This would lead to lactate production and 
decrease in  cell concentration due to waste product formation. Of the three cell lines in 
Panel C Hubc e has the highest FRET ratio which means the lowest glucose concentration. 
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This cell line also shows a sharp peak then a sharp decrease. In terms of glucose 
concentrations this equals a low initial glucose concentration followed by a sudden large 
increase then a steady metabolism as the steady FRET ratio indicates. Hubc f and g show a 
very similar FRET ratio with only a 5% difference at any time. These two cells lines have a 
uniform FRET ratio (Panel C) throughout the culture, which means they have the most 
uniform glucose utilisation rates.  
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Figure 54: FRET ratios for CHO cells with Hubc and the glucose biosensor 
progressed in the BioLector™. 
The FRET ratios as calculated from the readings on the BioLector™. Panel A 
shows the first 2 cell lines that were progressed with a final FRET ratio of 0.05. 
Panel B the next 2 cell lines with a final FRET ratio of 0.07 and Panel C shows 
the final cell lines with an average final FRET ratio of 0.05 N=3 technical 
replicates, error bars represent the standard deviation 
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Figure 55: FRET ratios for CHO cells with the MFE23 scFv and the glucose 
biosensor progressed in the BioLector™ 
The FRET ratios as calculated from the readings on the BioLector™. Panel A 
shows the first 2 cell lines that were progressed with a final FRET ratio of 0.05. 
Panel B the next 2 cell lines with a final FRET ratio of 0.066 and Panel C shows 
the final cell lines with an average final FRET ratio of 0.05 N=3 technical 
replicates, error bars represent the standard deviation 
 
Looking at Figures 49 and Figure 53 it can be seen that the early cells have an average FRET 
ratio of 0.05 when these cells were progressed. The mid cells lines were progressed at an 
average FRET ratio of 0.07 whilst the late cell lines were progressed with an average FRET 
ratio of 0.056. Whilst the MFE23 CHO cells have three different ratios are noted for the 
three separate cell line groups. Figure 55a displays average FRET ratios of 0.05 for the early 
cell lines, 0.066 for the mid cell line and 0.053 for the late.  
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6.1.3 FRET ratios for CHO cells (glutamine) with the two scFv’s 
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Figure 56: FRET ratios for CHO cells with Hubc and the glutamine biosensor 
progressed in the BioLector™. 
The FRET ratios as calculated from the readings on the BioLector™. Panel A 
shows the first 2 cell lines that were progressed with a final FRET ratio of 0.03. 
Panel B the next 2 cell lines with a final FRET ratio of 0.03 and Panel C shows 
the final cell lines with an average final FRET ratio of 0.05 N=3 technical 
replicates, error bars represent the standard deviation 
 
The FRET ratios for the CHO cells expressing the glutamine biosensor and transfected with 
the Hubc scFv are presented in Figure 60 (Panels A-C). All Panels shows fluctuations in the 
FRET ratio which would indicate that the glutamine levels within the cells are also 
fluctuating, this is seen after the 60 hour mark. Panel A highlights the variation between the 
cells lines that were progressed at the earliest stage. This Figure suggests that even though 
the cells reached the desired biomass of 1000 on the same day, they have a different FRET 
ratio, and, in turn, a different glutamine concentration (the difference is 1mM). While Hubc 
a shows a steady FRET ratio during the course of the culture, Hubc b shows a very different 
trend. Here the points increase and decrease with no pattern. A familiar trend in FRET is 
seen in Panel B, where the highest FRET is seen during the early days then a decrease in 
FRET over time as the intracellular glutamine is being used by the cells. This trend is also 
seen in Panel C where initially the FRET is high then decreases over the course of the 
culture.  
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Figure 57: FRET ratios for for CHO cells with the MFE 23scFv and the 
glutamine biosensor progressed in the BioLector™. 
The FRET ratios as calculated from the readings on the BioLector™. Panel A 
shows the first 2 cell lines that were progressed with a final FRET ratio of 
0.042. Panel B the next 2 cell lines with a final FRET ratio of 0.044 and Panel C 
shows the final cell lines with an average final FRET ratio of 0.03. N=3 technical 
replicates, error bars represent the standard deviation 
 
Figure 56 depicts the FRET ratios for CHO cells expressing the glutamine biosensor and 
transfected with the MFE 23 scFv. Here there appears to be a much tighter distribution of 
FRET ratios and a clearer trend is suggested. As with Figure 59 Panel A shows variation 
between the two cell lines, MFE 23 c and d (Panel C) also show varying trends. The tightest 
and expected trend is seen in Panel C. This Panel also indicates slightly higher FRET ratios 
during the early days and then a steady decrease as the glutamine is being used. The results 
from the two above Figures show that with respect to the two scFvs in question, the 
greatest impact on FRET ratio is the production of the Hubc as the FRET ratios fluctuate 
greatly. Figure 60 shows that the early cell lines were progressed with a FRET ratio of 0.03, 
the mid cell lines also 0.03 whilst the late cell lines were progressed with a FRET ratio of 
0.05. Whilst in Figure 61 the MFE 23 transfected CHO cells have FRET ratios of 0.042 (early), 
0.044(mid) and 0.03 (late).  
Using the above information and Figures it may be seen that a possible link between FRET 
ratio and different production rates may be drawn. For glucose utilization, using Panel A in 
Figure 53 it is seen that two late cell lines are present in the high producers, these high 
producers would have a FRET ratio of 0.05, since this ratio is also the ratio at the point the 
late cell lines were used, this maybe a way to discard the mid cells with a ratio of FRET 
(0.07).  Using the ratios obtained for the glutamine CHO cells with the with scFvs it may be 
possible to use the lower ratio of 0.03 to distinguish between the three sets of cell lines 
progressed to keep the late cell lines and discard the mid and early cell lines (0.043). 
However these results need much more testing. This extra information could be useful in 
the screening process for cell selection, however more data is needed for to confirm these 
findings. 
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6.1.4 scFv-producing batch and fed-batch cell culture investigation 
The highest producing cell lines from Panel A in Figure 53 were used in a batch (Figure 58) 
and fed–batch (Figure 62) study in shake flasks in order to help evaluate whether the 
highest producer in the smaller scale was reproducible in the larger scale and to observe if 
there is a link between product concentration and FRET ratios. These top six cell lines were 
fed at days 2, 4, 6, 8, 10 and 12 with a commercially available feed (Feed C from Invitrogen). 
Simultaneously, a batch cell culture study was conducted for comparison. Samples were 
taken daily for viability counts as well determination of scFv concentration.  Below are the 
results of these experiments beginning with the growth curves for the fed-batch and batch 
cultures.  
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Figure 58: Batch growth curve for the top six highest scFv producing cell lines. 
CHO cells expressing the glutamine or glucose biosensor and either the MFE 23 or 
the Hubc scFv. The lines are colour coded from the previous experiments to 
indicate purple: early cell lines, green: mid cell lines and blue: late cells lines. The 
highest cell concentration seen is from the three late cell lines. This would suggest 
that the early cell lines do not have the highest cell concentrations, as seen in the 
BioLector™. N=2 biological replicates, error bars represent the standard deviation. 
 
The highest producer from Figure 53 Panel A was the CHO cells transfected with the 
glutamine biosensor and the scFv MFE23 f. From the batch cell growth curve in Figure 63 it 
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is clear that this cell line has the highest viable cell density reaching a maximum of 8.1 x106 
cells/mL at day 7. The next two highest cell densities are exhibited by the other two late cell 
lines from Panel A. The only cell line that was progressed early had a peak at day 6 with a 
concentration of 3.2 x 106 cells/mL, this cell line also has a specific growth rate of 0.34 day-1 
in batch and 0.39 day-1 in fed-batch. These growth rates are similar to the mid cell lines but 
the late cell lines still have higher growth rates. The cell lines progressed in the middle 
(green lines) show consistent results up to day 5 when a split is seen. The CHO glutamine 
Hubc d cell line peaked at day 7 with 3.4 x 106 cells/mL and CHO glucose biosensor cell line 
with the MFE 23 peaking at day 5 at 2.3 x 106 cells/mL (Figure 62).    
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Figure 59: Fed-batch growth curve for the top six highest scFv producing cell 
lines. 
CHO cells expressing the glutamine or glucose biosensor and either the MFE 23 or 
the Hubc scFv. The lines are colour coded from the previous experiments to 
indicate purple: early cell lines, green: mid cell lines and blue: late cells lines. Cells 
were fed Feed C on days 2,4,6,8, 10 and 12. The cell growth profiles for all cell 
lines have been prolonged. The highest cell concentration is again seen from the 
late cell lines. N=2 biological replicates, error bars represent the standard 
deviation. 
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Figure 59 shows the fed-batch study of these top six cell lines. It is seen that the feeding 
strategy has increased the viable cell density and the culture time was extended to 18 days 
compared to 10 days in the batch culture. The highest cell concentration from Figure 62 was 
the CHO cells transfected with the glutamine biosesnor and the scFv MFE23 f, this cell line 
still has the highest cell concentration in a Fed-batch system. This cell line also has the 
highest specific growth rate in the exponential phase, reaching 0.33 day-1 in batch and 0.38 
day-1 fed-batch. This cell line showed a peak at day 12 with a concentration of 2.1 x 107 
cells/mL, an increase of 60% of that reached in Figure 58. The five other cell lines also had a 
big increase in their maximum concentrations reached. Indeed, the early cell line had an 
almost five-fold increase in concentration reaching a peak of 1.0 x 107 cells/mL. This 
increase is seen in growth rate as well. Every cell line has a large increase in growth rate as a 
result of feeding.  The final point to note is that after the final feeding day on day 12 all five 
cell lines began their decline phase, with the sharpest fall coming from the CHO cells 
transfected with the glucose biosensor and the MFE 23 scFv e. 
As mentioned above, samples were taken daily from the above growth curves for protein 
determination using the Nano-drop™. Below are the graphs from these experiments. They 
have been split into type of biosensor being expressed (glucose or glutamine) and type of 
culture (fed-batch or batch) for ease of reading. Figure 60 shows the data for cells 
expressing the glucose biosensor.  The protein concentration shows a steady increase for all 
three cell lines and for all three the concentration of protein in the supernatant is 
comparable up to day 6. The MFE23g scFv transfected into the glucose biosensor containing 
CHO cells shows the highest protein concentration from 1.35g/L (day 7) up to 2.5 g/L (day 
10). Whilst the CHO cells with the MFE 23 e shows a more modest increase, going from 
1.5g/L (day 7) to 1.9g/L (day 10).    
Figure 61 shows the protein concentrations for CHO cells expressing the glutamine 
biosensor and one of the two scFvs again in batch cultures. Here the CHO cells expressing 
the MFE 23 f has very little protein between days 0-5 and then sharply increase for days 5-8 
then decreases again at the final two days after reaching a peak of 1.6g/L. The most 
consistent protein concentration comes from the CHO cells with the Hubc b. The protein 
concentrations measured for this cell line are higher than the other two cell lines in all days. 
Figure 53 shows that CHO cells with the glutamine with the MFE 23 f cell line is the highest 
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producer in the BioLector™. In shake flasks however, it shows very inconsistent production.  
This is likely due to the difference in culture conditions between the flask and the 
BioLector™.  
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Figure 60: The scFv concentration (g/L) as measured with the Nano-drop™ 
over the course of the 10 day batch curve for glucose CHO cells.  
For all three cell lines there is an increase in protein concentration. MFE 23 g 
scFv expressing the glucose biosensor shows the highest protein 
concentration. N=3 technical replicates, error bars represent the standard 
deviation. 
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Figure 61: The scFv concentration (g/L) as measured with the Nano-drop™ 
over the course of the 10 day batch curve for glutamine CHO cells 
For all three cell lines there is an increase in protein concentration. The most 
consistent protein concentration comes from the CHO cells secreting the Hubc 
b scFv. N=3 technical replicates, error bars represent the standard deviation. 
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Figure 62: The scFv concentration (g/L) as measured with the Nano-drop™ 
over the course of the 17 day fed-batch curve for glucose CHO cells 
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For all three cell lines there is an increase in protein concentration as a result 
of feeding. MFE23 d has the most consistently high protein production. N=3 
technical replicates, error bars represent the standard deviation. 
 
Focusing on the orange bars in Figure 62 reveals a steady increase in protein production, 
reaching a peak at day 13 at 3.2 g/L. As a result of the feeding all the cell lines have 
increased protein production. The maximum protein production for these cell lines in the 
batch graph is passed on day 6 in the above fed graph. The cell line that out produces the 
others in almost every day is the CHO-S glucose MFE 23 d cell line, with a peak at day 8 of 
4.4 g/L of protein. This Figure (62) also shows that the mid cell line from Figure 53, Panel A 
(black bars) and late cell (red bars) line out produces the early cell line (orange) in nearly all 
days (by at least 10%).   
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Figure 63: The scFv concentration (g/L) as measured with the Nano-drop™ 
over the course of the 17 day fed-batch curve for glutamine CHO cells 
Hubc d cell line is the highest producer in this graph with a peak at day 12. 
Again feeding has increased the protein production and the duration of the 
growth profile. N=3 technical replicates, error bars represent the standard 
deviation. 
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In Figure 63, the highest producer from the BioLector™ (CHO cells with the glutamine 
biosensor and MFE 23f) increases up to day 11, then the protein production decreases.  A 
peak of 3.2 g/L is reached on day 11. The Hubc d cell line is the highest producer in this 
graph with a peak at day 12 giving a corresponding protein concentration of 4.2g/L. The 
early cell (CHO cells with the Hubc b) line shows a steady increase in protein production for 
every day, going from 0.5 g/L (day 0) to 3.9 g/L (day 17). For all three cell lines, the feeding 
has not only increased the growth curve but also the protein concentration. Whilst in the 
BioLector™ it was found that the glutamine transfected CHO-S cells with the MFE23 cell line 
(f) Figure 53a was the highest protein producer. In flasks this was not the case. At the batch 
stage in flasks the CHO-S cells with the glucose biosensor and the MFE 23 g was the highest 
producer and in the fed-batch test the CHO-S cells transfected with the glucose biosensor 
and MFE 23 was the highest. This highlights the variability in the protein production 
capabilities of this scFv at both scales.  
 
Table 14: The FRET ratios as calculated from the Tecan™ fluorescent plate 
reader (Chapter 4) for the batch growth curve.  
All of the FRET ratios for the glutamine CHO cells are within the calibration 
curves in chapter 4. Whilst only the FRET ratios for the glucose CHO cells from 
days 4-9 are in the calibration curve from chapter 4. This is typical for the 
glucose biosensor as it was established that this 4-8/9 days is the window for 
use of the FRET ratios.  
 
 FRET ratios 
 Day gln mf gln hd gln hb glc me glc md glc mg 
0 0.36 0.42 0.32 0.34 0.36 0.38 
1 0.38 0.37 0.39 0.31 0.26 0.32 
2 0.41 0.42 0.48 0.53 0.53 0.74 
3 0.9 0.88 0.87 1 0.99 1.24 
4 1.17 1.17 1.27 2.18 2.28 3.37 
5 2.1 2.03 1.24 2.58 2.96 2.64 
6 2.18 2.17 2.25 3.43 3.43 3.27 
7 1.34 1.2 1.21 3.58 3.69 3.66 
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8 1.17 1.12 1.12 4.17 4.16 4.13 
9 0.45 0.43 0.41 5.17 5.34 5.21 
10 0.35 0.34 0.34 0.26 0.23 0.28 
 
Looking at the last three columns it is clear that that FRET ratios are increasing until day 9. 
However, the initial testing of the CHO cells transfected with the glucose biosensor shows a 
different pattern. There the increase in FRET is seen between days 4-8. The table shows that 
the expected trend between increasing FRET ratio and decreasing intracellular glucose is 
seen in the initial 9 days. However, the FRET ranges between days 4 and 9 fall within the 
calibration curve from chapter 4 (FRET ratio range of 1.5-7. A difference is also seen with the 
CHO cells transfected with the glutamine biosensor when compared to the above table. 
Figure 32a shows that the FRET ratios fluctuate until day 4 then decreases until 7 with 
fluctuations seen until day 11. The above table however shows a steady increase in FRET 
until day 6 then decreases from days 7-10. Also of note is that all the FRET ratios for each 
day are between the calibration curve range for the glutamine transfected cells in chapter 4 
(0.2- 3.5).  
Table 15: The FRET ratios as calculated from the Tecan™ fluorescent plate 
reader (Chapter 4) for the fed-batch growth curve.  
All of the FRET ratios for the glutamine CHO cells are within the calibration 
curves in chapter 4. Only the FRET ratios for days 0,1 and 17 are out of the 
range for the glucose CHO cells. This may mean that feeding has given the cells 
enough nutrition for them to have a high enough cell number to be within the 
range at an earlier day. Yellow highlighted area shows feeding on these days. 
 
 FRET ratios 
 Day gln mf gln hd gln hb glc me glc md glc mg 
0 0.49 0.34 0.3 0.1 0.1 0.1 
1 0.43 0.45 0.48 1.01 1.01 1.01 
2 1.9 1.74 1.71 2.14 2.16 2.14 
3 2.03 1.92 1.91 2.42 2.19 2.26 
4 2.18 2.29 2.27 2.2 2.05 2.4 
5 2.53 2.77 2.58 2.1 1.69 2.3 
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6 2.39 2.33 2.45 2 1.85 2.26 
7 2.3 2.53 2.31 2.12 2.3 2.19 
8 2.45 2.46 2.57 2.04 1.85 1.89 
9 2.3 2.48 2.35 2.16 2.06 2.15 
10 2.43 2.47 2.49 1.87 2.45 2.02 
11 2.47 2.42 2.49 1.88 2.18 1.88 
12 2.51 2.36 2.31 3.64 3.73 3.84 
13 1.77 1.8 1.73 3.47 3.53 3.47 
14 1.59 1.7 1.66 4.89 4.52 4.96 
15 1.12 1.13 1.14 5.4 5.41 5.92 
16 0.99 0.97 0.97 6.31 5.57 6.43 
17 0.4 0.42 0.43 0.69 0.61 0.62 
 
 
Table 15 highlights the FRET ratios as a consequence of the addition of feed C. The 
glutamine transfected CHO cells show a consistent FRET ratio. In that from days 2 to 12 the 
ratio stays between 1.7-2.57 for all three cell lines. On days 0-17 this FRET ratio is also 
within the calibration curve. There is a much larger window of measurement and this maybe 
as a result of the feed; the cells have a constant supply of glutamine and hence the FRET 
ratio is steady. Furthermore it has been confirmed by Lifetech that feed C contains both 
glucose and glutamine (personal communication with Ryan Ying, Lifetech). However, as 
soon as feeding is discontinued on day 12 the ratio decreases, which indicates a decrease in 
the glutamine concentration as well. This pattern is seen with the CHO cells expressing the 
glucose biosensor as well (days 2-16 show that the FRET ratio is within the calibration range 
seen in chapter 4), with the addition of feed C having the effect of keeping the FRET ratio 
steady until feeding ceases. The ratio then increases suddenly indicating a decrease in the 
glucose concentration. The above FRET ratios from the cell lines are all within the calibration 
range (glutamine) and mostly within the range (days 2-16) for the glucose.  
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Figure 64: The calculated intracellular glucose concentration based on the 
calibration curve in chapter 4 for batch CHO cell culture. 
A steady decrease in glucose is seen as the metabolite is used up over the 
growth of the cells.  N=3 technical replicates, error bars represent the standard 
deviation. 
 
The above calculated intracellular glucose concentrations agree with the FRET data in table 
11. These calculations are based on the in vivo calibration curves in chapter 4. This indicates 
that in batch growth the CHO cells are using glucose for metabolism and production at a 
steady rate until day 9. Day 10 once again gives us an anomalous result as explained above. 
There is also very little difference (5%) between the various cell lines and scFvs produced. 
The maximum glucose concentration reached is by the MFE 23 d cell line (green) 6.1mM. 
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Figure 65: The calculated intracellular glutamine concentration based on the 
calibration curve in chapter 4 for batch CHO cell culture. 
A steady increase in glutamine concentration is seen until a peak at day 6 
where the decline begins. This makes sense as the peak is day 6 as the 
glutamine runs out this would suggest a decrease in cell concentration 
decrease as well.   N=3 technical replicates, error bars represent the standard 
deviation. 
 
Figure 65 shows the calculated intracellular glutamine concentration against the number of 
days in the growth curve. As the FRET ratios showed, the glutamine concentration is 
increasing until the peak at day 6 and then a steady decrease is seen. The highest peak is 
reached at day 6 by the early cell line (CHO + glutamine + Hubc b) 1.4mM. At day 5 there is a 
decrease in the early cell line compared with the other cell lines on that day. This is the only 
instance where this happens and may well be an anomalous result.  
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Figure 66: The calculated intracellular glucose concentration based on the 
calibration curve in chapter 4 for fed-batch CHO cell culture. 
Feeding has increased the cell concentration and this is due to the steady 
intracellular glucose concentration as confirmed by the Figure above based on 
the FRET ratios. Once feeding was stopped at day 12 a decrease is seen in the 
intracellular concentration.  N=3 technical replicates, error bars represent the 
standard deviation. 
 
Using the FRET ratios obtained in table 9 to calculate the intracellular glucose concentration 
shows that the feeding has kept the glucose concentration stable for the duration for the 
fed-batch cell culture. Only after feeding was ceased at day 12 did the glucose 
concentrations begin to decrease. Once again, the different scvFs that were present in the 
cells did not change the glucose concentrations and the pattern observed. Although these 
cell lines were fed, the actual concentration of glucose has not increased greatly over the 
batch data (Figure 64), this means that the extra glucose fed has been used for growth and 
not for protein production. The maximum intracellular glucose concentration reached in the 
fed-batch experiment is 6.4mM compared to 6.1mM for the batch; this does not represent a 
significant difference.  
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Figure 67: The calculated intracellular glutamine concentration based on the 
calibration curve in chapter 4 for fed-batch CHO cell culture. 
A steady glutamine concentration is seen from day 2-12 this would indicate the 
feed had enough glutamine to supply the cells when they needed it. As soon as 
the feeding was stopped on day 12 a decrease in concentration is seen.  N=3 
technical replicates, error bars represent the standard deviation. 
 
As a result of feeding a steady glutamine rate is observed after day 2 until day 12 when 
feeding was stopped. It is also of note that the highest peak concentration is again not much 
higher that the unfed corresponding cells. Here the peak is 1.7mM whilst the batch culture 
results show a peak of 1.4mM, which is not significant. This lack of an increase maybe due to 
the fact the cells need a greater amount of glutamine for growth and product production 
than the batch cells, to produce more scFv protein as Figures 67 shows. There is a higher 
protein concentration in the fed-batch culture. This may also account for the uniform 
glutamine concentration from days 5-12 as the utilisation rates and the transport are in a 
balance for the cells to grow and for protein production. Looking at the batch and fed-batch 
Figures above it can be suggested that no product specific differences exist. Indeed the 
presence of one or another of the scFvs does not cause any differences. Despite the fact 
that the MFE23 scFv has more glutamine in its sequence this seems to have no influence on 
growth or protein production.  
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6.2 Conclusions 
As mentioned before a paper which was funded and carried out by Lonza found that the 
fastest growing cells were not the highest producers, in fact they found that out of the top 
ten cells progressed the traditional way only three were the highest producers (Porter et al., 
2010). This represents a 30% rate of highest producers linked to the early progressed cell 
lines. The study in this thesis had comparable findings. During the transfections in the 
BioLector™ three groups of cell lines were progressed (early, mid and late),based on time of 
progression based on when biomass readings of 1000U were reached Supernatant samples 
were taken and protein concentration therein was measured using the Nano-drop. It was 
found that of the highest producers only one of the top six was from the early cell line this 
represents a 17% rate of the highest producers linked to the early progressed cell lines. The 
top 6 cell lines were then taken and a fed-batch study was undertaken in flasks. The highest 
producer in the BioLector™ showed the highest viable cell concentration in flasks as well. 
However it was not amongst the highest producer in the flask level. This highlights the 
variability between the two working scales. The data in this section may also show that a 
high initial glutamine FRET ratio leads to a cell line that has a high cell concentration and 
hence a high IVCC. This trend is also seen for the glucose biosensor transfected cells as the 
lowest FRET ratio leads to the cell line with the highest cell concentration. This suggests a 
possible link between FRET ratio and high cell concentration.  
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Chapter 7. Final conclusions and 
recommendations for future work 
The following conclusions can be drawn from this work: 
7.1 Biosensor development 
FLIPglu-600µ-Delta11aphrodite was chosen for the glucose biosensor to use for this work as 
it measured the expected intracellular concentration ranges with a linear relationship, after 
using the Amplex™ red glucose oxidase kit on intracellular samples from CHO-S cells. One 
glutamine biosensor was identified D157N which measured the correct linear range as 
found with the EnzyChrom™ kit. The transfection of the glucose biosensor into the non-
transfected CHO-S cells had an effect on the specific growth rate in the exponential phase as 
it was bought down from 0.62 day-1 (non-transfected) to 0.60 day-1. The IVCC for this 
biosensor was also reduced by 50% . Whilst the effect of the glutamine biosensor was a 
decrease of the specific growth rate reaching 0.52 day-1 and a reduction in the IVCC by 40%. 
Specifity to glucose and glutamine binding of these biosensors were shown by interference 
and competetive binding tests with G-6-P for glucose and various amino acids and di-
peptide sources for glutamine. The in vivo callibration curve shows a strong relationship in 
that as the FRET ratio increases the intracellular glucose concentration decreases, the 
results suggest that the FRET signal is best correlated with the intracellular concentrations 
between 1 and 5mM. The in vivo callibration curve presents a strong relationship between 
FRET ratio and intracellular glutamine concentrations between 0.3 and 2 mM. As the FRET 
ratio increases the intracellular glutamine concentration is also increases. As the FRET 
decreases the glutamine concentraion also decreases.  
 
Biosensor readings have a limited range during which they accurately reflect the 
intracellular glucose and glutamine concentrations, (days 4-8). These findings suggest that 
the FRET signal is best correlated with the intracellular concentrations between 1 and 5 mM 
for glucose and 0.3 and 2 mM for glutamine. A proof-of-concept study showed using a fed-
batch culture showed that the FRET ratio could be used to predict the intracellular 
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concentration of metabolites within 28%, which highlights that these biosensors can be 
used for quantification as well as a tool for measurement  
 
7.2 Bioprocess and BioLector™ 
7.2.1 Growth and FRET readings 
CHO cells that were grown in the BioLector™ show a higher cell concentration and the 
culture lasts for 3 days longer. The corresponding IVCC seen in the BioLector™ is 38% 
higher.However the specific growth rate in the exponential phase shows that cells at the 
flask stage have a higher growth rate of 0.62 day-1 when compared to the BioLector™ which 
had a specific growth rate of 0.37 day-1 cultivated CHO-S cells. The limitations  of the 
BioLector™ which respect to accurate biomass measurements have been discussed, a 
possible threshold of 5.00 x 106 cells/ml as the cut off for the reliability of the biomass 
readings to be used as a predictive tool for cell viability is suggested.  
 
7.2.2 Case studies 1 and 2 
The cells treated with the glutamine source show that 6mM and 4mM have the highest cell 
concentration. These cells also have the highest specific growth rates with 6mM having the 
highest rate in the exponential phase reaching 0.33 day-1. This may indeed indicate that 
after a threshold of possibly 6mM the uptake rate of glutamine will not increase. Indeed 
adding 10mM decrease the IVCC, maybe due to build up of ammonia. 6Mm of 
Ultraglutamine I (alanyl-L-glutamine) increased the maximum cell concentration by 30%, 
this is also the concentration that gave the highest specific growth rate of 0.42 day-1. Again 
the highest concentration (10mM) gives the lowest IVCC and the lowest specific growth rate 
of 0.29 day-1. Ultraglutamine II resulted in lower cell concentrations with all concnetrations 
and lower specific growth rates. Even the highest specific growth rate reached by the 6mM 
(0.22 day-1) is lower that the lowest specific growth rate of Ultraglutamine I with 0.29 day-1  
for 10mM) this may be due to a better uptake rate for Ultraglutamine I. Indeed 
ultraglutamine I is more stable and far more water soluble (Hassell et al., 1991) than regular 
glutamine. The above results for the di-peptide sources may mean that a concentration 
between 4-6mM is most efficient for growth. Feed 1 has a significant effect on growth 
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profile of CHO-S transfected with the glucose biosensor. The specific growth rate in the 
exponential phase for feed 1 is the highest with 0.32 day-1, which is seen in the IVCC, which 
is 43% higher compared to feeds 2, 3 and the batch cell line. This may imply that feeding 
with feed 1 gives the higest growth and cell concentrations. Due to the feeding both cell 
lines have an increased growth curve vs. the unfed (11 days). Feed 1 (17 days), feed 2 and 3 
(14 days). This maybe as a result of a higher glucose and glutamine concentration as the 
FRET ratios would imply. This higher concentration would supply more metabolites for 
cellular respiration.  It has also been suggested that using the initial FRET ratio it may be 
possible to predict the cells with the highest viabilities.  
 
7.2.3 Development of scFv-producing cell lines and evaluation of cell line 
selection methodology 
Three groups of cell lines were progressed (early, mid and late) after successful 
transfections in the BioLector™. Using the FRET ratios at the time of progression it may be 
possible to exclude certain cell lines however this needs more work and data. Out of the 
above cell line the top 6 were grown in flasks and the highest scFv producers in the 
BioLector™ showed the highest viable cell concentration in flasks as well. However it was 
not amongst the highest producer in the flask level. This shows the differences between the 
scales. It has also been suggested that there is no product specific differences between the 
transfection of either of the scFvs. However successful transfections are possible to 
perform, which will allow many more cell lines to be transfected simultaneously.  
 
7.3 Recommendations for future work  
7.3.1 Further biosensor development  
Whilst the two metabolites discussed are key in the cellular respiration of cells, a good 
continuation of this project would be the development of other biosensors which are 
sensitive to different metabolites, such as lactate, for example. Whilst glucose is one of the 
primary energy sources for cultured cells and during cellular respiration it is converted into 
pyruvate with the net production of 2 ATP molecules per molecule of glucose. As well as 
generating excess reducing agents which can be converted to more ATP through the 
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electron transport chain. Once this pyruvate is produced it then enters the matrix of a 
mitochondrion, where it encounters the enzyme pyruvate dehydrogenase. This enzyme 
catalyses the reaction of pyruvate with coenzyme A to form acetyl CoA. This reaction is 
sometimes called the link reaction, as it links glycolysis to the Krebs cycle.  
In some cases (anaerobic respiration), pyruvate may not enter the mitochondria, however; 
it may be reduced to lactic acid by lactic acid dehydrogenase as a mechanism to oxidize 
NADH to regenerate NAD to maintain redox balance and keep glycolysis working. Lactic acid 
dehydrogenase (LDH) can re-oxidise cytoplasmic NADH by converting pyruvate to lactic acid 
(a wasteful process that leads to a metabolic dead-end).  At high levels, lactic acid becomes 
toxic to cells and as Lao et al. (1997) reports inhibits growth of CHO cells by 25%. It has also 
been shown that  cell concentration can be significantly enhanced by limiting lactate 
production levels in culture (Jeong et al., 2006 and Irani et al., 1999). Therefore a low lactate 
concentration is ideal to keep cellular respiration at an optimum rate, which leads to a 
higher therapeutic protein production ratio. This statement is supported by Chen et al. 
(2001) who showed that antibody production of a mammalian cell line was increased when 
lactate formation was reduced by genetic manipulation of the pathway of lactate synthesis. 
Therefore a lactate biosensor that would allow in vivo measurements of the lactate levels 
during cell growth would give important information on the choice of cells to progress. 
(Dwyer et al., 2004). 
7.3.2 Simultaneous measurements of glucose and glutamine 
Since the biosensors have the same emission and excitation wavelengths it is not possible to 
accurately measure their individual FRET signals without cross talk. A solution to solve this 
may be the implementation of a different fluorescent protein namely mOrange/mCherry 
(Ouyang et al., 2008). This FRET pair was used alongside CFP/YFP to show that Src kinase 
and membrane type 1 matrix metalloproteinase act globally in the same signalling pathway, 
and that their activations differ in space and time upon epithelial growth factor stimulation, 
possibly mediated by different sets of intermediates at different subcellular locations. 
Ouyang et al., 2008 showed that using this pair it was possible to use different wavelengths 
of light to measure the different FRET ratios simultaneously. Niino et al., 2009 went one 
step further they reported that by using four-color imaging with a single excitation light and 
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subsequent linear un-mixing to distinguish fluorescent proteins they constructed new FRET 
sensors with Sapphire/RFP to combine with CFP/YFP, and accomplished simultaneous 
imaging of cAMP and cGMP in single cells.  
It is true however that multipair FRET approaches that monitor multiple distances have 
been developed, they are technically challenging and difficult to extend, mainly because of 
their reliance on spectrally distinct acceptors. This problem can be overcome with the use of 
switchable FRET probes that can switch between a single donor and a spectrally identical 
acceptor. This was used by Uphoff et al., 2010 by placing one FRET donor and two acceptors 
on a single biomolecule and then cycling between the different acceptors. It was presented 
that they could probe the structure and dynamics of both a protein-DNA complex and a 
Holliday junction (Uphoff et al., 2010). 
7.3.3 Scale up 
Thus far the application and usefulness of these biosensors in a flask level and a scale down, 
automated BioLector™ method has been shown. The next logical step would be scale up 
into bioreactors and see if the bench top results can be reproduced at the BioLector™ level 
with the possibility of further testing at the fed-batch stage in such a large volume. This 
system would ideally be a machine that is capable of being connected to a few bioreactors 
at the same time, these bioreactors would contain CHO-S cells transfected with either the 
glucose or glutamine biosensor and transfected with whatever therapeutic protein of 
interest. An online sampler should be employed with an analyser set up to access the results 
automatically. Once the results are obtained a feed pump should automatically inject the 
needed vitamins, nutrients and metabolite when needed. If positive this may validate these 
biosensors for large studies. 
7.3.4 Inducible systems 
A method to modulate the amount of biosensor produced would be the use of an inducible 
system, this would allow the user to effectively repress the biosensors production whilst not 
harming the cells’ ability to produce the protein of interest. Such a system would be more 
efficient as it would allow the cell to possibly produce more specific protein as the burden of 
producing the biosensor would be negated. The T-Rex system from life technologies is one 
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such example. Here tetracycline is used to regulate mammalian expression, this is done by 
binding of tetracycline to the Tet repressor and depression of the promoter that controls 
expression of the biosensor is achieved. The Tet repressor is encoded in a regulatory 
plasmid called the pcDNA6/TR, under the control of the CMV promoter for tetracycline for 
the expression. Therefore the biosensor expression would be repressed in the absence of 
tetracycline and induced in the presence of tetracycline.  
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Appendix A 
Below are the primers used for the PCR steps undertaken in this thesis 
 
Primers:  
FLIPglu-600µ-Delta11aphrodite:  
Forward: GCAATGGAATTCATGCGGGGTTCTCATCATCATCATCATCATGG 
Reverse: GAATGGCTGCAGTCACTATATGCCCGCCGTGACGAACTCC 
 
scFv 
Hubc: 
Forward:  
ATCGAAGCTTGCCGCCACCATGGGCGTGAAAGTGCTGTTCGCCCTGATCTGCATCGCCGTGGCC
GAGGCC   
Reverse: 
ATGCTTCGAACGGCGGTGGTACCCGCACTTTCACGACAAFCFFACTAGACGTAGCGGCACCGGC
TCCGG 
 
MFE23:  
Forward: 
CATGAAGCTTGCCGCCACCATGGGCGTGAAAGTGCTGTTCGCCCAGGTGAAACTGCAGCAGTCTG 
Reverse:  
CACCAAGCTGGAGCTGAAACGGTAGGGATCCCCGG                    
 
Example of FRET calculation data:  
Below shows some raw data and the way the FRET ratios were calculated. Backgrounds 
were subtracted from the below wavelnegths first then: 
 
Blue wavelength reading: 3877.188 
Yellow wavelength reading: 1474.938  
Cell count for this sample: 8.16 E+05 
  190 
The blue wavelength is normalised against the cell count: 3877.188/8.16 E+05 =4.75E-03The 
yellow wavelength is normalised against the cell count: 1474.938/8.16 E+05= 1.81E-03 
Resultant FRET ratio is the yellow normalised ratio / blue normalised ratio: 4.75E-03/1.81E-03            
= 0.38  
 
 
